Anxiety in Health Behaviors and Physical Illness
SERIES IN ANXIETY AND RELATED DISORDERS Series Editor: Martin M. Antony, Professor, Department of Psychology, Ryerson University, Toronto, Ontario, Canada ACCEPTANCE AND MINDFULNESS-BASED APPROACHES TO ANXIETY Conceptualization and Treatment Edited by Susan M. Orsillo and Lizabeth Roemer CONCEPTS AND CONTROVERSIES IN OBSESSIVE-COMPULSIVE DISORDER Edited by Jonathan S. Abramowitz and Arthur C. Houts SOCIAL ANXIETY AND SOCIAL PHOBIA IN YOUTH Characteristics, Assessment, and Psychological Treatment Christopher A. Kearney TREATING HEALTH ANXIETY AND FEAR OF DEATH A Practitioner’s Guide Patricia Furer, John R. Walker, and Murray B. Stein TREATING TRICHOTILLOMANIA Cognitive-Behavioral Therapy for Hairpulling and Related Problems Martin E. Franklin and David F. Tolin ANXIETY IN HEALTH BEHAVIORS AND PHYSICAL ILLNESS Edited by Michael J. Zvolensky and Jasper A. J. Smits
A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher.
Anxiety in Health Behaviors and Physical Illness Michael J. Zvolensky University of Vermont Burlington, Vermont, USA
Jasper A. J. Smits Southern Methodist University Dallas, Texas, USA
Michael J. Zvolensky, Ph.D. Department of Psychology University of Vermont John Dewey Hall 2 Colchester Avenue Burlington, VT 05405-0134 USA
[email protected]
ISBN 978-0-387-74752-1
Jasper A. J. Smits, Ph.D. Department of Psychology Southern Methodist University 6424 Hilltop Lane Dallas, TX 75205 USA
[email protected]
e-ISBN 978-0-387-74753-8
Library of Congress Control Number: 2007935078 © 2008 Springer Science+Business Media, LLC All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. Printed on acid-free paper. 9 8 7 6 5 4 3 2 1 springer.com
Preface
Research has been accumulating on the prevalence and nature of the cooccurrence between various forms of anxiety disorders and problematic health behaviors as well as physical illness. This research has significant implications for both those interested and affected by anxiety as well as physical health factors. Yet, it is striking that there has been little systematic integration of this health-oriented research in contemporary science and practice on anxiety and its disorders. This relative neglect is unfortunate given that the co-occurrence of anxiety and health problems is a major public health priority when measured both in human and financial terms. The overarching aim of this book is to provide a single resource that offers current theoretical perspectives and cutting eZdge reviews of scientific research on health behaviors and physical illness in relation to anxiety and its disorders. A critical analysis of this emerging literature is needed to help move this field forward, making this proposed volume timely. The specific objectives of this edited book are to (1) provide a review of the literature on the link between anxiety and certain health behaviors and processes as well as physical illness; (2) present contemporary theories of their co-occurrence and interplay (e.g., onset, maintenance, and relapse); and (3) provide an analysis of recent research in regard to therapeutic models for targeting these problems. The book is organized into two general sections. In the first part of the book, prototypical health behaviors – smoking, alcohol, illicit substance use, exercise, and sleep – are discussed in relation to anxiety and its disorders. In the second part of the book, the association between anxiety psychopathology and physical health conditions – chronic pain, cardiovascular disease, asthma, HIV/ AIDS – and their treatment are covered. In this same section, the potential role of puberty and the menstrual cycle in the onset and maintenance of anxiety psychopathology are discussed. Inspection of the excellent and comprehensive works has yielded a number of broad-based conclusions relevant to informing research and practice for anxiety disorders. First, there is consistent empirical evidence that medical problems and poor health behaviors are overrepresented among persons with anxiety disorders, and vice versa. Thus, there is a pressing need to marshal information on anxiety-health processes to better serve this population. Second, as each v
vi
Preface
contribution makes clear, there is uniform evidence that both health behaviors and physical illness can, and do, affect the nature of anxiety psychopathology. Yet, the exact nature of these associations depends on the specific disorder and health factor in question. And finally, a variety of the chapters make clear that persons suffering from anxiety psychopathology and poor health behaviors or medical illnesses may need specialized interventions to prompt clinical change. That is, traditional interventions may not be ideally suited or maximize clinical benefit for this population. For us, the present book offers the opportunity to appreciate the importance and complexity involved with the study of anxiety disorders. For many years, health behaviors and medical illnesses have been a neglected facet of anxiety disorder research and practice. The contributions in this book help drive home the message that such neglect is unwarranted, and that by working to better understand the enigmas between health status and functioning and anxiety psychopathology, significant clinically-relevant strides can likely be achieved. We hope the present book helps move such work forward and bring a better quality of life and reduced morbidity to persons with anxiety disorders in the future. We owe gratitude to many people who have helped us complete this project. First among these are the experts who authored the chapters. We would like to thank them for their hard work and dedication. We also appreciate the comments and suggestions of Dr. Martin Antony, the editor of the Series in Anxiety and Related Disorders, and the assistance of Anna Tobias of Spinger with the publishing of this book. Lastly, we continue to be appreciative of our respective family members, Heidi and Jack Zvolensky and Jill and Stella Smits, for their love and support. April 2007
Michael J. Zvolensky, Ph.D. University of Vermont Jasper A. J. Smits, Ph.D. Southern Methodist University
Contents
Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
v
Contributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ix
Part I: Health Behaviors and Anxiety Disorders Tobacco Use and Panic Psychopathology: Current Status and Future Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Michael J. Zvolensky, Theresa Leyro, Amit Bernstein, Matthew T. Feldner, Andrew R. Yartz, Kimberly Babson, and Marcel O. Bonn-Miller Alcohol Use and Anxiety Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Brigitte C. Sabourin and Sherry H. Stewart Illicit Drug Use Across the Anxiety Disorders: Prevalence, Underlying Mechanisms, and Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Matthew T. Tull, David E. Baruch, Michelle S. Duplinsky, and C. W. Lejuez The Promise of Exercise Interventions for the Anxiety Disorders . . . . . . . . Jasper A. J. Smits, Angela C. Berry, Mark B. Powers, Tracy L. Greer, and Michael W. Otto
3
29
55
81
Anxiety and Insomnia: Theoretical Relationship and Future Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105 Thomas W. Uhde and Bernadette M. Cortese Part II: Physical Conditions and Anxiety Disorders Anxiety Disorders and Physical Illness Comorbidity: An Overview . . . . . . 131 Tanya Sala, Brian J. Cox, and Jitender Sareen
vii
viii
Contents
The Relation Between Puberty and Adolescent Anxiety: Theory and Evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155 Ellen W. Leen-Feldner, Laura E. Reardon, Chris Hayward, and Rose C. Smith Anxiety, Anxiety Disorders, and the Menstrual Cycle . . . . . . . . . . . . . . . . 181 Sandra T. Sigmon and Janell G. Schartel Pain and Anxiety Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207 Gordon J.G. Asmundson, Murray P. Abrams, and Kelsey C. Collimore Asthma in Anxiety and Its Disorders: Overview and Synthesis . . . . . . . . . . 237 Lisa S. Elwood and Bunmi O. Olatunji Cardiovascular Disease and Anxiety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 279 Kamila S. White HIV and Anxiety. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317 Conall O’Cleirigh, Trevor A. Hart, and Carolyn A. James Physical Illness and Treatment of Anxiety Disorders: A Review . . . . . . . . . 341 Norman B. Schmidt, Meghan E. Keough, Lora Rose Hunter, and Ann P. Funk Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 367
Contributors
Murray P. Abrams, B.A., Anxiety and Illness Behaviours Laboratory, University of Regina Gordon J.G. Asmundson, Ph.D. Anxiety and Illness Behaviours Laboratory, University of Regina Kimberly Babson, B.A., Department of Psychology, University of Arkansas David E. Baruch, Center for Addictions, Personality, and Emotion Research and the University of Maryland Amit Bernstein, Ph.D., Veterans Affairs Palo Alto Health Care System and University of Vermont Angela C. Berry, M.A., Department of Psychology, Southern Methodist University Marcel Bonn-Miller, B.A., Department of Psychology, University of Vermont Kelsey C. Collimore, B.S., Anxiety and Illness Behaviours Laboratory, University of Regina
Bernadette M. Cortese, Ph.D., Department of Psychiatry, Penn State College of Medicine and Hershey Medical Center Brian J. Cox Ph.D., Department of Community Health Sciences and Department of Psychiatry, University of Manitoba Michelle S. Duplinsky, Center for Addictions, Personality, and Emotion Research and the University of Maryland Lisa S. Elwood, M.A., Department of Psychology, University of Arkansas Matthew T. Feldner, Ph.D., Department of Psychology, University of Arkansas Ann P. Funk, M.A., Department of Psychology, Florida State University Tracy L. Greer, Ph.D., Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas
ix
x
Contributors
Trevor A. Hart, Ph.D., Department of Psychology, York University
Mark B. Powers, Ph.D., Department of Psychology, University of Amsterdam
Chris Hayward, M.D., M.P.H., Department of Psychiatry and Behavioral Sciences, Stanford University
Laura E. Reardon, M.A., Department of Psychology, University of Arkansas
Lora Rose Hunter, B.A., Department of Psychology, Florida State University
Brigitte C. Sabourin, B.A., Department of Psychology, Dalhousie University
Carolyn A. James, M.A., Department of Psychology, York University, Toronto
Tanya Sala, M.D., FRCPC, Department of Psychiatry, University of Manitoba
Meghan E. Keough, M.S., Department of Psychology, Florida State University
Jitender Sareen B.Sc., M.D., FRCPC, Department of Community Health Sciences and Department of Psychiatry, University of Manitoba
Ellen W. Leen-Feldner, Ph.D., Department of Psychology, University of Arkansas
Janell G. Schartel, M.A., Department of Psychology, University of Maine
Carl W. Lejuez, Ph.D., Center for Addictions, Personality, and Emotion Research and the University of Maryland
Norman B. Schmidt, Ph.D., Department of Psychology, Florida State University
Teresa Leyro, B.A., Department of Psychology, University of Vermont
Sandra T. Sigmon, Ph.D. Department of Psychology, University of Maine
Conall O’Cleirigh, Ph.D., Massachusetts General Hospital/ Harvard Medical School and Fenway Community Health
Rose C. Smith, B.A., Department of Psychology, University of Arkansas
Bunmi O. Olatunji, Ph.D., Department of Psychology, Vanderbilt University
Jasper A. J. Smits, Ph.D., Department of Psychology, Southern Methodist University
Michael W. Otto, Ph.D., Center for Anxiety and Related Disorders, Boston University
Sherry H. Stewart, Ph.D., Departments of Psychiatry and Psychology, Dalhousie University
Contributors
Matthew T. Tull, Ph.D., Center for Addictions, Personality, and Emotion Research and the University of Maryland
Thomas W. Uhde, M.D. Department of Psychiatry, Penn State College of Medicine and Hershey Medical Center
xi
Kamila S. White, Ph.D., University of Missouri-Saint Louis Andrew R. Yartz, Ph.D., Department of Psychology, University of Vermont Michael J. Zvolensky, Ph.D., Department of Psychology, University of Vermont
Part I
Health Behaviors and Anxiety Disorders
Tobacco Use and Panic Psychopathology: Current Status and Future Directions Michael J. Zvolensky, Teresa Leyro, Amit Bernstein, Matthew T. Feldner, Andrew R. Yartz, Kimberly Babson, and Marcel O. Bonn-Miller
Recently, there has been increased effort to better understand linkages between tobacco use and the anxiety disorders (Feldner, Babson, & Zvolensky, 2007; Morissette, Tull, Gulliver, Kamholz, & Zimering, 2007; Morrell & Cohen, 2006; Zvolensky, Bernstein, Marshall, & Feldner, 2006; Zvolensky, Feldner, Leen-Feldner, & McLeish, 2005; Zvolensky, Schmidt, & Stewart, 2003). These efforts are theoretically and clinically important because substance use problems frequently co-occur with anxiety psychopathology, and anxiety-related factors often play a role in tobacco use and dependence (Morissette et al., 2007; Morrell & Cohen, 2006; Zvolensky, Bernstein et al., 2006). However, our understanding of the explanatory nature of these comorbid relations is only beginning to emerge. The purpose of the present chapter is to provide a current review of extant empirical work pertaining to the inter-relations between tobacco use and panic psychopathology. We expressly and specifically focus on panic psychopathology, rather than anxiety disorders more broadly, as most of the work on tobacco and anxiety relations to date has focused on panic. This chapter is organized into four sections. First, we briefly describe panic psychopathology. Second, we review risk factor terminology developed by Kraemer, Kazdin, and Offord (1997), in order to establish a nomenclature for conceptualizing interrelations between tobacco and panic psychopathology. Third, we describe tobacco use and common patterns of use. Fourth, we discuss the nature of comorbidity between tobacco use and panic psychopathology and review and evaluate the related empirical evidence. We focus both on the role of tobacco use in the onset and maintenance of panic psychopathology, and the role of panic factors and processes in the onset and maintenance of smoking. Within each of these sections, we identify gaps in the existing literature and highlight formative questions for future research.
Michael J. Zvolensky University of Vermont, John Dewey Hall, Burlington, VT 05405-0134, Tel: 802-656-8994, Fax: 802-656-8783
[email protected]
M. J. Zvolensky, J. A. Smits (eds.), Anxiety in Health Behaviors and Physical Illness. Ó Springer 2008
3
4
M. J. Zvolensky et al.
Panic Psychopathology The term ‘‘panic psychopathology’’ is used in this chapter to denote panic attacks, panic disorder, and agoraphobia (with or without panic disorder). Panic attacks are a subjective sense of extreme fear or impending doom accompanied by an autonomic nervous system surge and a strong flight-or-fight action tendency (Barlow, Brown, & Craske, 1994). Recent estimates of unexpected (‘‘out of the blue’’) panic attacks in representative samples suggest that approximately 20% of individuals experience such attacks at one point in their lives and 11.2% in the past 12-months (Kessler, Chiu, Jin, Ruscio, Shear, & Walters, 2006). Thus, panic attacks are a relatively common psychological experience and many people experience panic attacks without necessarily developing panic disorder (i.e., nonclinical panic attacks; Norton, Cox, & Malan, 1992). Typically, individuals who experience nonclinical panic attacks do not experience these attacks as ‘‘spontaneous’’ or ‘‘uncued’’ (as is generally the case in panic disorder), but rather in certain contexts such as stressful or threatening social situations (Norton, 1989). Panic attacks also occur among those with other types of psychopathology (i.e., beyond panic disorder; Bryant & Panasetis, 2005). Panic attack onset can occur across the lifespan, but early onset tends to first occur between the ages of 12–13 years (Hayward et al., 1992; Warren & Zgourides, 1988; please see ‘‘Developmental Course’’ section below for further details). Panic disorder involves recurrent unexpected panic attacks and anxious apprehension about the possibility of experiencing future panic episodes (American Psychiatric Association, 2000). Lifetime estimates of panic disorder without agoraphobia are 3.7% and 1.1% for panic disorder with agoraphobia (Kessler et al., 2006). Twelve-month estimates for panic disorder (with or without agoraphobia) are approximately 2.8% (Kessler et al., 2006). Thus, panic disorder is a relatively common psychiatric disorder both in terms of lifetime and 12-month prevalence rates. This clinical condition is generally regarded as a disorder of adulthood with a median age of onset of 24 (Burke, Burke, Regier, & Rae, 1990), although emerging research has noted that another possible ‘‘peak onset period’’ may be between ages 45–54 years (Burke et al., 1990). Panic disorder with and without agoraphobia is associated with a chronic, fluctuating course and high rates of both psychiatric comorbidity and substance use disorders (Zvolensky, Bernstein et al., 2006). Although not all persons with panic disorder will meet diagnostic criteria for agoraphobia, individuals with panic disorder often show signs of avoiding potentially threatening situations in which a panic attack might occur (Feldner, Zvolensky, & Leen-Feldner, 2004). Agoraphobia reflects a pattern of behavior characterized by consistent avoidance of threatening situations where a panic attack or high anxiety is perceived to be likely (e.g., limited options to escape), or experiencing marked emotional distress when in such situations. Avoidance behavior can be multifaceted, with a wide range of stimuli that are perceived as
Panic and Tobacco
5
threat-relevant (e.g., anything from being in crowds to certain substances like caffeine; Feldner et al., 2004). Although agoraphobia does not necessarily require the presence of panic attacks or panic disorder (Fava, Grandi, & Canestrari, 1988), researchers frequently conceptualize agoraphobia as a complication of (severe) panic disorder (Barlow, 2002). However, it is noteworthy that this approach has been increasingly called into question in recent years, as research indicates that there may be differing forms of agoraphobic avoidance (Hayward & Wilson, in press). Regardless, agoraphobia with or without panic disorder often is related to higher rates of clinically significant life impairment and severity of illness (Kessler et al., 2006). The onset of agoraphobia with or without panic disorder is not as firmly established as that of panic attacks and panic disorder; though research suggests it likely occurs later in life than the onset of panic attacks and panic disorder (Lindesay, 1991).
Vulnerability Nomenclature Explicit delineation of terminology facilitates efforts to understand the nature of associations between tobacco use and panic psychopathology. Led by the work of Kraemer and colleagues, groundbreaking conceptual strides have created a clearer understanding of various risk processes (Kazdin, Kraemer, Kessler, Kupfer, & Offord, 1997; Kraemer et al., 1997; Kraemer, Lowe, and Kupfer, 2005; Kraemer, Stice, Kazdin, Offord, & Kupfer, 2001). Specifically, as is reviewed in this section, Kraemer and colleagues have worked to standardize operational definitions for risk processes to increase the clarity and consistency with which these factors are communicated across studies. Risk factors. A risk factor is a variable that is related to, and temporally precedes, an unwanted outcome (Kraemer et al., 1997). Causal risk factors reflect variables that, when modified in some way (e.g., through an intervention), produce change (increase or decrease) in the dependent variable of interest (Kraemer et al., 1997). Controlled research designs are necessary to document causal effects because they can rule out competing alternative explanations (e.g., ‘‘confounding variables’’). Proxy risk factors are variables that are related to an outcome of interest, but this association is due to the proxy risk factor’s relation with another causal risk factor (Kraemer et al., 2001). Thus, change in a proxy risk factor would not yield corresponding systematic change in an outcome variable; accordingly, a proxy risk factor may ‘‘mark’’ risk, but not explain or account for such risk. Due to the importance of the ability to change a risk factor, both risk and proxy risk factors often are further categorized on the basis of whether or not they are malleable (i.e., can be changed or altered). When a risk factor cannot be changed, it can be classified as a fixed marker, whereas when it can be changed, it can be classified as a variable risk factor (Kraemer et al., 2005).
6
M. J. Zvolensky et al.
A risk factor also can be contrasted with a maintenance factor. A maintenance factor is a variable that predicts the persistence of an existing condition over time among individuals already demonstrating the outcome (Stice, 2002). In theory, the same categorization scheme could be applied to maintenance factors in terms of whether or not they are causal or proxy maintenance factors (Kazdin et al., 1997). Moreover, a risk factor also may subsequently function as a maintenance factor. Qualifying conditions for risk factor effects. Clarifying relations between vulnerability processes and outcomes represents only the ‘‘first step’’ in a larger process of risk factor research. That is, this step represents a focus on ‘‘main effects,’’ but does not explicate how, when, or among whom a specified risk process unfolds (see Zvolensky, Schmidt, Bernstein, & Keough, 2006). We do not delve fully into these explanatory processes within the present chapter, as extant work has largely focused on questions of main effects at this early developmental stage of this area of study.
Tobacco Use: Definition, Nature, and Prevalence Cigarette smoking. Cigarette smoking is widely recognized as the most popular form of tobacco use and as a major public health problem (Windle & Windle, 1999). Indeed, cigarette smoking remains a leading preventable cause of death and disability in the United States (Centers for Disease Control and Prevention [CDC], 1994). Smoking is considered a key factor in various types of medical illness, including heart disease, a variety of pulmonary diseases (e.g., chronic obstructive pulmonary disease), and many types of cancer (CDC, 1994, 2002). For instance, smoking is responsible for almost 31% of all cancer-related deaths (American Cancer Society [ACS], 2006a). Although smoking increases one’s risk for developing many of these lethal medical diseases, quitting smoking decreases the risk of developing such problems and may increase the survival time among persons who have already developed such medical problems (Samet, 1992). Despite a reduction in smoking prevalence over the past 25 years, approximately 45–48 million (approximately 22% to 25%) adults in the U.S. currently smoke (CDC, 1996). Though nearly 70% of these smokers are motivated to quit (CDC, 2002), approximately 90–95% of smokers who do try to quit smoking on their own (Cohen et al., 1989), and 60–80% who attend treatment programs, relapse to smoking (CDC, 2002). Additional work suggests that 64% of youth (adolescents) report having tried cigarettes and 14% have smoked frequently in the past month (i.e., 20 out of the past 30 days; CDC, 2002). Thus, there is evidence that smoking is not only a major source of death and disability, but that once started it is often difficult to stop. Smokeless tobacco use. Although cigarettes are the most common type of tobacco use, there also is a significant population of smokeless tobacco
Panic and Tobacco
7
users in the U.S. and other regions of the world (e.g., India; ACS, 1999). Epidemiological data in the U.S., for example, suggest that approximately 3% of individuals have used some form of smokeless tobacco – either snuff (finely ground, shredded tobacco) or chewing tobacco – in the past month (ACS, 1999). These rates of use are elevated among young Caucasian males compared to females, and among those in southeastern and north central states compared to other regions, as well as rural compared to urban settings (Hatsukami & Severson, 1999). For example, past work suggests that the highest rates of current use (16.6%) are among Caucasian males 18–25 years of age (CDC, 1994). In general, rates of smokeless tobacco use are noteworthy because smokeless tobacco contains carcinogens (e.g., tobacco-specific nitrosamines [TSNAs]; National Cancer Institute and National Institute of Health (NCI/NIH), 2006) known to be causal agents in lung, oral, esophageal, liver, and pancreatic cancer (About: Smoking Cessation, 2006b). In addition, smokeless tobacco use is associated with greater nicotine absorption and for longer periods of time (e.g., stays in the bloodstream for greater durations of time) than cigarette smoking (ACS, 2006; NCI/NIH 2006b). Similar to cigarettes, smokeless tobacco use can lead to increased rates of physical disease (e.g., oral cancer, gum disease) and nicotine addiction (ACS, 1999). Whereas the risks associated with cigarette use have become well-publicized in the U.S., public awareness about the dangers of smokeless tobacco remains limited. Indeed, many perceive smokeless tobacco as a ‘‘risk-free alternative’’ to cigarette smoking (CDC, 1994). Although as many as 50% of smokeless tobacco users report wanting to quit (ACS, 2006a), as with cigarettes, rates of relapse remain high (Hatsukami, Jensen, Allen, Grillo, & Bliss, 1996). In a recent review of smokeless tobacco treatment programs, Hatsukami and Severson (1999) estimated a 3–6 month abstinent rate of 12%–30% with intensive behavioral treatments fairing better than other intervention options. Thus, similar to cigarette use, smokeless tobacco use is an addictive behavior that is difficult to quit and more intensive care appears to yield relatively better outcomes.
Prevalence of Comorbid Tobacco Use and Panic Psychopathology There have been both representative surveys and community-based studies focused on addressing the extent of the co-occurrence between tobacco use and panic psychopathology. To date, this work has largely centered on cigarette smoking rather than smokeless tobacco. Additionally, from a historical perspective, the vast majority of early work in this domain did not focus on panic or other specific anxiety conditions, but rather, addressed anxiety disorders as a single ‘‘class of problems’’ (e.g., Breslau, 1995; Brown, Lewinsohn, Seeley, & Wagner, 1996; Costello, Erkanli, Federman, & Angold, 1999; Degenhardt, Hall, & Lynskey, 2001; Hughes, Hatsukami, Mitchell, & Dalgren, 1986;
8
M. J. Zvolensky et al.
Kandel, Huang, & Davies, 2001; Kandel et al., 1997; Merikangas et al., 1998; Tilley, 1987). Although such work has importantly directed scientific attention to tobacco-anxiety relations at the broadest level, it is limited in demarcating specific rates of co-occurrence for (particular) disorders of interest, such as panic. Thus, for the sake of explanatory specificity, we focus our summary on investigations that expressly distinguished panic psychopathology from other anxiety disorders. Comorbidity prevalence. The majority of studies have focused on documenting rates of smoking among persons with panic psychopathology. The criteria for smoking behavior has varied across investigations. Moreover, treatmentbased recruitment strategies have been most commonly employed, perhaps making these data somewhat less generalizable to the overall smoking population. Nonetheless, among treatment-seeking adults, several studies have reported that current daily smoking among patients with panic psychopathology (either panic disorder or agoraphobia or both) ranged from 19% Panic (Baker-Morissette, Gulliver, Wiegel, & Barlow, 2004) to 57% (Himle, Thyer, & Fischer, 1988), with the vast majority of investigations falling between 30% to 50% (Amering et al., 1999; Lopes et al., 2002; McCabe et al., 2004; Pohl, Yeragani, Balon, Lycaki, & McBride, 1992). These rates of daily smoking are typically higher than comparison groups involving persons without psychiatric problems and typically higher, or as high as, rates among persons with other anxiety or mood disorders (McCabe et al., 2004). Thus, these data collectively suggest that smoking is a relatively common unhealthy behavior among treatment-seeking individuals with panic psychopathology. Studies focused on non-treatment seekers are currently limited. Of the available work, one study focused on youth (Hayward, Killen, & Taylor, 1989; 95 9th graders in public schools) and the other on college students (Valentiner, Mounts, & Deacon, 2004, n = 337). In both investigations, individuals with panic attacks, but not necessarily panic disorder or agoraphobia, had higher rates of cigarette use on a ‘‘regular basis’’ (Hayward et al., 1989; Valentiner et al., 2004). For example, Hayward et al. (1989) reported that of those with a lifetime history of panic attacks, 77% had engaged in ‘‘experimental’’ or ‘‘regular’’ cigarette use compared with 48% of adolescents without a lifetime history of panic attacks. These results, albeit highly limited in overall scope, generally parallel those of the treatment-oriented investigations noted earlier in terms of documenting elevated use prevalence among individuals with panic problems. Another set of investigations has utilized representative sampling methods to explore the nature of tobacco use among those with panic psychopathology (Covey, Hughes, Glassman, Blazer, & George, 1994; Farrell et al., 2001; Lasser et al., 2000). In perhaps the most comprehensive and well-known of these investigations, Lasser et al. (2000) examined smoking status according to psychiatric diagnoses using data from the National Comorbidity Survey (NCS), a nationally representative study that used structured clinical interviews to document mental illness (Kessler et al., 1994). Participants were 4,411 individuals aged
Panic and Tobacco
9
15 to 54 years. Among individuals diagnosed with panic attacks, panic disorder, and agoraphobia in their lifetime, 38%, 35%, and 38% were current smokers, respectively. These rates were significantly greater than rates of current smoking among individuals without mental illness. By comparison, 36% of individuals with a lifetime history of major depression and 49% of individuals with a lifetime diagnosis of drug abuse or dependence were current smokers. Rates of lifetime smoking among persons with a lifetime history of panic psychopathology (i.e., panic attacks, panic disorder, or agoraphobia) ranged from 58% to 61%. When diagnostic status in the past month was used as the grouping variable, current rates of smoking were 46% among persons with panic attacks, 42% among persons with panic disorder, and 48.1% among persons with agoraphobia. It is noteworthy that as number of mental diagnoses increased (ranging from 0 to 4 or more), the percentage of heavy (i.e., peak consumption exceeding 24 cigarettes a day) compared to relatively lighter (i.e., peak consumption less than 24 cigarettes per day) smokers increased. Overall, these data, coupled with the treatment-seeking data noted earlier, suggest that smoking occurs at relatively higher rates among those with panic psychopathology compared to those with no mental illness. Whereas the studies just reviewed focused on smoking among those with panic psychopathology, other investigations have sought to evaluate rates of panic psychopathology among smokers (Black, Zimmerman, & Coryell, 1999; Breslau, Kilbey, & Andreski, 1991; Goodwin, Zvolensky, & Keyes, 2007; Nelson & Wittchen, 1998). All of these investigations except that by Black and colleagues (1999), which involved community-based recruitment, involved some sort of representative sampling strategy. In contrast to the studies reviewed earlier, these investigations attempt to understand panic within the context of tobacco dependence and severity. Here, across studies, results indicate that among those persons meeting criteria for more addictive use of cigarettes (e.g., nicotine dependence), there is a greater prevalence of panic psychopathology (Breslau et al., 1991). For example, Breslau and colleagues (1991) found that 6.6% of persons meeting criteria for moderate dependence, 4.8% of those with mild dependence, and 2.4% of those with no dependence had a lifetime diagnosis of panic disorder. Nelson and Wittchen (1998) similarly found that among participants endorsing a lifetime history of smoking (yes/no), 7.6% met lifetime diagnostic criteria for panic attacks, 2% for panic disorder, and 4.4% for agoraphobia. These rates of panic psychopathology were significantly greater than those reported among nonsmokers; 2.4% had a panic attack history, 0.7% had panic disorder, and 1.6% had agoraphobia. Smokers with a lifetime nicotine dependence diagnosis compared to smokers without such a diagnosis evidenced greater rates of panic attacks (11.3% versus 4.0%), panic disorder (2.2% versus 1.8%), and agoraphobia (6.4% versus 2.5%). It should be noted that a similar, albeit not uniform, pattern of findings was apparent for individuals with other psychiatric disorders (e.g., alcohol dependence, drug dependence).
10
M. J. Zvolensky et al.
In the only study to focus on cigarette and smokeless tobacco use, Goodwin and colleagues (2007) found that among a representative sample from the U.S., rates of past-year panic attacks (with or without agoraphobia) were greatest among smokers with nicotine dependence (6.7%), followed by cigarette use with no dependence (2.2%), both of which were greater than among those with no past year cigarette or smokeless tobacco use (1.5%). Being dependent on smokeless tobacco (1.9%) was largely comparable to no past year tobacco use, both of which were greater than smokeless tobacco use without nicotine dependence (0.6%). Overall, the extant literature suggests that heavier rates of cigarette use (greater degrees of dependence) are associated with a greater rate of comorbidity with panic psychopathology. Although limited, this pattern of findings does not yet seem to be apparent for smokeless tobacco use, suggesting that factors related to the ‘‘mode of administration’’ may be an important domain to further understand in tobacco-panic linkages. Future directions. Though there are many avenues for future inquiry into the nature of tobacco-panic comorbidity, here we highlight a few domains of primary importance based upon the gaps in the existing literature. Before specific recommendations are made, it is striking to point out that, to the best of our knowledge, none of the past work focused on comorbidity issues has been a priori oriented on tobacco-panic relations. Thus, it is, perhaps, not surprising that some of the assessment approaches used in past work may not be fully comprehensive or geared towards maximizing information about the nature of the co-occurrence of these specific behavioral problems. As such, a first-step in improving research in this domain would be to design evaluations specifically focused on better understanding tobacco-panic comorbidity. Beyond this general issue, there are at least three specific points within this domain that would be particularly useful to address. First, only one study has provided data on smokeless tobacco and panic comorbidity. Thus, to foster further empirical knowledge in this domain, it is necessary to complete investigations wherein multiple forms of tobacco use are assessed to provide information on both cigarette use and smokeless tobacco. Aside from providing much needed data on smokeless tobacco and psychopathology, this type of work would help to define the parameters of tobacco-panic relations more generally. In this same context, it would be advisable to clarify the extent to which the observed co-occurrence rates between tobacco use and panic psychopathology are similar to, or different from, other health behaviors (e.g., alcohol use, physical exercise). In general, research suggests smoking is strongly positively related to alcohol and other substance use and negatively related to exercise (Zvolensky & Bernstein, 2005). This work is necessary because it would further explicate the degree to which tobacco use is or is not unique to the co-occurrence of panic psychopathology. As the present book illustrates, research in the health-anxiety linkage is only now emerging.
Panic and Tobacco
11
Second, there are a number of issues central to the generalizability of the reviewed investigations. The large majority of these studies have nottilized representative samples and therefore selection biases may be operative. It also is noteworthy that only one study (Hayward et al., 1989) focused exclusively on youth. Therefore, it is not possible to generalize the present tobacco-panic relations to other segments of the lifespan (e.g., adolescents) or the various stages of tobacco use (e.g., initiation, maintenance) that would presumably be apparent across different age ranges. Additionally, there are very limited data on tobacco-panic psychopathology linkages from a cross-national perspective. As factors that govern tobacco use may vary across communities and cultures, and in conjunction with the world-wide public health impact of both smoking and panic problems, it is important to extend work in this area to more diverse global populations. Finally, existing work has largely utilized limited assessments of smoking and panic psychopathology. Due to the focus on the ‘‘presence or absence of daily smoking,’’ little is known about the nature or topography of smoking behavior in terms of its association with panic psychopathology (e.g., age of onset, age of daily use, amount used when smoking the heaviest). This work would be improved by broadening smoking assessments to include a more detailed account of smoking history. It also may be productive to incorporate a multidimensional approach that takes into consideration theoretically-relevant motivational processes underlying cigarette use (Piper et al., 2004). This type of approach could be particularly valuable when examining linkages between smoking and panic psychopathology, whereby motivation to smoke to avoid negative affect might be a formative psychological process (Zvolensky, Schmidt, Antony et al., 2005).
Nature of the Associations Between Tobacco Use and Panic Psychopathology Developmental course. As a basis for understanding the nature of the relations between tobacco use and panic psychopathology, it is important to first clarify their developmental course. Representative data on the age of onset of panic attacks and smoking provide a means to evaluate temporal sequence. Research suggests that the onset of daily smoking typically occurs between the ages of 15 and 20 and rarely after age 25 (Breslau, Johnson, & Hiripi, 2001). For example, the CDC reports that in the United States, approximately 3,900 adolescents between the ages of 12 and 17 years initiate cigarette smoking each day (CDC, 2004), and an additional 1,500 become daily cigarette smokers each day (Substance Abuse and Mental Health Services Administration, 2005). Early studies of smokeless tobacco use indicate a mean age of onset between 10 and 12 years (i.e., Gottlieb, Pope, Rickert, & Hardin, 1993).
12
M. J. Zvolensky et al.
Studies examining the typical age of onset for panic attacks also suggest that such problems often first occur in adolescence. For example, Goodwin and Gotlib (2004) reported that the mean age of panic attack onset was 13.4 years (n = 1,285; age range 9–17). Other studies based on community or school samples have found similar results, with the modal age of onset of panic attacks being 12 years old (Hayward et al., 1992; Warren & Zgourides, 1988), and clinical samples report a slightly younger age of panic attack onset (Alessi & Magen, 1988; Black & Robbins, 1990). These data suggest that, across studies, panic attack onset tends to first occur between the ages of 12–13 years. One important interpretative caveat to these investigations is that they focus exclusively on youth and expressly do not sample from a larger age range. Thus, it is possible that the ‘‘average’’ age of onset of panic attacks may be different if the sampling strategy incorporated adults. Based on available indirect data from smoking and panic attack age of onset studies, it appears that in many instances the typical age of onset of panic attacks precedes the typical age of onset of smoking. However, retrospective reports of smokers with ‘‘active panic problems’’ are not entirely consistent with this perspective. For example, Amering and colleagues (1999) examined 102 consecutive panic disorder patients with or without agoraphobia attending an academic treatment clinic in Austria. Participants were diagnosed using the SCID-III-R (First, Spitzer, Gibbon, & Williams, 1995) and interviewed about their smoking status. Individuals presenting with ‘‘severe somatic illness’’ and comorbid depression and other psychiatric illnesses were excluded from the study. Amering and colleagues (1999) reported that the onset of smoking preceded the onset of panic disorder (cf. panic attacks) by 12.3 years (SD = 9.4) in a community sample of individuals with the condition (n = 102). Bernstein, Zvolensky, Schmidt, and Sachs-Ericsson (2007) directly evaluated onset patterns among 4,409 adults (Mage = 33.1, SD = 10.7, females = 2,221) from the NCS (Kessler et al., 1997). Results indicated that among cases with a lifetime history of comorbid daily smoking and panic attacks (n = 167), the onset of daily smoking (M = 16.0 years, SD = 3.0) preceded the onset of panic attacks (M = 27.8 years, SD = 7.6) in the majority, but not among all, of the comorbid cases (63.7%, n = 106). A relatively large minority of comorbid cases (33%; n = 55) reported that panic attacks (M = 11.4 years, SD = 5.2) preceded the onset of daily smoking (M = 18.2 years, SD = 4.7). The concurrent (same year) onset of these two problems appeared rarely (3.3%, n = 6). Also, as the pattern of ages of onset above illustrate, daily smoking demonstrated a relatively consistent mean age of onset (mid to late adolescence) across comorbid sub-samples and the uni-morbid sub-sample of smokers (age 18.5 years). In contrast, the mean ages of onset of panic attacks differed markedly between the comorbid sub-samples and the uni-morbid sub-sample of nonsmokers with panic attacks (age 20.3 years). Overall, while data focused expressly on developmental course and smoking-panic psychopathology is limited, extant studies suggest that the majority of cases may involve smoking preceding panic attacks.
Panic and Tobacco
13
Future directions. Again, it is important to highlight that work in this domain, although important for illuminating basic facets of tobacco-panic relations, is currently limited. First, to the best of our knowledge, no studies have examined the developmental course for smokeless tobacco. Future prospective work is therefore needed to expand this area of knowledge. Second, future study is needed to more carefully examine the putative smoking-to-panic and panic-to-smoking developmental courses. Third, smoking often occurs in a context of other substance use patterns. Thus, it may be useful to understand the developmental relations of tobacco and panic within the larger developmental context of panic-substance use comorbidity. In this sense, understanding the relative degree of ‘‘specificity’’ of initial findings vis a vis other substance use patterns and problems as well as health behaviors (e.g., physical exercise) may be a fruitful next research step. Current knowledge regarding tobacco use and panic psychopathology. Cross-sectional studies that have utilized interview and self-report methods have uniformly indicated that smoking, compared to non-smoking, is associated with more panic-relevant symptoms and impairment among nonclinical (Zvolensky, Forsyth, Fuse, Feldner, & Leen-Feldner, 2002) and clinical (McCabe et al., 2004; Zvolensky, Eifert, Feldner, & Leen-Feldner, 2003) samples. For example, Zvolensky, Schmidt and McCreary (2003) found that treatment-seeking smokers with panic disorder compared to nonsmokers with panic disorder reported more severe and intense anxiety symptoms, greater interview-based overall severity ratings of panic symptoms, and more social impairment. In these investigations, effects did not vary by gender, age, or other forms of substance use. Moreover, there is emerging evidence that these types of effects are relatively specific to panic disorder and psychopathology that frequently co-occurs with panic (e.g., posttraumatic stress disorder; Feldner et al., 2007). For example, Morissette and colleagues (2006) found that smokers with anxiety disorders, as compared to their non-smoking counterparts, reported higher levels of anxiety sensitivity (i.e., fear of anxiety and bodily-related sensations; McNally, 2002), anxiety symptoms, and agoraphobic avoidance. However, this association was specific to panic disorder and not evident for any of the other studied anxiety disorders, which did not include posttraumatic stress disorder (Morissette et al., 2006). Laboratory studies, although less common, have yielded similar findings. Zvolensky and colleagues (2004), for example, employed a voluntary hyperventilation paradigm to examine associations between smoking and panic-relevant fearful responding to bodily sensations. Results indicated smokers with panic disorder reported greater levels of anxiety than smokers without panic disorder at baseline, and also showed greater increases in anxiety during the post-challenge assessment and recovery periods. Although smokers with, versus without, panic disorder did not differ on baseline or post-challenge anxiety, smokers with, compared to without, panic disorder, demonstrated slower affective recovery from the challenge. These results indicate that smoking compared to not smoking is related to greater affective distress in response to
14
M. J. Zvolensky et al.
panic-relevant cues even among those with panic disorder. Less attention has been focused on determining the relation between smoking rate and level of affective distress or impairment. Yet, a number of studies, some involving prospective measurement (discussed in greater detail below), have found that smoking rate is related to greater degrees of panic-specific emotional symptoms (e.g., panic-relevant avoidance; Breslau & Klein, 1999; Goodwin, Lewinsohn, & Seeley, 2005; Johnson et al., 2000; McLeish, Zvolensky, & Bucossi, 2007; Zvolensky, Kotov, Antipova, & Schmidt, 2003). Thus, there is empirical evidence that both smoking status and rate are related to increased risk for panic-relevant emotional vulnerability. Cross-sectional tests also have helped to clarify factors that may affect the smoking-panic relation. In one study of epidemiologically-defined (i.e., representative) adult residents of Moscow (n = 95 daily smokers from a larger sample of about 400 persons; Zvolensky, Kotov et al., 2003), anxiety sensitivity moderated the effects of cigarettes smoked per day (m = 15) on level of agoraphobic avoidance. This significant interaction accounted for approximately 10% of unique variance after controlling for their respective main effects and the theoretically-relevant factors of problematic alcohol use and negative affectivity. No interaction, however, was found for panic attacks, potentially due to the fact that assessment of this factor was restricted to the past (most recent) week to enhance the validity of panic reports (but probably truncating variability). Similar moderating effects have been evident for perceived health among young adult daily smokers (McLeish, Zvolensky, Bonn-Miller, & Bernstein, 2006), and for neuroticism among a representative sample of adult smokers (Zvolensky, Sachs-Ericsson, Feldner, Schmidt, & Bowman, 2006). Overall, these findings suggest smokers are not a homogeneous group in regard to their risk for panic problems and that individual differences in anxiety sensitivity (or other cognitive-affective factors like perceived health or neuroticism) may be key factors in accounting for such differences. Moderating effects for anxiety sensitivity also have been evident in between-group tests involving smokers and nonsmokers. For example, the combination of high levels of anxiety sensitivity and a positive current smoking status predicted panic symptoms and somatic complaints, but not depressive symptoms in a biological challenge test (Leen-Feldner et al., 2007). Again, such findings suggest that anxiety sensitivity (and possibly other factors) may moderate the relation between smoking and prototypical panic psychopathology variables (panic attacks and somatic complaints) even after controlling for gender and negative affectivity. Moreover, these associations are specific to panic-relevant processes. In a re-analysis of the Russian epidemiological study reported earlier, Zvolensky and colleagues extended this smoking and anxiety sensitivity effect (Zvolensky, Kotov, Bonn-Miller, Schmidt, & Antipova, in press). Here, anxiety sensitivity, again, moderated the association of smoking status with indices of anxiety symptoms; effects were evident after controlling for the variance accounted for by alcohol use problems, environmental stress (past month), and gender.
Panic and Tobacco
15
Although cross-sectional data are informative in the study of tobacco-panic psychopathology relations, their utility also is limited. Prospective studies offer unique insight into the nature of the observed relations over time, and by extension, the order or temporal sequence of the associations. Researchers have evaluated the association between smoking and risk of panic psychopathology in a number of studies. Breslau and Klein (1999) tested the association between daily smoking and risk for panic attacks and panic disorder. Participants were drawn from two separate epidemiologically-defined data sets. Across both data sets, results indicated that there was a significant lifetime and prospective association between daily smoking and onset of panic attacks and panic disorder; daily smokers were almost 4 times more likely to experience panic attacks and 13 times more likely to develop panic disorder after controlling for major depression and gender. Additionally, among individuals who continued to smoke, compared to those who had quit, there was a significantly increased risk for experiencing a panic attack and panic disorder. Johnson and colleagues (2000) also found that anxiety disorders during adolescence were not significantly related to smoking in young adulthood. However, smoking in adolescence increased the risk for developing agoraphobia and panic disorder during early adulthood. These effects were observed above and beyond the variance accounted for by temperament, family history of psychopathology, drug/alcohol use and other theoretically-relevant factors. Specifically, adolescents who were heavy smokers were 15.6 times more likely to develop panic disorder in early adulthood than non-smokers. Interestingly, adolescents who smoked fewer than 20 cigarettes per day were not at elevated risk for the development of (later) anxiety disorders, potentially suggesting, once again, that heavier smoking levels impart greater panic-related risk. In another prospective study recently completed in Germany, 2,500 participants (ages 14–24 years at baseline) were evaluated over 4 years (Isensee, Wittchen, Stein, Ho¨fler, & Lieb, 2003). Compared with all other levels of smoking, dependent regular smokers at baseline were significantly more likely to develop panic attacks and panic disorder, and a similar pattern was observed for agoraphobia. Similarly, Breslau, Novak, and Kessler (2004) evaluated daily smoking and subsequent onset of psychiatric disorders. Results indicated that the onset of panic disorder (odds ratio = 2.6) and agoraphobia (odds ratio = 4.4) were associated with pre-existing daily smoking after controlling for age, gender, ethnicity, and educational level. Additionally, after controlling for pre-existing psychiatric disorders and sociodemographic characteristics, current nicotine dependent smokers were significantly more likely to have panic disorder compared to current non-dependent smokers and former smokers. Importantly, the likelihood of panic disorder and agoraphobia was significantly reduced as time since quitting increased; these effects were specific to these conditions and not other psychiatric disorders (e.g., major depressive disorder), suggesting quitting smoking likely decreases the risk of developing panic problems, an issue that is discussed in greater detail
16
M. J. Zvolensky et al.
later in the chapter. More recently, Goodwin and colleagues (2005) replicated the results of Breslau and Klein (1999), Johnson et al. (2000), and Isensee et al. (2003) by finding that daily smoking during adolescence was associated with an increased risk for panic attacks and panic disorder in young adulthood. Moreover, the observed effects were no longer evident after controlling for parental smoking and anxiety disorder status, suggesting that these family history characteristics may be formative in the linkages between smoking and panic psychopathology. Prospective tests examining moderating factors in the tobacco use-panic relation are very limited. In the only study to date on this topic, McLeish and colleagues (2007) evaluated the moderating role of anxiety sensitivity in the relation between smoking rate and panic vulnerability variables among a community-based sample of 125 daily smokers (60 females; Mage = 26.02 years). Findings indicate that the interaction between anxiety sensitivity and smoking rate significantly predicted concurrent agoraphobic avoidance (3.2% of unique variance) and change in levels of anticipatory anxiety about bodily sensations during the 3-month follow-up period (4.7% unique variance). Smokers high in anxiety sensitivity who also smoked at greater rates reported the highest levels of avoidance and greatest increase in anticipatory anxiety. These data, in accord with cross-sectional findings (LeenFeldner et al., 2007; Zvolensky, Kotov et al., 2003), once again suggest that anxiety sensitivity is an important individual difference factor that, when coupled with higher rates of smoking, is associated with greater levels of avoidance and anticipatory anxiety among daily smokers, both of which contribute to the development of panic psychopathology. Overall, research co-addressing smoking and panic psychopathology suggests that smoking can be considered a variable risk factor for panic problems. Indeed, existing work provides evidence regarding relations with panic problems based on cross-sectional and prospective studies, but it is noteworthy that this work is rarely multi-method in its approach. To have more confidence in smoking-panic psychopathology relations, the incorporation of multi-method assessment protocols would be an important next research step. Additionally, evidence from cross-sectional, and to a lesser extent, prospective studies indicates that fears of internal sensations (anxiety sensitivity) and perhaps other ‘‘affect-amplifiers’’ (e.g., perceived health, neuroticism) may moderate smoking-panic processes. Future directions. There is a rapidly developing empirical literature on tobacco-use and panic psychopathology relations. Such scientific interest in this work underscores its public health relevance and potential clinical implications (see Zvolensky, Bernstein, Yartz, McLeish, & Feldner, in press, for an expanded discussion of treatment implications of tobacco-panic relations). At the same time, this literature remains relatively under-developed and there are a number of key areas in need of future study. First, as in the area of comorbidity prevalence studies reviewed earlier, there is a dearth of data on smokeless tobacco-panic relations. Virtually no scientific
Panic and Tobacco
17
data exists on this important topic, making it a fertile area for future exploration. Second, available data suggest daily smoking tends to precede the onset of panic attacks in the majority of cases, although direct evaluations with panic disorder and agoraphobia have not been completed. Given that smoking can be changed via intervention (Abrams et al., 2003), there is evidence of its potential malleability, and hence, possible application to prevention programs for panic psychopathology. Overall, then, evidence that changing cigarette smoking rate or smoking cessation will alter the future risk of panic psychopathology from a preventative standpoint is lacking. Thus, it is currently not clear if smoking represents a variable marker or a variable causal risk factor for panic psychopathology. To clarify this issue, it is important for future research to examine changes in smoking prospectively following experimental manipulation (e.g., smoking cessation intervention; Zvolensky, Schmidt, Bernstein, & Keough, 2006). Third, research has yet to examine the possibility that shared or common risk factors may further explain the development of comorbid tobacco use and panic. It is theoretically possible that certain biological, psychological, and social factors may partially underlie the etiology and maintenance of these behavior problems. And finally, while there is a growing literature on moderating factors, there has been little scientific attention to mediators of smoking-panic associations and therefore almost no empirical knowledge exists pertaining to the putative causal mechanisms of interest. Intensifying the focus on mediators of smoking-panic relations is a clinicallyrelevant and timely task. Specifically, clarification of key mechanisms through which smoking achieves its panicogenic effects will stimulate the development of targeted interventions focused on therapeutic processes, and help to establish such processes (e.g., emotional reactivity) as important in the etiology and/or maintenance of panic-related problems. Only Breslau and Klein (1999) conducted exploratory analyses of possible mediators by evaluating the role of lung disease. Although medical illness is one useful process to better understand, other factors such as perceived health, affect tolerance, various trajectories of emotional distress (e.g., delayed recovery), withdrawal symptoms, and avoidance-oriented smoking patterns are all examples of theoretically-relevant factors deserving of future study (see Zvolensky & Bernstein, 2005, for an expanded discussion). Current knowledge regarding the relation between panic psychopathology. pre-morbid panic risk variables, and tobacco use. Although much of the most highly publicized work on smoking and panic psychopathology pertains to the potential role of smoking in the onset or maintenance of panic problems, panic vulnerability characteristics, broadly encompassing both pre-morbid variables and full-blown panic problems, may conversely impact smoking behavior (Zvolensky & Bernstein, 2005). Work in this domain has focused on empirical evidence related to smoking cessation outcome, expression of withdrawal symptoms, and motivational and cognitive processes related to smoking behavior (e.g., outcome expectancies). A major strength of work in this domain is that study of smoking has involved measurement of various facets of
18
M. J. Zvolensky et al.
smoking-related problems and processes (i.e., motivational processes) as opposed to focusing more narrowly on rates of tobacco use. This multidimensional conceptualization and measurement of smoking behavior is central to theoretical and clinical advances relevant to tobacco-panic relations. Moreover, it provides Moreover, it provides a means by which to further examine the role of panic-specific, and other anxiety factors (e.g., traumatic event exposure, negative affectivity), in smoking initiation (Bernstein, Zvolensky et al., 2007; Feldner et al., 2007; Isensee et al., 2003). Research has shown that affective vulnerability factors like panic psychopathology may be related to problems in quitting smoking. Lasser et al. (2000), for example, reported quit rates (i.e., proportion of lifetime smokers who were not current smokers) in relation to psychiatric diagnosis among a representative sample from the U.S. Using 1-month diagnostic status as a criterion point, the quit rate was 29% for persons with panic attacks, 32% for those with panic disorder, and 23% for persons with agoraphobia. Individuals with both panic attacks and agoraphobia in the past month were significantly less successful in quitting smoking compared to individuals with no mental illness (42%). Covey and colleagues (1994) reported conceptually similar findings that panic psychopathology may be related to poorer success in quitting, although it is not clear whether this effect is more robust than the types of association(s) between psychiatric disorders more generally and quit success. Other cross-sectional field and laboratory work using a community sample has found that daily smokers with a history of panic attacks, but no axis I histories, reported significantly shorter average quit attempt histories, measured in days, compared to smokers without panic (Zvolensky, Lejuez, Kahler, & Brown, 2004). Similar results have been observed in laboratory investigations (Zvolensky, Feldner, Eifert, & Brown, 2001). Although limited by cross-sectional design, and by extension, possible reporting errors (e.g., recall biases), these data provide evidence of a relation between panic psychopathology variables and problems in quitting. A related line of work has focused on anxiety sensitivity and success in quitting smoking. Anxiety sensitivity tends to be elevated among individuals who fear anxiety and arousal-related sensations such as panic disorder (Bernstein & Zvolensky, 2007). In the earliest study in this domain, Brown, Kahler, Zvolensky, Lejuez, and Ramsey (2001) examined a subset of data from a randomized controlled clinical trial comparing standard smoking cessation treatment versus standard smoking cessation plus cognitive-behavioral treatment for depression in smokers with past major depressive disorder. In this investigation, the association between anxiety sensitivity and relapse during the early stages of a quit attempt (e.g., first week), when individuals are most apt to experience symptoms of anxiety (Hughes, Higgins, & Hatsukami, 1990), was examined. Anxiety sensitivity was significantly associated with increased odds of lapsing during the first week after quit day (odds ratio = 2.0). Subsequent work has conceptually replicated and extended the results of Brown and colleagues (2001). For example, Zvolensky, Bonn-Miller, Bernstein, and
Panic and Tobacco
19
Marshall (2006) found anxiety sensitivity was significantly associated with increased risk of early smoking relapse among a community sample of daily smokers; these effects were evident above and beyond smoking rate and negative affectivity. Such work has recently been extended to low-level smokers from Mexico, adding cross-national empirical support (Zvolensky, Bernstein, et al., in press). Collectively, there is a growing amount of empirical evidence suggesting that panic psychopathology or pre-morbid panic-relevant variables such as elevated anxiety sensitivity is related to early relapse problems, and possibly, lower rates of overall success in quitting. Here again, controlled, prospective studies are an important next research step, as they would remove concerns that observed effects to date are attributable to reporting biases. A closely related line of inquiry has suggested that anxiety sensitivity is related to motivation to quit, barriers to quitting, and reasons for quitting. For example, Zvolensky, Baker and colleagues (2004) found anxiety sensitivity was related to higher levels of current motivation to quit smoking among adult daily smokers (Mage = 20.4], Mcigarettes per day = 10.2); effects were not attributable to other theoretically-relevant factors (e.g., gender, smoking rate; Zvolensky, Baker et al., 2004). These findings may at first seem counterintuitive in that it seems logical that individuals with high levels of anxiety sensitivity would be less likely to express interest or motivation in quitting due to the feared negative consequences related to quitting (e.g., withdrawal symptoms, emotional dyscontrol). Yet, related work suggests that smokers who worry about the negative health-related effects of smoking may engage in more quitting behavior (Dijkstra & Brosschot, 2003). From this perspective, high anxiety sensitivity smokers may be more apt to perceive a personal vulnerability to the negative effects of smoking (e.g., health risks), and as such, express greater motivation to quit (Zvolensky & Bernstein, 2005) despite their greater difficulty in successfully doing so (Brown et al., 2001). In line with this reasoning, Zvolensky, Vujanovic and colleagues (2007) more recently examined the relations between anxiety sensitivity and (1) motivation to quit smoking, (2) barriers to smoking cessation, and (3) reasons for quitting smoking among 329 (160 females; Mage = 26.08 years, SD = 10.92) adult daily smokers. After covarying for theoretically-relevant variables (negative affectivity, gender, axis I psychopathology, non-clinical panic attack history, number of cigarettes smoked per day, and current levels of alcohol consumption), anxiety sensitivity was significantly incrementally related to level of motivation to quit smoking, as well as perceived barriers to quitting smoking. Additionally, after accounting for the variance explained by other theoretically relevant variables, anxiety sensitivity was significantly associated with self control reasons for quitting smoking (intrinsic factors) as well as immediate reinforcement and social influence reasons for quitting (extrinsic factors). These results provide empirical evidence that anxiety sensitivity is uniquely related to level of motivation to quit smoking, perceived barriers to quitting, and certain intrinsic and extrinsic reasons for quitting.
20
M. J. Zvolensky et al.
Panic psychopathology or pre-morbid risk factors also appear to be related to severity of acute nicotine withdrawal. In an early study in this domain, Breslau, Kilbey, and Andreski (1992) found tobacco withdrawal symptoms in a sample of young adults were significantly elevated among smokers with ‘‘any anxiety disorder’’ compared to individuals without a history of such disorders; however, specific anxiety diagnoses were not provided, rendering unclear the specificity of such results to panic psychopathology per se. Zvolensky and colleagues (2004) found that daily smokers with a history of panic attacks reported significantly more intense anxiety-related withdrawal symptoms (anxiety, restlessness, difficulty concentrating, and irritability) compared to smokers without such a history; no differences were evident for the other tobacco withdrawal symptoms (e.g., increased appetite). In another study, Zvolensky, Baker et al. (2004) tested whether anxiety sensitivity predicted the intensity of withdrawal symptoms during the first week of daily smokers’ most recent quit attempt. Results indicated that anxiety sensitivity predicted the intensity of nicotine withdrawal symptoms during the first week of smokers’ most recent quit attempt, and this effect was above and beyond variance accounted for by negative affectivity, panic attack history, gender, cigarettes per day, and age of smoking onset, accounting for 16% of unique variance in withdrawal symptoms. This work is promising in suggesting panic-specific factors are related to an enhanced reactivity to nicotine withdrawal symptoms. Experimental work, which is now underway in our laboratory, is necessary to provide an additional degree of confidence in such conclusions. Another facet of evidence in support of a panic-tobacco relation is apparent from motivational and outcome expectancy research. In regard to smokingrelated motivational processes, there is a large empirical literature documenting that smokers often attribute their smoking, at least in part, to its mood-regulating functions and believe that smoking will reduce negative affect states (Parrott, 1999). Due to their affective vulnerability, smokers with panic-relevant vulnerabilities (i.e., high anxiety sensitivity) may be particularly motivated to smoke to escape from emotional distress elicited by acute nicotine withdrawal or non-withdrawal states (e.g., anticipatory anxiety; Zvolensky & Bernstein, 2005). A number of cross-sectional studies support this theory. Specifically, studies have indicated that anxiety sensitivity is associated with coping-oriented smoking motives among young adults with no history of psychopathology (Novak, Burgess, Clark, Zvolensky, & Brown, 2003; Stewart, Karp, Pihl, & Peterson, 1997; Zvolensky, Bonn-Miller et al., 2006), adolescents (Comeau, Stewart, & Loba, 2001), and individuals with a past history of major depression (Brown, Kahler et al., 2001). Zvolensky, Feldner, Leen-Feldner et al. (2004) report conceptually similar findings for relations between anxiety sensitivity and negative-reinforcement outcome expectancies for smoking. The Comeau et al. (2001) investigation, in particular, is noteworthy in that anxiety sensitivity moderated the relation between trait anxiety (frequency of anxiety symptoms) and use of cigarettes to cope with affective distress, reporting a stronger relationship between anxiety and use of cigarettes to cope with negative emotions
Panic and Tobacco
21
among high anxiety sensitive compared with low anxiety sensitive youth. Using a sample of panic disorder patients, Zvolensky and colleagues (2005) also found that smokers with panic disorder reported higher levels of smoking to reduce negative affect than their counterparts without such a history. These cross-sectional studies are not capable of elucidating the direction of the effects. Theoretically, coping-oriented smoking motives may have bi-directional effects, influencing, and being influenced by, affective vulnerability. An initial investigation exploring this possibility was consistent with such an account (Gregor, Zvolensky, Bernstein, Marshall, & Yartz, 2007), reporting that coping-oriented motives were incrementally related to a variety of negative affective and cognitive factors. Overall, there are a variety of separate, but related, lines of inquiry indicating panic psychopathology and a select number of pre-morbid risk factors are meaningfully related to smoking behavior. These lines of work differ in their focus, but broadly indicate that panic factors (full blown disorders and certain pre-morbid risk factors) are related to abstinence duration during smoking cessation outcome expectancies related to smoking, perceived barriers and reasons for quitting, nicotine withdrawal symptom severity, and motivational bases for smoking. Thus, it is most appropriate to conceptualize many of the studied variables (e.g., anxiety sensitivity) as variable risk factors. Although definitive prospective work has not been conducted to firmly establish temporal precedence in many, if not most, of the investigations, theoretically, panic variables would precede the smoking factors. It also is theoretically possible that panic and panic-relevant risk factors may not necessarily developmentally precede smoking, but nevertheless meaningfully influence the course and nature of smoking behavior over time via many of the processes described throughout this chapter. Further prospective work will delineate the possibility that these panic-smoking relations may be transactional over development. Future directions. As in the earlier sections of this chapter, a first observation and recommendation for future research is to better understand the relations between panic psychopathology and smokeless tobacco use. There is no empirical work completed in this domain to the best of our knowledge, leaving this facet of the tobacco-panic linkage undocumented. Second, essentially all of the existing work on panic psychopathology (and related factors) and smoking behavior is focused on main effects. This approach seems appropriate given the currently limited knowledge in the area, but represents only a ‘‘first step’’ in a larger scientific effort. Future work is needed to increase understanding about linkages among these factors beyond main effects by including moderational and mediational tests of theoretically relevant variables. Similarly, the possibility that shared or common risk factors may underlie panic problems, panic-relevant risk factors, and these smoking-related problems and processes has received little theoretical or empirical evaluation. Third, the generalizability of panic psychopathology and smoking research is limited in that it has focused largely on adults from the U.S. Furthermore, there is very little information on the nature of these relations among youth. Given the early age of onset of these
22
M. J. Zvolensky et al.
behaviors and their health relevance, as well as the international scope of this public health problem, research development in these domains is needed. Finally, little research has directly targeted panic vulnerability factors in smoking cessation interventions. Similarly, there is little work addressing smoking in the context of panic-related treatments. Given the consistent empirical evidence of bi-directional associations between these often comorbid behavioral problems, it is important to develop specialized treatments, as generic interventions may not target the affective vulnerability processes functioning to maintain smoking in this population. For example, it may be useful to integrate interoceptive exposure, cognitive restructuring, and psychoeducation exercises developed for panic prevention and treatment programs with standard smoking cessation strategies and nicotine replacement therapy. These therapeutic tactics may be most effective when they target theoretically-relevant panic risk factors like anxiety sensitivity in order to facilitate cessation. As a second illustration, it may be useful to target smoking cessation as part of evidence-based panicproblem treatment strategies. While there have been some inroads made in this domain, with successful case reports and pilot studies now being reported (Zvolensky, Bernstein et al., in press; Zvolensky, Lejuez, Kahler, & Brown, 2003; Zvolensky, Schmidt et al., 2006), much work is yet to be addressed in this domain.
Summary The present chapter provides an updated review of extant empirical work pertaining to the inter-relations between tobacco use and panic psychopathology. Although a relatively nascent area of research, a recent spate of empirical evidence indicates that theoretically and clinically important associations exist between tobacco use and panic psychopathology. Although promising, there are a multitude of critical gaps in the research literature that need to be addressed in future studies. We hope that such ongoing research may help translate knowledge about basic processes to the development and dissemination of powerful clinical intervention strategies for tobacco users with panic-related vulnerabilities or psychopathology.
References About: Smoking Cessation (2006). Retrieved October 1, 2006 from http://quitsmoking.about. com/od/glossaryofterms/g/TSNA.htm. Abrams, D. B., Niaura, R., Brown, R. A., Emmons, K. M., Goldstein, M. G., & Monti, P. M. (2003). The tobacco dependence treatment handbook: A guide to best practices. New York: Guilford Press. Alessi, N. E., & Magen, J. (1988). Panic disorder in psychiatrically hospitalized children. American Journal of Psychiatry, 145, 1450–1452.
Panic and Tobacco
23
American Cancer Society. (2006a). Cancer Facts & Figures – 2006. American Cancer Society. American Cancer Society (2006b, February 13). Prevention and Early Detection: Quitting Spit (Smokeless) Tobacco. Retrieved September 18th from http://www.cancer. org/docroot/PED/content/PED_10_13X_Quitting. American Cancer Society (1999). Cancer facts and figures –1999. American Cancer Society. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed. text revision). Washington, DC: Author. Amering, M., Banker, B., Berger, P., Griengl, H., Windhaber, J., & Katschnig, H. (1999). Panic disorder and cigarette smoking behavior. Comprehensive Psychiatry, 40, 35–38. Baker-Morissette, S. L., Gulliver, S. B., Wiegel, M., & Barlow, D. H. (2004). Prevalence of smoking in anxiety disorders uncomplicated b comorbid alcohol of substance abuse. Journal of Psychopathology and Behavioral Assessment, 26, 107–112. Barlow, D. H. (2002). Anxiety and its disorders: The nature and treatment of anxiety and panic (2nd ed.). New York: Guilford Press. Barlow, D. H., Brown, T. A., & Craske, M. G. (1994). Definitions of panic attacks and panic disorder in the DSM-IV: Implications for research. Journal of Abnormal Psychology, 103, 553–564. Bernstein, A., & Zvolensky, M. J. (2007). Anxiety sensitivity: Selective review of promising research and future directions. Expert Review in Neurotherapeutics, 7, 97–101. Bernstein, A., Zvolensky, M. J., Schmidt, N. B., & Sachs-Ericsson, N. (2007). Developmental course(s) of lifetime cigarette use and panic attack comorbidity: An equifinal phenomenon. Behavior Modification, 31, 117–135. Black, B., & Robbins, D. R. (1990). Panic disorder in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 29, 36–44. Black, B., Zimmerman, M., & Coryell, W. H. (1999). Cigarette smoking and psychiatric disorder in a community sample. Annals of Clinical Psychiatry, 11, 129–136. Breslau, N. (1995). Psychiatric comorbidity of smoking and nicotine dependence. Behavior Genetics, 25, 95–101. Breslau, N., Johnson, E. O., & Hiripi, E. (2001). Nicotine dependence in the United States. Archives of General Psychiatry, 58, 810–816. Breslau, N., Kilbey, M., & Andreski, P. (1991). Nicotine dependence, major depression, and anxiety in young adults. Archives of General Psychiatry, 48, 1069–1074. Breslau, N., Kilbey, M. M., & Andreski, P. (1992). Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. American Journal of Psychiatry, 149, 464–469. Breslau, N., & Klein, D. F. (1999). Smoking and panic attacks: An epidemiologic investigation. Archives of General Psychiatry, 56,1141–1147. Breslau, N., Novak, S. P., & Kessler, R. C. (2004). Daily smoking and the subsequent onset of psychiatric disorders. Psychological Medicine, 34, 323–333. Brown, R. A., Kahler, C. W., Zvolensky, M. J., Lejuez, C. W., & Ramsey, S. E. (2001). Anxiety sensitivity: Relationship to negative affect smoking and smoking cessation in smokers with past major depressive disorder. Addictive Behaviors, 26, 887–899. Brown, R. A., Lewinsohn, P. M., Seeley, J. R., & Wagner, E. F. (1996). Cigarette smoking, major depression, and other psychiatric disorders among adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1602–1610. Bryant, R. A., & Panasetis, P. (2005). The role of panic in acute dissociative reactions following trauma. British Journal of Clinical Psychology, 44, 489–494. Burke, K. C., Burke, J. D., Regier, D. A., & Rae, D. S. (1990). Age at onset of selected mental disorders in five community populations. Archives of General Psychiatry, 47, 511–518. Centers for Disease Control and Prevention (CDC). (1994). Preventing Tobacco Use Among Young People: A Report of the Surgeon General. Atlanta, GA: Department of Health and Human Services.
24
M. J. Zvolensky et al.
Centers for Disease Control and Prevention (CDC). (1996). Cigarette smoking among adults–United States, 1994. Morbidity and Mortality Weekly Report, 45, 588–590. Centers for Disease Control and Prevention (CDC). (2002). Cigarette smoking among adults–United States, 2000. Morbidity and Mortality Weekly Report, 51, 642–645. Centers for Disease Control and Prevention (CDC). (2004). State-specific prevalence of current cigarette smoking among adults–United States, 2002. Morbidity and Mortality Weekly Report, 52, 1277–1280. Cohen, S., Lichtenstein, E., Prochaska, J. O., Rossi, J. S., Gritz, E. R., Carr, C. R. et al. (1989). Debunking myths about self-quitting: Evidence from 10 prospective studies of persons who attempt to quit smoking by themselves. American Psychologist, 44, 1355–1365. Comeau, N., Stewart, S. H., & Loba, P. (2001). The relations of trait anxiety, anxiety sensitivity, and sensation seeking to adolescents’ motivations for alcohol, cigarette, and marijuana use. Addictive Behaviors, 26, 803–825. Costello, E. J., Erkanli, A., Federman, E., & Angold, A. (1999). Development of psychiatric comorbidity with substance abuse in adolescents: Effects of timing and sex. Journal of Clinical Child Psychology, 28, 298–311. Covey, L. S., Hughes, D. C., Glassman, A. H., Blazer, D. G., & George, L. K. (1994). Ever-smoking, quitting, and psychiatric disorders: Evidence from the Durham, North Carolina, epidemiologic catchment area. Tobacco Control, 3, 222–227. Degenhardt, L., Hall, W., & Lynskey, M. (2001). Alcohol, cannabis, and tobacco use among Australians: A comparison of their associations with other drug use and disorders, affective and anxiety disorders, and psychosis. Addiction, 96, 1603–1614. Dijkstra, A., & Brosschot, J. (2003). Worry about health in smoking behaviour change. Behaviour Research and Therapy, 41, 1081–1092. Farrell, M., Howes, S., Bebbington, P., Brugha, T., Jenkins, R., Lewis, G., et al. (2001). Nicotine, alcohol and drug dependence and psychiatric comorbidity. British Journal of Psychiatry, 179, 432–437. Fava, G. A., Grandi, S., & Canestrari, R. (1988). Prodromal symptoms in panic disorder with agoraphobia. American Journal of Psychiatry, 145, 1564–1567. Feldner, M. T., Babson, K. A., & Zvolensky, M. J. (2007). Smoking, traumatic event exposure, and post-traumatic stress: A critical review of the empirical literature. Clinical Psychology Review, 27, 14–45. Feldner, M. T., Zvolensky, M. J., & Leen-Feldner, E. (2004). A critical review of the empirical literature on coping and panic disorder. Clinical Psychology Review, 24, 123–148. First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (1995). Structured Clinical Interview for DSM-III-R Axis I Disorders. New York: New York State Psychiatric Institute. Goodwin, R. D., & Gotlib, I. H. (2004). Panic attacks and psychopathology among youth. Acta Pyschiatrica Scandinavica, 109, 216–221. Goodwin, R. D., Lewinsohn, P. M., & Seeley, J. R. (2005). Cigarette smoking and panic attacks among young adults in the community: The role of parental smoking and anxiety disorders. Biological Psychiatry, 58, 686–693. Goodwin, R. D., Zvolensky, M. J., & Keyes, K. (2007). Nicotine dependence and mental disorders among adults in the United States: Evaluating the role of mode of administration. Manuscript submitted for publication. Gottlieb, A., Pope, S. K., Rickert, V. I., & Hardin, B. H. (1993). Patterns of smokeless tobacco use by young adolescents. Pediatrics, 91, 75–78. Gregor, K., Zvolensky, M. J., Bernstein, A., Marshall, E. C., & Yartz, A. (2007). Smoking motives in the prediction of affective vulnerability among young adult daily smokers. Behaviour Research and Therapy, 45, 471–482. Hatsukami, D., Jensen, J., Allen, S., Grillo, M., & Bliss, R. (1996). Effects of behavioral and pharmacological treatment on smokeless tobacco users. Journal of Consulting and Clinical Psychology, 64, 153–161.
Panic and Tobacco
25
Hatsukami, D. A., & Severson, (1999). Oral spit tobacco: addiction, prevention, and treatment. Nicotine & Tobacco Research, 1, 21–44. Hayward, C., Killen, J. D., Hammer, L. D., Litt, I. F., Wilson, D. M., Simmonds, B., et al. (1992). Pubertal stage and panic attack history in sixth- and seventh-grade girls. American Journal of Psychiatry, 149, 1239–1243. Hayward, C., Killen, J. D., & Taylor, C. B. (1989). Panic attacks in young adolescents. American Journal of Psychiatry, 146, 1061–1062. Hayward, C., & Wilson, K. (in press). Anxiety sensitivity: The missing piece to the agoraphobia-without-panic puzzle. Behavior Modification. Himle, J., Thyer, B. A., & Fischer, D. J. (1988). Prevalence of smoking among anxious outpatients. Phobia Practice and Research Journal, 1, 25–31. Hughes, J. R., Hatsukami, D. K., Mitchell, J. E., & Dalgren, L. A. (1986). Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry, 143, 993–997. Hughes, J. R., Higgins, S. T., & Hatsukami, D. (1990). Effects of abstinence from tobacco: A critical review. In L. T. Kozlowski, H. M. Annis, H. D. Cappell, F. B. Kalant, E. M., & E. R. Sellers, Vingilis (Eds.), Research advances in alcohol and drug problems (Vol. 10). Plenum publishing. Isensee, B., Wittchen, H-U., Stein, M. B., Ho¨fler, M., & Lieb, R. (2003). Smoking increases the risk of panic: Findings from a prospective community study. Archives of General Psychiatry, 60, 692–700. Johnson, J. G., Cohen, P., Pine, D. S., Klein, D. F., Kasen, S., & Brook, J. S. (2000). Association between cigarette smoking and anxiety disorders during adolescence and early adulthood. JAMA: Journal of the American Medical Association, 284, 2348–2351. Kandel, D. B., Huang, F. Y., & Davies, M. (2001). Comorbidity between patterns of substance use dependence and psychiatric syndromes. Drug and Alcohol Dependence, 64, 233–241. Kandel, D. B., Johnson, J. G., Bird, H. R., Canino, G., Goodman, S. H., Lahey, B. B., et al. (1997). Psychiatric disorders associated with substance use among children and adolescents: Findings form the Methods for the Epidemiology of Child and Adolescent Mental Disorders (MECA) Study. Journal of Abnormal Child Psychology, 25, 121–132. Kazdin, A. E., Kraemer, H. C., Kessler, R. C., Kupfer, D. J., & Offord, D. R. (1997). Contributions of risk-factor research to developmental psychopathology. Clinical Psychology Review, 17, 375–406. Kessler, R. C., Anthony, J. C., Blazer, D. G., Bromet, E., Eaton, W. W., Kendler, K., et al. (1997). The US national cormorbidity survey: Overview and future directions. Epidemiologiae Psichiatria Sociale, 6, 4–16. Kessler, R. C., Chiu, W. T., Jin, R., Ruscio, A. M., Shear, K., & Walters, E. E. (2006). The epidemiology of panic attacks, panic disorder, and agoraphobia in the national comorbidity survey replication. Archives of General Psychiatry, 63, 415–424. Kessler, R. C., McGonagle, K. A., Zhao, S., Nelson, C. B., Hughes, M., Eshleman, S., et al. (1994). Lifetime and 12-month prevalence rates of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Archives of General Psychiatry, 51, 8–19. Kraemer, H. C., Kazdin, A. E., & Offord, D. R. (1997). Coming to terms with terms of risk. Archives of General Psychiatry, 54, 337–343. Kraemer, H. C., Lowe, K. K., & Kupfer, D. J. (2005). To your health: How to understand what research tells us about risk. New York: Oxford University Press Kraemer, H. C., Stice, E., Kazdin, A., Offord, D., & Kupfer, D. (2001). How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors. American Journal of Psychiatry, 158, 848–856. Lasser, K., Boyd, J. W., Woolhandler, S., Himmelstein, D. U., McCormick, D., & Bor, D. H. (2000). Smoking and mental illness: A population-based prevalence study. Journal of the American Medical Association, 284, 2606–2610.
26
M. J. Zvolensky et al.
Leen-Feldner, E. W., Zvolensky, M. J., van Lent, J., Vujanovic, A. A., Bleau, T., Bernstein, A., et al. (2007). Anxiety sensitivity moderates tobacco smoking in regard to panic attack symptoms and bodily complaints: A concurrent test among adolescents. Journal of Psychopathology and Behavioral Assessment, 29, 69–79. Lindesay, J. (1991). Phobic disorders in the elderly. British Journal of Psychiatry, 159, 531–541. Lopes, F. L., Nascimento, I., Zin, W. A., Valenca, A. M., Mezzasalma, M. A., Figueira, I., et al. (2002). Smoking and psychiatric disorders: A comorbidity survey. Brazilian Journal of Medical and Biological Research, 35, 961–967. McCabe, R. E., Chudzik, S. M., Antony, M. M., Young, L, Swinson, R. P., & Zvolensky, M. J. (2004). Smoking behaviors across anxiety disorders. Journal of Anxiety Disorders, 18, 7–18. McLeish, A. C., Zvolensky, M. J., Bonn-Miller, M. O., & Bernstein, A. (2006). Perceived health moderates the association between smoking rate and panic vulnerability among daily smokers. Depression and Anxiety, 23, 257–265. McLeish, A. C., Zvolensky, M. J., & Bucossi, M. M. (2007). Interaction between smoking rate and anxiety sensitivity: Relation to anticipatory anxiety and panic-relevant avoidance among daily smokers. Journal of Anxiety Disorders, 21, 849–859. McNally, R. J. (2002). Anxiety sensitivity and panic disorder. Biological Psychiatry, 52, 938–946. Merikangas, K. R., Mehta, R. L., Molnar, B. E., Walters, E. E., Swendsen, J. D., AguilarGaziola, S., et al. (1998). Comorbidity of substance use disorders with mood and anxiety disorders: Results of the International Consortium in Psychiatric Epidemiology. Addictive Behaviors, 23, 893–907. Morissette, S. B., Brown, T. A., Kamholz, B., & Gulliver, S. (2006). Differences between smokers and nonsmokers with anxiety disorders. Journal of Anxiety Disorders, 20, 597–613. Morissette, S. B., Tull, M. T., Gulliver, S. B., Kamholz, B. W., & Zimering, R. T. (2007). Anxiety, anxiety disorders, tobacco use, and nicotine: A critical review of interrelationships. Psychological Bulletin, 133, 245–272. Morrell, H. E. R., & Cohen, L. M. (2006). Cigarette smoking, anxiety, and depression. Journal of Psychopathology and Behavioral Assessment, 28, 281–295. National Cancer Institute and National Institute of Health (NCI/NIH). (2006). Smokeless Tobacco and Cancer: Questions and Answers. Retrieved September 18th, 2006, from http://www.nci.nih.gov/cancertopics/factsheet/Tobacco/smokeless Nelson, C. B., & Wittchen, H-U. (1998). Smoking and nicotine dependence. European Addictive Research, 4, 42–49. Norton, G. R. (1989). Panic attack questionnaire. In M. Hersen and A. Bellack (Eds.), Dictionary of behavioral assessment techniques (pp. 332–334). New York: Pergamon Press. Norton, G. R., Cox, B. J., & Malan, J. (1992). Nonclinical panickers: A critical review. Clinical Psychology Review, 12, 121–139. Novak, A., Burgess, E. S., Clark, M., Zvolensky, M. J., & Brown, R. A. (2003). Anxiety sensitivity, self-reported motives for alcohol and nicotine use and level of consumption. Journal of Anxiety Disorders, 17, 165–180. Parrott, A. C. (1999). Does cigarette smoking cause stress? American Psychologist, 18, 817–820. Piper, M. E., Piasecki, T. M., Federman, E. B., Bolt, D. M., Smith, S. S., Fiore, M. C., et al. (2004). A multiple motives approach to tobacco dependence: The Wisconsin Inventory of Smoking Dependence Motives (WISDM-68). Journal of Consulting and Clinical Psychology, 72, 139–154. Pohl, R., Yeragani, V. K., Balon, R., Lycaki, H., & McBride, R. (1992). Smoking in patients with panic disorder. Psychiatry Research, 43, 253–262. Samet, J. M. (1992). The health benefits of smoking cessation. The Medical Clinics of North America, 76, 399–414.
Panic and Tobacco
27
Stewart, S. H., Karp, J., Pihl, R. O., & Peterson, R. A. (1997). Anxiety sensitivity and self-reported reasons for drug use. Journal of Substance Abuse, 9, 223–240. Stice, E. (2002). Risk and maintenance factors for eating pathology: A meta-analytic review. Psychological Bulletin, 128, 825–848. Substance Abuse and Mental Health Services Administration. (2005). Science-based prevention programs and principles. Rockville, MD: U.S. Department of Health and Human Services, Center for Substance Abuse Prevention. Tilley, S. (1987). Alcohol, other drugs and tobacco use and anxiolytic effectiveness: a comparison of anxious patients and psychiatric nurses. British Journal of Psychiatry 151, 389–92. Valentiner, D. P., Mounts, N. S., & Deacon, B. J. (2004). Panic attacks, depression and anxiety symptoms, and substance use behaviors during late adolescence. Journal of Anxiety Disorders, 18, 573–586. Warren, R., & Zgourides, G. (1988). Panic attacks in high school students: Implications for prevention and intervention. Phobia Practice and Research Journal, 1, 97–113. Windle, M., & Windle, R. (1999). Adolescent tobacco, alcohol and drug use: Current findings. Adolescent Medicine, 10, 153–163 Zvolensky, M. J., Baker, K. M., Leen-Feldner, E. W., Bonn-Miller, M. O., Feldner, M. T., & Brown, R. A. (2004). Anxiety sensitivity: Association with intensity of retrospectivelyrated smoking-related withdrawal symptoms and motivation to quit. Cognitive Behaviour Therapy, 33, 114–125. Zvolensky, M. J., & Bernstein, A. (2005). Cigarette smoking and panic psychopathology. Current Directions in Psychological Science, 14, 301–305. Zvolensky, M. J., Bernstein, A., Marshall, E. C., & Feldner, M. T. (2006). Panic attacks, panic disorder, and agoraphobia: Associations with substance use, abuse, and dependence. Current Psychiatry Reports, 8(4), 279–285. Zvolensky, M. J., Bernstein, A., Sachs-Ericsson, N., Schmidt, N. B., Buckner, J. D., & Bonn-Miller, M. O. (2006). Lifetime associations between cannabis, use, abuse, and dependence and panic attacks in a representative sample. Behaviour Research and Therapy, 44, 907–924. Zvolensky, M. J., Bernstein, A., Yartz, A. R., McLeish, A., & Feldner, M. T. (in press). Cognitive-behavioral treatment of comorbid panic psychopathology and tobacco use and dependence. In S. H. Stewart & P. Conrad (Eds.), Comorbidity of anxiety and substance use disorders. New York: Springer. Zvolensky, M. J., Bonn-Miller, M. O., Bernstein, A., & Marshall, E. C. (2006). Anxiety sensitivity and abstinence duration to smoking. Journal of Mental Health, 15, 659–670. Zvolensky, M. J., Eifert, G. H., Feldner, M. T., & Leen-Feldner, E. W. (2003). Heart-focused anxiety and chest pain in post-angiography medical patients. Journal of Behavioral Medicine, 26, 197–209. Zvolensky, M. J., Feldner, M. T., Eifert, G. H., & Brown, R. A. (2001). Affective style among smokers: Understanding anxiety sensitivity, emotional reactivity, and distress tolerance using biological challenge. Addictive Behaviors, 26, 901–915. Zvolensky, M. J., Feldner, M. T., Leen-Feldner, E. W., Bonn-Miller, M. O., McLeish, A. C., & Gregor, K. (2004). Evaluating the role of anxiety sensitivity in smoking outcome expectancies among regular smokers. Cognitive Therapy and Research, 28, 473–486. Zvolensky, M. J., Feldner, M.T., Leen-Feldner, E. W., & McLeish, A. C. (2005). Smoking and panic attacks, panic disorder, and agoraphobia: A review of the empirical literature. Clinical Psychology Review, 25, 761–789. Zvolensky, M. J., Forsyth, J. P, Fuse, T., Feldner, M. T., & Leen-Feldner, E. W. (2002). Smoking and non-clinical panic attacks: An initial empirical test of panic-relevant cognitive processes. Cognitive Behaviour Therapy, 31, 170–182.
28
M. J. Zvolensky et al.
Zvolensky, M. J., Kotov, R., Antipova, A. V., & Schmidt, N. B. (2003). Cross cultural evaluation of smokers risk for panic and anxiety pathology: A test in a Russian epidemiological sample. Behaviour Research and Therapy, 41, 1199–1215. Zvolensky, M. J., Kotov, R., Bonn-Miller, M. O., Schmidt, N. B., & Antipova, (in press). Anxiety sensitivity as a moderator of association between smoking status and panic-related processes in a representative sample of adults. Journal of Psychiatric Research. Zvolensky, M. J., Lejuez, C. W., Kahler, C. W., & Brown, R. A. (2004). Panic attack history and smoking cessation: An initial examination. Addictive Behaviors, 29, 825–830. Zvolensky, M. J., Lejuez, C. W., Kahler, C. W., & Brown, R. A. (2003). Integrating an interoceptive exposure-based smoking cessation program into the cognitive-behavioral treatment of panic disorder: Theoretical relevance and clinical demonstration. Cognitive and Behavioral Practice, 10, 348–358. Zvolensky, M. J., Sachs-Ericsson, N., Feldner, M. T., Schmidt, B., & Bowman, C. (2006). Neuroticism moderates the effect of maximum smoking level on lifetime panic disorder: A test using an epidemiologically defined national sample of smokers. Psychiatry Research, 141, 321–332. Zvolensky, M. J., Schmidt, N. B., Antony, M. M., McCabe, R. E., Forsyth, J. P., Feldner, M. T., et al. (2005). Evaluating the role of panic disorder in emotional sensitivity processes involved with smoking. Journal of Anxiety Disorders, 19, 673–686. Zvolensky, M. J., Schmidt, N. B., Bernstein, A., & Keough, M. E. (2006). Risk-factor research and prevention programs for anxiety disorders: A translational framework. Behaviour Research and Therapy, 44, 1219–1239. Zvolensky, M. J., Schmidt, N. B., & McCreary, B. T. (2003). The impact of smoking on panic disorder: An initial investigation of a pathoplastic relationship. Journal of Anxiety Disorders, 17, 447–460. Zvolensky, M. J., Schmidt, N. B., & Stewart, S. H. (2003). Panic disorder and smoking. Clinical Psychology: Science and Practice, 10, 29–51. Zvolensky, M. J., Vujanovic, A. A., Bonn-Miller, M. O., Bernstein, A., Yartz, A. R., Gregor, K. L., et al. (2007). Incremental validity of anxiety sensitivity in terms of motivation to quit, reasons for quitting, and barriers to quitting among community-recruited smokers. Nicotine and Tobacco Research, 9, 965–975.
Alcohol Use and Anxiety Disorders Brigitte C. Sabourin and Sherry H. Stewart
The relationship between anxiety and alcohol use is a topic of great theoretical and practical interest for both scientists interested in the nature and causes of psychopathology and practitioners working with anxious and/or alcohol abusing clients. Although it has been clearly established that anxiety disorders and alcohol use disorders are highly ‘‘comorbid’’ or co-occurring conditions (e.g., see Kushner, Abrams & Borchardt, 2000a for a review), the relationship between the symptoms or behaviors involved in each disorder (e.g., feelings of anxiety and levels of alcohol use) has not been as extensively reviewed. This chapter will review recent empirical evidence linking anxiety and alcohol at both the behavioral and disorder level to determine if similar conclusions can be derived regarding their relationship from data at both of these levels of enquiry. We will first briefly describe epidemiological studies linking anxiety disorders and alcohol use disorders. Then we will examine some of the etiological theories of the relationship between anxiety and alcohol use and their disorders, with a review of the empirical evidence supporting each theory. Next, some specific factors moderating and mediating the relationship between anxiety and alcohol use will be explored, with an emphasis on individual differences and specific processes involved in the relationship. A brief discussion of the differences between factors affecting onset, maintenance, and relapse in the anxiety and alcohol relationship will follow. The latest empirical evidence and thoughts about treating both alcohol use and anxiety related problems will also be reviewed. Finally, we conclude the chapter with some remarks about where the field stands and directions that future research in this area might profitably take.
Brigitte C. Sabourin Department of Psychology, Life Sciences Center, Dalhousie University, Halifax, Nova Scotia, Canada, B3H 4J1, Tel: +902 494 3793, Fax: +902 494 6585
[email protected]
M. J. Zvolensky, J. A. Smits (eds.), Anxiety in Health Behaviors and Physical Illness. Ó Springer 2007
29
30
B. C. Sabourin, S. H. Stewart
Symptomatic and Syndromal Levels of Enquiry in the Anxiety – Alcohol Relationship Anxiety and alcohol use can both be characterized at two different levels: symptomatic and syndromal. An association at the former level would entail a clear relationship, for example, between feelings of anxiety and drinking behavior. That is, one would expect that higher levels of anxiety would be related to higher quantities and/or frequency of drinking behavior. In a classic paper, Persons (1986) describes the advantages of studying psychological phenomena at the symptomatic level rather than at the diagnostic category (or syndromal) level. The symptom approach allows for study of important phenomena that may be ignored by examining only the diagnostic category in question. For example, level of alcohol consumption is not considered in the diagnosis of alcohol abuse or dependence according to the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; American Psychiatric Association [APA], 1994), although there have been some recommendations for incorporating heavy drinking behaviors in the diagnostic definitions in future editions (Helzer, Bucholz, & Bierut, 2006). Nonetheless, level of consumption may be an important risk factor for alcohol problems (Dawson & Archer, 1993) and thus may be of interest as a ‘‘symptom’’ when considering the anxiety – alcohol relation from the symptom perspective. Also, the symptom approach recognizes the continuity of clinical phenomena and behaviors with normal phenomena and behaviors. This is a crucial point in the study of both drinking behavior and anxiety. For example, some argue that drinking problems are best viewed as lying on a continuum ranging from normal, non-problematic social drinking on one end to severe and pathological alcohol dependence on the other extreme (Sobell et al., 1996). In addition to the arguments presented above in favor of focusing on symptoms rather than diagnostic categories, Chilcoat and Breslau’s (1998) discussion of criteria for establishing causation between anxiety and alcohol abuse also demands a symptom-focused approach rather than a syndromal- focused approach. According to Chilcoat and Breslau, one of the criteria for causation includes a ‘‘gradient of effect’’, or dose response relationship between the two phenomena of interest. That is, as the level of exposure to the causal agent increases, a resulting increase in the level of the causal outcome should be expected. The gradient of effect relationship can be studied as it pertains to the relation of any anxiety-related symptom (e.g., number of panic attacks; severity of cognitive re-experiencing) with any alcohol-related symptom (e.g., severity of negative consequences resulting from alcohol use; usual number of alcohol beverages consumed per week). The relationship between anxiety and alcohol can also be considered at the syndromal level. At this level, a relationship between alcohol and anxiety would be demonstrated if a diagnosis of one of the two disorders (i.e., anxiety disorder or alcohol use disorder) was associated with an increased likelihood of a diagnosis of the other disorder. The DSM IV (APA, 1994) distinguishes between two distinct types of alcohol use disorders: alcohol abuse and alcohol dependence.
Alcohol and Anxiety
31
Alcohol abuse is characterized by ‘‘recurrent and significant adverse consequences related to the repeated use of alcohol’’ (p. 198), whereas alcohol dependence must include ‘‘evidence of tolerance, withdrawal, or compulsive behavior related to alcohol use’’ (p.214). Alcohol dependence is considered more severe than alcohol abuse and always overrides the latter diagnosis. As was mentioned earlier, consumption levels are not considered in the diagnosis of either alcohol abuse or dependence. On the other hand, for anxiety disorders, both symptom levels (e.g., repeated panic attacks in the case of panic disorder) and/or negative consequences of the symptoms (e.g., distress about having another panic attack in the case of panic disorder) are considered in making a diagnosis.
Epidemiological Findings on the Anxiety – Alcohol Relationship The relationship between anxiety and alcohol can be described using the concept of comorbidity, which can be defined as diagnosable, problematic alcohol use and anxiety symptoms that are both present at some point in a person’s lifetime, but not necessarily at the same time (Kushner et al., 2000a). Comorbidity rates can be estimated using either clinical or community samples. Because individuals with more than one disorder are more likely to seek treatment, clinical samples may in fact inflate comorbidity estimates (Berkson, 1949). It is believed that community surveys provide more accurate reflections of the anxiety disorder – alcohol use disorder relationship. We will review the two most recent large-scale community surveys, which are representative of the results of these types of surveys. In this chapter, we will present odds ratios (ORs) to quantify the comorbid relationship between anxiety disorders and alcohol use disorders. An OR reflects the odds that individuals will display a second disorder if a first disorder is present versus if it is not present. An OR of 1.0 reflects a lack of relationship, with higher ORs reflecting more significant relationships between two disorders. ORs of less than 1.0 reflect a decreased probability of having the second disorder given the presence of the first disorder. The National Comorbidity Survey (NCS: e.g., Kessler et al., 1996) reported 12-month ORs for individuals with alcohol dependence and alcohol abuse of also having suffered from panic disorder (1.7 and 0.5 respectively), social phobia (2.8 and 2.3), generalized anxiety disorder (4.6 and 0.4), posttraumatic stress disorder (2.2 and 1.5), and specific phobias (2.2 and 1.2). The 12-month ORs associated with alcohol dependence are significant for all anxiety disorders with the exception of panic disorder (although the lifetime OR of alcohol dependence is significant for panic disorder). On the other hand, although having any anxiety disorder leads to a significant OR of developing alcohol abuse, the only specific anxiety disorder with a significant OR is social phobia. More recently, the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC; e.g., Grant et al., 2004) reported 12-month ORs for individuals with alcohol dependence and abuse to also display any anxiety
32
B. C. Sabourin, S. H. Stewart
disorder (2.6 and 1.1, respectively), panic disorder with agoraphobia (3.6 and 1.4) and without agoraphobia (3.4 and 0.8), social phobia (2.5 and 0.9), a specific phobia (2.2 and 1.1), and generalized anxiety disorder (3.1 and 0.9).1 The NCS (Kessler et al., 1997) also examined sex differences in comorbidity between alcohol use disorders and anxiety disorders. Anxiety disordered women and men do not differ significantly in their risk of developing alcohol dependence; however, women with social phobia, simple phobias or post traumatic stress disorder hive higher ORs of abusing alcohol than men with these anxiety disorders. Similarly, the NESARC (Smith et al., 2006) reported ORs of alcohol use disorders and anxiety disorders by race/ethnicity. Across all races/ethnic groups, there were significant ORs of any anxiety disorder with alcohol dependence but not with alcohol abuse. However, the pattern of comorbidity across specific anxiety disorders reveals significant racial/ethnic effects. For Whites and Blacks, the ORs for alcohol dependence and anxiety disorders were significant across almost all anxiety disorders. The only exception was that the OR for panic disorder with agoraphobia was significant for alcohol abuse but not for alcohol dependence among Blacks. On the other hand, for Native Americans and Hispanics, only a few of the anxiety disorders were significantly associated with alcohol dependence and none with alcohol abuse. Two general conclusions can be made from the data reported across these large-scale community surveys. First, the relationship between anxiety disorders and alcohol dependence appears to be much stronger than between anxiety disorders and alcohol abuse, with the ORs for dependence much more likely to be significant than those for abuse. In other words, having a comorbid anxiety disorder increases the chances of displaying the more severe type of alcohol use disorder (dependence) moreso than the less severe type (abuse), suggesting a gradient of effect relationship. . Second, the relationship between alcohol use disorders and anxiety disorders differs between sexes and racial/ethnic groups. Although alcohol use is generally more common among men than women (Paavola, Vartiainen, & Haukkala, 2004), alcohol abuse and anxiety disorders are more closely related for women than for men. Furthermore, it appears that for Whites and Blacks, anxiety and alcohol dependence are more closely associated than for Native Americans and Hispanics. The following sections cover etiological models of the relationship between alcohol and anxiety, their maintenance, and their relapse, in an attempt to explicate the high level of comorbidity between anxiety disorders and alcohol use disorders observed in the epidemiologic surveys.
Etiological Models of the Relationship In order to gain a better understanding of the relationship between anxiety and alcohol use, it is important to explore the mechanisms that may affect the etiology of the co-occurrence of symptoms of both of their disorders. There 1
The NESARC did not specify significance of reported 12-month ORs.
Alcohol and Anxiety
33
are three main hypotheses that have been put forward, with some evidence supporting each hypothesis. First, there is some evidence that the associations between anxiety and alcohol arise from common underlying variables, such as common genetic or environmental factors, that cause both anxiety symptoms and problematic alcohol use. Second, some believe that certain aspects of problematic alcohol use, such as repeated experiences with alcohol withdrawal, cause anxiety symptoms and ultimately an anxiety disorder. Finally, others argue that anxiety symptoms cause alcohol misuse, culminating in an alcohol use disorder. Evidence examining these three hypotheses is presented below.
Common Underlying Variables There is some evidence, provided by two main lines of research, to support the hypothesis that certain common, underlying factors are causing both anxiety symptoms and problematic alcohol use (Kushner et al., 2000a). First, family and twin studies have provided some evidence of possible common genetic contributions to the correlation between anxiety symptoms and alcohol consumption (e.g., Tambs, Harris, & Magnus, 1997). Family and twin studies have also examined the heritability of common underlying personality traits associated with both anxiety and alcohol use disorders. For example, several crosssectional and longitudinal studies have linked the highly heritable personality trait of neuroticism (Jang, Livesley, & Vernon, 1996) with anxiety and its disorders (e.g., Jorm et al., 2000; Weinstock & Whisman, 2006). Neuroticism has also been linked to alcohol use disorders (Cox, 1987). Another personality dimension that is closely related to neuroticism, negative emotionality, has been associated with alcohol use disorders (Swendsen, Conway, Rounsaville, & Merikangas, 2002). In a study by Swendsen et al. (2002) examining heritability of negative emotionality, non-alcoholic individuals with alcoholic relatives did not differ significantly on scores of negative emotionality than those without alcoholic relatives. If negative emotionality were a heritable risk factor, nonalcoholic individuals with alcoholic relatives would score higher on this trait than those without alcoholic relatives. These findings suggest that negative emotionality may indeed be an individual risk factor rather than a heritable risk factor for alcohol use disorders. The inconsistent results between these two related personality traits (i.e. both associated with negative emotional states) demonstrates that common heritability for some of the personality traits relevant to the anxiety – alcohol relationship is still in need of further investigation. Conversely, another personality risk factor for both anxiety disorders and alcohol use disorders, anxiety sensitivity (i.e. fear of anxiety; Stewart & Kushner, 2001), does have a strong heritable component that accounts for nearly half of the variance in scores on anxiety sensitivity measures (Stein, Lang, & Livesley, 1999). Therefore, it appears that some, but not necessarily all, underlying personality risk factors associated with both alcohol use disorders and anxiety disorders have a shared heritable component.
34
B. C. Sabourin, S. H. Stewart
Second, results from some prospective studies suggest a possible common ‘‘third variable’’ contribution to the alcohol – anxiety relationship. For example, Zimmerman et al. (2003) found that remitted panic disorder and social phobia were as important as current panic/social phobia diagnoses in predicting future alcohol outcomes. That is, even individuals who were not currently experiencing sufficient symptoms to receive any anxiety disorder diagnosis were at higher risk of developing alcohol problems if they had ever been diagnosed with either panic or social phobia in the past. These findings can be interpreted to suggest that a third underlying factor (such as a common personality vulnerability or genetic predisposition) was driving both the alcohol problem and the past or current anxiety disorder. A 21-year longitudinal study (Goodwin, Fergusson, & Horwood, 2004) found that once other factors were controlled (i.e., prior substance dependence, concurrent major depression, and affiliations with deviant peers), the ability of anxiety disorders to predict the development of alcohol dependence was no longer significant. The study points to a number of possible third variables including prior substance dependence which could contribute both to the development of anxiety disorder (see Norton, Norton, Cox, & Belik, in press) and of alcohol dependence (e.g., alcohol is consumed in larger quantities when combined with other substances; Barrett, Darredeau, & Pihl, 2006). Unfortunately the study did not test which of these factors was most important in explaining the link between anxiety and alcohol dependence. Some factors that have emerged as possible contributors to the increased vulnerability of developing comorbid anxiety and alcohol use problems include either common genetic pre-dispositions (e.g., anxiety sensitivity), biological environment risk factors (e.g., fetal alcohol syndrome), or non-biological environmental risk factors (e.g., disruptive familial environment; Merikangas, Stevens, & Fenton, 1996). Unfortunately, no research has yet confirmed one or more of these candidate factors. More research needs to be conducted exploring these additional underlying mechanisms before one can make conclusions about their influence.
Alcohol Use Causes Anxiety The second hypothesis dealing with the relationship between anxiety and alcohol use posits that prolonged drinking is actually a causal factor in anxiety symptoms and disorders. This alcohol-induced anxiety can occur through either psychosocial or physiological mechanisms. Psychosocially, it is hypothesized that alcohol may interfere with normal adaptation to stressful stimuli or that negative consequences produced by problematic drinking (e.g., loss of job or relational problems) can lead to anxiety symptoms and increased vulnerability of developing anxiety disorders (Kushner et al., 2000a). Physiologically, alcohol withdrawal can often produce anxiety symptoms such as shakiness (see Kushner et al., 2000a) or increased startle, a common symptom of PTSD (Stewart et al., 1998). In addition, neural adaptation occurs
Alcohol and Anxiety
35
with frequent and excessive alcohol use over time such that repeated alcohol withdrawals actually sensitize this withdrawal-induced anxiety (Breese, Overstreet, & Knapp, 2005). This has often been referred to as the ‘‘kindling-stress hypothesis’’; that is, repeated withdrawals from chronic heavy drinking are thought to worsen, or ‘‘kindle’’ withdrawal-induced anxiety. A number of studies have also demonstrated increased norepinephrine activity as well as hyperexcitability of the central nervous system, especially of limbic structures, during alcohol withdrawal (Kushner et al., 2000a; Marshall, 1997). These are the same neural systems that have been implicated in panic attacks and panic disorder, providing a possible physiological explanation for the link between panic disorder and alcohol use disorders (Marshall, 1997). A final area of research supporting the hypothesis that alcohol problems cause anxiety involves prospective studies. One such study by Kushner, Sher, and Erickson (1999), for example, found that a diagnosis of alcohol dependence at baseline quadrupled the risk of developing an anxiety disorder three to six years later. Prospective studies have also examined the relationship between PTSD and alcohol abuse to ascertain whether heavy alcohol use can be a risk factor for developing PTSD. It has been hypothesized that physiological and neurochemical changes due to prolonged heavy alcohol use and/or past reliance on alcohol to deal with life stressors at the expense of developing other coping mechanisms may increase an individual’s susceptibility of developing PTSD after a traumatic experience (Brown & Wolfe, 1994; Stewart et al., 1998). A prospective study by Acierno, Resnick, Kilpatrick, Saunders, and Best (1999) found that a history of alcohol abuse increased the risk of developing PTSD in rape victims almost three-fold (OR = 2.65) when compared to the absence of this factor.
Anxiety Causes Alcohol Use It has been hypothesized that anxiety symptoms and anxiety disorders promote alcohol use, as individuals drink to self-medicate their anxiety. The ‘‘self-medication hypothesis’’ (and the related tension reduction hypothesis) as applied to the understanding of the relationship between anxiety and alcohol posits that the pharmacological and/or psychological effects of alcohol lead to decreases in aversive anxiety symptoms, thereby motivating anxious individuals to increase their quantity and/or frequency of alcohol use via the process of negative reinforcement (Kushner et al., 2000a). Although the self-medication and tension reduction hypotheses clearly do not account for all drinking behavior (Greeley & Oei, 1999), there has been a good deal of empirical evidence to support these hypotheses as they apply to the understanding of comorbid anxiety and alcohol use disorders (Kushner et al., 2000a). Anxiety disordered individuals do in fact self-report using alcohol to manage their anxiety (Kushner, Abrams, Thuras, & Hanson, 2000b; Thomas, Randall,
36
B. C. Sabourin, S. H. Stewart
& Carrigan, 2003; see also Kushner, et al., 2000a for a review). In addition, Thomas and colleagues (2003) found that socially anxious individuals not only reported that they drank to feel more comfortable in social situations, but that they would actually avoid social situations if alcohol were unavailable. As introduced earlier in this chapter, one possible criterion for establishing causation (Chilcoat & Breslau, 1998) is a dose response, or gradient of effect relationship: if anxiety causes alcohol use, one would expect that higher levels of anxiety would be associated with higher levels of alcohol use. Studies have found positive correlations between severity of PTSD arousal symptoms and severity of alcohol use disorder symptoms (McFall, Mackay, & Donovan, 1992; Stewart et al., 1998). Because correlation does not determine causation, one must rely on laboratory-based studies, such as a study by Abrams, Kushner, Medina, and Voight (2002), for evidence that induction of anxiety symptoms causes heavier drinking. The study found that participants with social phobia consumed more alcohol following an anxiety provoking activity (speaking in front of a group) than a control activity (reading a book), presumably in an effort to dampen the anxious feelings caused by the anxiety provoking activity. Prospective research on non-clinical populations also supports a doseresponse relationship between anxiety and alcohol use. In a diary-based study by Swendsen and colleagues (2000), moderate drinkers documented their daily drinking and mood states for a one-month period. The study revealed that only anxious feelings and not sadness or other negative affective states preceded and predicted increased alcohol consumption. As can be observed above, findings from correlational, laboratory-based experimental, and diary-based prospective research conducted with both clinical and non-clinical populations converge to provide some evidence for a relationship between anxiety symptoms and alcohol use where anxiety precedes and contributes to increased alcohol use. Social anxiety appears to have a more complicated relationship with alcohol use than do other types of anxiety, however. Specifically, some studies examining the relationship between social anxiety and alcohol consumption show a positive relationship, whereas other studies show either no linear relationship or even a negative relationship (Ham & Hope, 2005; Stewart, Morris, Mellings, & Komar, 2006; Tran, Haaga, & Chambless, 1997). The negative relationship between social anxiety and alcohol consumption may exist because socially anxious individuals actually avoid the types of social situations that involve drinking because of their social anxiety, thus leading to lower levels of alcohol consumption (Stewart et al., 2006). Nonetheless, social anxiety has been found to predict alcohol dependence, as well as problems caused by alcohol (Gilles, Turk, & Fresco, 2006; Stewart et al., 2006). Thus, social anxiety does appear related to alcohol-related consequences, even if it does not always predict increased alcohol use. Another criterion discussed by Chilcoat and Breslau (1998) as necessary for causation is temporality. If anxiety causes increased or problematic alcohol use, then anxiety symptoms should predate alcohol-related problems, and anxiety
Alcohol and Anxiety
37
disorder diagnoses should precede alcohol disorder diagnoses. In the cases of social phobia, panic disorder, and PTSD diagnoses, the anxiety disorder usually preceded the onset of the alcohol use disorder in comorbid individuals (Cox, Norton, Swinson, & Endler, 1990; Kushner, Sher, & Beitman, 1990; Stewart & Conrod, 2002).Furthermore, a cross-national investigation by Merikangas et al. (1998) confirmed that anxiety disorders preceded alcohol use disorders for the majority of participants. Assessing temporality or relative order of onset of symptoms of alcohol use disorders and anxiety disorders among comorbid cases can also help elucidate the anxiety – alcohol causal relationship. For example, a recent study by Bernstein, Zvolensky, Sachs-Ericsson, Schmidt, and Bonn-Miller (2006) found that the symptom of panic attacks predated the onset of heavy drinking behaviors for the vast majority of participants with both panic attacks and heavy drinking in a community sample. Although many anxiety disorders and their symptoms predate alcohol use disorders and heavy drinking, this relationship is normally inverse for individuals with generalized anxiety disorder (GAD). For the majority of individuals with GAD, alcohol use disorder predated the GAD (Kushner et al., 1990), suggesting that, for those cases, anxiety could not have been the cause of the alcohol use disorder. Thus, as can be seen from the findings above, for most comorbid individuals (excluding a majority of GAD individuals), the order of onset supports the possibility that anxiety may play a causal role in the development of alcohol use disorders. And conversely, for those with GAD, the alcohol use may play a causal role in the development of the anxiety disorder. However, Chilcoat and Breslau (1998) clarify that the temporality criterion is necessary but not sufficient for determining a causal association between disorders. Finally, the prospective study by Kushner and colleagues (1999) mentioned earlier in the chapter that found an increased risk of future anxiety disorders for individuals with alcohol dependence also found the converse. That is, having a diagnosis of anxiety at baseline increased the risk three- to five-fold for a new onset of alcohol dependence three to six years later (see also Goodwin et al., 2004). The study demonstrates that the causal relationship between anxiety and alcohol is potentially bi-directional in nature. Overall, the evidence presented above does seem to support the fact that, at least in some instances, anxiety symptoms and anxiety disorders do precede and possibly promote problematic alcohol use.
Moderating and Mediating Variables in the Anxiety – Alcohol Relationship More recent work has focused on finding specific variables that either moderate or mediate the causal relationship between anxiety and alcohol use. A moderator variable is a qualitative (e.g., sex) or quantitative (e.g., anxiety level) variable that affects the direction and/or strength of the relation between two
38
B. C. Sabourin, S. H. Stewart
other variables (Baron & Kenny, 1986). A mediator variable, on the other hand, explains how or why the relationship between a predictor and given criterion (e.g., between anxiety and alcohol use) exists. That is, the mediator actually accounts for the relationship between the two variables (Baron & Kenny). Alcohol expectancies. A potential moderator variable between anxiety and problematic alcohol use includes certain ‘‘alcohol outcome expectancies’’ (i.e., beliefs about the consequences of drinking alcohol). For anxious individuals who self-medicate to avoid anxiety, an important aspect of the self-medication hypothesis involves the notion that self-medicators anticipate anxiety, and that they expect that alcohol will actually decrease their feelings of anxiety (e.g., Kushner, Sher, Wood, & Wood, 1994; Tran et al., 1997). Studies have shown that tension reduction expectancies predict drinking frequency and quantity in non-alcoholic drinkers with panic disorder (Kushner et al., 2000b) and comorbid problem drinking in women with PTSD (Ullman, Filipas, & Townswend, 2005). These results support the role of tension reduction alcohol expectancies as a moderator: increased or problematic drinking occurs among anxiety disorder patients only when tension reduction alcohol expectancies are present. Another methodology that has been employed to investigate the role of alcohol outcome expectancies in the anxiety – alcohol relationship is the experimental manipulation of expectancies via the placebo-controlled design. If expecting alcohol were to induce a cognitive or placebo-induced anxiety reducing effect among anxious individuals, such an effect would provide additional evidence for the contribution of alcohol expectancies in explaining the anxiety – alcohol relationship. The empirical evidence provided thus far has found mixed results for this placebo anxiolytic effect. Some studies have found that the belief that one was consuming alcohol, even when one was actually consuming a placebo, was enough to lower feelings of anxiety among anxiety-disordered patients (Abrams, Kushner, Lisdahl, Medina, & Voight, 2001; Lehman, Brown, Palfai, & Barlow 2002). On the other hand, research by MacDonald, Stewart, Hutson, Rhyno, and Loughlin (2001) conducted with participants high in anxiety sensitivity did not support a cognitively-mediated tension reduction effect of alcohol. The researchers actually found a ‘‘reverse placebo’’ effect, where high AS participants in a placebo condition, who had expectations of alcohol-induced tension reduction, but did not benefit from alcohol’s physiological tension-reduction properties, appeared to have even higher levels of anxiety than participants in a control condition where they neither received nor expected alcohol. Regardless of the direction of the placebo effect, all of these findings do suggest a role for cognitive expectancy variables in accounting for the effects of alcohol among anxious individuals. A number of studies have examined specific aspects of alcohol expectancies in individuals with social anxiety. For people high in social anxiety, expecting that alcohol would decrease social anxiety or increase social assertiveness was associated with both higher self-reported drinking quantities (Tran et al., 1997) and higher alcohol consumption in a laboratory setting (Kidorf & Lang, 1999). More general tension reduction expectancies, on the other hand, had no effect
Alcohol and Anxiety
39
on alcohol consumption. In addition, socially related alcohol expectancies have been associated with higher levels of alcohol dependence in socially anxious individuals (Ham, Carrigan, Moak, & Randall, 2005). These studies demonstrate that different expectancies affect alcohol consumption depending on the particular type of anxiety-related psychopathology involved. For individuals with panic disorder or PTSD, the research until now appears to indicate that general tension reduction expectancies provide sufficient motivation for increasing alcohol consumption. However, for individuals with social anxiety, it appears that specific social-related alcohol expectancies, but not general tension reduction expectancies, tend to motivate these individuals to drink, resulting in greater risk of developing alcohol dependence. As has been done with social anxiety, increasingly directed research in other types of anxiety-related psychopathology is needed to determine more precisely the kinds of expectancies that help explain each group’s increased risk for alcohol problems in order to target these more specifically in treatment. Self-efficacy. Self-efficacy has been defined by Bandura (1977) as the conviction that one can successfully execute a behavior required to produce a certain outcome. Research conducted with socially anxious individuals suggests that self-efficacy may act as a link between alcohol expectancies, social anxiety and heavy drinking behaviors. Positive socially related alcohol expectancies and low self-efficacy to avoid heavy drinking interact with one another in increasing problematic drinking among socially anxious individuals (Burke & Stephens, 1997; Gilles, Turk, & Fresco, 2006). Thus, increasing individuals’ self-efficacy in refusing alcohol or avoiding heavy drinking could be incorporated when developing treatment programs for comorbid individuals, at least in the case of social phobia comorbidity. More research is needed to determine the relevance of the self-efficacy construct to the comorbidity of alcohol use disorders with anxiety disorders other than social phobia. Drinking motives. Problematic drinking can arise because of maladaptive drinking motives (reasons for drinking) even in the absence of particularly elevated levels of alcohol consumption (Stewart et al., 2006). For some individuals who experience fear or anxiety, avoidance behaviors, such as drinking to self-medicate, become negative reinforcement strategies used to attenuate or cope with anxious states. Because such avoidance strategies are negatively reinforcing through their effects in alleviating anxiety, the drinking behavior continues over time and the individual comes to rely on drinking as a primary coping strategy. For example, in many cases, social anxiety is not associated with higher drinking levels (Tran et al., 1997), but it is with problematic reasons for drinking, such as drinking to cope with negative emotional states, as well as with greater risks of developing alcohol problems (Thomas, Randall, & Carrigan, 2003; Stewart et al., 2006). A further problem with coping-related drinking is that, as an avoidance behavior, it may serve to maintain anxiety by preventing habituation of the anxiety response. Research by Cooper (1994; see also Cooper, Russell, Skinner, & Windle, 1992) exploring drinking motives and their relation to problematic drinking
40
B. C. Sabourin, S. H. Stewart
uncovered four factors explaining motivation for drinking. Two of these motives involve positive reinforcement from drinking: social (i.e. to obtain social rewards) and enhancement (i.e. to enhance positive mood or well being), whereas the other two motives involve negative reinforcement from drinking: coping (i.e. to cope with negative emotions), and conformity (i.e. to avoid negative social consequences such as social rejection). Only the negative reinforcement motives of coping and conformity predict alcohol problems after controlling for quantity and frequency of alcohol use. A study by Stewart and colleagues (2006) also found that for undergraduate students, problem-drinking symptoms were positively associated with the negative reinforcement motives of coping and conformity drinking. The study also found that coping and conformity drinking motives mediated the relationship between social anxiety (specifically, fear of negative evaluation) and drinking problems. That is, individuals with social anxiety experienced drinking problems because they drank either to cope with negative emotions (i.e. coping drinking motives), or to avoid negative social consequences (i.e. conformity drinking motives). In addition, the study found either no association or even a negative direction association between social anxiety measures and drinking quantity and frequency. Together, research by Cooper and her colleagues and Stewart and her colleagues support the notion that drinking to cope with anxiety or to conform with peer pressure confers additional risk for problem drinking over and above the risks associated with level of alcohol consumption. Additional support for coping and conformity drinking motives as important factors in the anxiety – alcohol relationship has been provided by studies conducted with non-clinically anxious participants. For example, Deacon and Valentiner (2000) found a significant association between scores on the Beck Anxiety Inventory (BAI, a widely-used measure of anxiety symptoms) and coping motivated drinking but not social or enhancement motivated drinking. In addition, Thomas et al. (2003) found that socially anxious individuals more often reported drinking before and during social situations in an effort to feel more comfortable (i.e. to cope with their social anxiety) than non-socially anxious individuals. Anxiety sensitivity has been associated with greater drinking levels and argued to be a potential risk factor for alcohol use disorders (Stewart & Kushner, 2001), as we describe in greater detail in the next section. Results from a study by Stewart et al. (2001) supported coping and conformity motives as mediators in the relationship between AS and higher drinking levels. That is, high AS individuals’ greater drinking behavior was at least partially explained by high coping and conformity motive scores. Anxiety sensitivity. Anxiety sensitivity (AS) is an important individual difference that may mediate the anxiety – alcohol relationship. It is possible that anxiety disordered patients are at increased risk of alcohol problems because of their higher levels of AS (i.e., higher levels of fear of anxiety), which, in turn, promote greater motivation and behaviors (e.g., alcohol use) to escape or avoid the feared symptoms (Stewart & Kushner, 2001). Thus, consistent with the
Alcohol and Anxiety
41
self-medication hypothesis, it is possible that individuals high in AS use alcohol for its anxiolytic or arousal dampening effects. In fact, high AS individuals have been found to prefer alcohol and other ‘‘depressants’’ over ‘‘stimulant’’ type drugs (DeHaas, Calamari, & Bair, 2002; Norton, Rockman, & Ediger, 1997). Additionally, elevated levels of AS have been associated with increased drinking behavior, including increased typical weekly drinking frequency, and yearly excessive drinking frequency (Stewart, Peterson, & Pihl, 1995; Cox & Klinger, 1988; Stewart, Zvolensky, & Eifert, 2001). Moreover, Stewart, Conrod, Samoluk, Pihl, and Dongier (2000) found evidence for the mediating role of AS in explaining the association between PTSD symptoms and negative reinforcement drinking. Stewart et al. (2001) also examined the relationship between lower-order components of AS and drinking behavior. AS consists of three lower-order factors: AS physical concerns (e.g., worrying that a rapidly beating heart is a sign of having a heart attack), AS psychological concerns (e.g., worrying that not being able to keep one’s mind on a task is a sign of going crazy), and AS social concerns (e.g., worrying about appearing nervous in front of others; see Zinbarg, Mohlman, & Hong, 1999). After controlling for the other two factors, AS social concerns emerged as the only significant predictor for weekly drinking frequency and yearly excessive drinking frequency. Thus, it is possible that AS also plays an important role in the relationship between social anxiety and drinking problems given the elevation of AS social concerns among those with social phobia (Zinbarg et al., 1999). Summary. Although these mediating and moderating variables are typically studied in isolation, as can be seen above, alcohol expectancies, self-efficacy, drinking motives, and anxiety sensitivity may interact with each other or intervene with one another in explaining problematic alcohol use in anxious individuals. For example, people with certain anxiety disorders may be more likely to drink to cope with their anxiety sensations (coping motives) because of their fear of these sensations (anxiety sensitivity), thereby increasing their risk for drinking problems. Additional research exploring the interplay between the different variables affecting the anxiety-alcohol relationship would provide important steps toward creating more effective treatments for comorbid individuals.
Anxiety, Alcohol Use, and Other Health Behaviors Alcohol consumption has been shown to be highly related to risky health behaviors, such as smoking and illicit drug use (Paavola, Vartiainen, & Haukkala, 2004; Tolstrup et al., 2005). In a longitudinal study (Paavola et al., 2004), earlier alcohol use was associated with later smoking, and smoking in adolescence predicted alcohol use in adulthood. Despite this close association between alcohol use and smoking, combining the two behaviors does not
42
B. C. Sabourin, S. H. Stewart
increase the rate of anxiety disorders above the rate associated with alcohol use only (Kandel, Huang, & Davies, 2001). A diagnosis of an anxiety disorder combined with a drug use disorder constitutes a significant risk factor for developing alcohol dependence (lifetime OR =5.81; Kessler et al., 1997). This increased risk appears to be even higher than the risk associated with being diagnosed with an anxiety disorder alone (i.e. without a drug use disorder; lifetime OR = 1.85). Unfortunately, like many epidemiological surveys, the National Comorbidity Survey does not break drug use disorders down by drug type/class, which could further elucidate the drug – anxiety – alcohol relationship. One possible explanation for this elevated risk for alcohol dependence among those with comorbid anxiety – drug use disorders is that problematic drug use, through the drugs’ potentially anxiogenic effects, exacerbates the need to self-medicate with alcohol, resulting in increased risk for alcohol dependence relative to those with non-comorbid anxiety disorders.
Maintenance of Comorbid Anxiety and Alcohol Problems Empirical findings supporting all three causal hypotheses suggest the possibility of multiple causal pathways involved in the etiology of comorbid alcohol use disorders and anxiety disorders. The specific causal pathway involved may vary across people or across anxiety sub-types. Regardless of the etiology of the comorbid anxiety symptoms and problematic alcohol use, there have been countless studies confirming that, once comorbid, anxiety and alcohol use do, in fact, exert important influences on each other (see Kushner et al., 2000a). Furthermore, processes involved in the initiation of the comorbidity may differ from those involved in the maintenance of problematic alcohol use and anxiety. A feed-forward model has been proposed (Kushner et al., 2000a) in which once both alcohol use and anxiety are present, each promotes the maintenance or exacerbation of the other. For example, anxious individuals may resort to alcohol to decrease feelings of anxiety, which might be an effective strategy in the short term, providing reinforcement for this pattern. However, alcohol, and especially withdrawal from alcohol, increases anxiety-like symptoms in the longer run via physiological mechanisms such as kindling. Alcohol may also worsen anxiety levels because of the negative familial, social or occupational consequences of heavy drinking. Individuals will then increase their drinking behavior in an attempt to alleviate these worsening feelings of anxiety because drinking has become a learned strategy for dealing with these symptoms, especially if there is a failure to recognize that the alcohol may actually be promoting the anxiety in the medium to long term. Finally, in individuals with PTSD, alcohol that is used to cope with anxiety may prevent normal ‘‘habituation’’ of the anxiety symptoms following trauma exposure. On the other hand, for individuals who are not drinking, anxious
Alcohol and Anxiety
43
feelings caused by PTSD may naturally remit with time. Thus, when individuals drink in an attempt to numb or avoid these feelings, they may be preventing this natural recovery from taking place, leading to maintenance of the anxiety symptoms in the long run (Stewart et al., 1998).
Treatment Outcome and Relapse When individuals who suffer from both anxiety disorders and alcohol use disorders enter treatment for either disorder, their treatment outcome is often negatively affected by their comorbidity. Alcohol use disorders have been found to predict poorer anxiety disorder treatment outcomes for patients with both PTSD (Forbes, Creamer, Hawthorne, Allen, & McHugh, 2003), panic disorder with agoraphobia, social phobia, and generalized anxiety disorder (Bruce et al., 2005). Comorbid anxiety problems also increase the likelihood of relapse in treated or abstinent alcoholics (e.g., Driessen et al., 2001; Kushner et al., 2005; Willinger et al., 2002). For example, if a comorbid PTSD – alcoholic individual does not know how to cope with flashbacks and nightmares of the traumatic event in ways other than through drinking, then continued reexperiencing symptoms can serve as a major risk factor for return to problem alcohol use following initially effective alcohol abuse treatment. Not all studies have shown this relationship, however. In one study (LaBounty, Hatsukami, Morgan, & Nelson, 1992), alcoholics with comorbid panic disorder did not differ in their rates of relapse to drinking problems from non comorbid alcoholics. However, in a recent review, Bradizza et al. (2006) noted some methodological issues with this paper, including the absence of a valid and reliable diagnostic measure and the failure to define relapse, limiting the conclusions that could be drawn from the study. Moreover, despite the similar relapse rates, the study did find that more comorbid alcoholic and panic disordered patients reported relapsing to cope with negative emotions than non comorbid alcoholics. Thus, these observed differences in the relapse process might be useful for improving treatments for this group. Another study compared relapse rates for alcoholic individuals with comorbid social phobia, or panic disorder with agoraphobia, or agoraphobia without a history of panic attacks to relapse rates for alcoholics without any comorbid anxiety disorder (individuals with other anxiety disorders were excluded) following treatment for alcoholism (Marquenie et al., 2006). The results suggested that the comorbid anxiety disorders did not have a significant impact on either relapse rates or days to relapse. Nonetheless, some methodological problems may account for this study’s failure to support higher alcoholism relapse among treated alcoholic patients with comorbid anxiety disorders. First, the study used a retrospective design. Participants were contacted for the study an average of 20.3 months (and up to 42 months) after baseline assessment, even though the majority of participants who relapsed did so within the first few months post
44
B. C. Sabourin, S. H. Stewart
baseline, raising issues concerning potential inaccuracy in the self-reports due to retrospective memory bias. Also, compared to the non comorbid group, the comorbid group had less chronic alcoholism and a shorter period between the initial and follow-up assessments, which could have led to underestimates of the rate of relapse in the comorbid group. Although the authors stated the failure to observe group differences in alcoholism relapse persisted when these group differences were statistically controlled in the analyses, statistical control of possible confounds is never definitive, (and in fact may even produce biased parameter estimates) especially when the confounding variables are correlated with the predictor of interest, again limiting any firm conclusions that can be drawn from the Marquenie et al. study. Several studies, on the other hand, have found higher relapse rates in comorbid patients. Driessen et al. (2001) found that treated alcoholic patients with comorbid anxiety had 29% higher alcoholism relapse rates than did alcoholics without comorbid anxiety. Furthermore, a study examining the relationship between trait anxiety and relapse in a sample of abstinent alcohol dependent patients found that higher trait anxiety was significantly predictive of relapse to uncontrolled drinking (Willinger et al., 2002). Finally, in the bestcontrolled study to date, Kushner et al. (2005) found that alcoholic patients with an anxiety disorder (especially those with comorbid panic disorder or social phobia) were significantly more likely to relapse to problem drinking (using multiple criteria for drinking relapse) than alcoholic patients without an anxiety disorder. These finding are particularly convincing given the methodological soundness of the study. For example, the study used a prospective design where all participants were contacted between 90 and 120 days after the beginning of treatment, thus increasing reporting accuracy by reducing reliance on long-term retrospective memory. Also, all participants were given the same standardized treatment and assessed at a consistent time following treatment. Taken together, it appears that comorbid alcohol and anxiety may have a negative effect on treatment outcome and relapse but with some mixed results. The methodologically superior studies do seem to suggest such a negative effect. In addition, although a couple of studies failed to show differences in relapse rates, one of these negative studies did provide some evidence for the self-medication hypothesis through highlighting the importance of coping with anxiety in explaining relapse to alcohol use among patients with comorbid alcohol and anxiety disorders. These differences could be useful in developing specific relapse prevention types of treatments (see Marlatt & Donovan, 2005) for comorbid patients.
Treatments of Comorbid Anxiety and Alcohol Use Disorders Individuals who suffer from both anxiety problems and alcohol use problems present a special and challenging population with regards to treatment. As was shown above, this population often suffers worse anxiety and alcohol treatment
Alcohol and Anxiety
45
outcomes than populations experiencing symptoms in only one of the two domains. Although the study of specific treatments for anxiety – alcohol comorbidity is still in its infancy, this area is growing and there are now several promising approaches to treating comorbid anxiety and alcohol use disorders (Stewart & Conrod, in press). There have been mixed findings regarding the effects of pharmacological treatment for anxiety on drinking outcomes with some studies finding improvements in alcohol outcomes and others finding more equivocal results (see review by Kushner et al., 2000a). One study (Randall et al., 2001) found that treating individuals with comorbid social phobia and alcohol use disorder with paroxetine (a selective serotonin reuptake inhibitor) did improve anxiety, but did not result in significant decreases in drinking frequency and quantity. Relative to placebo, paroxetine treatment did, on the other hand, lead to improvements on the Clinical Global Index for alcohol. Other studies have found that successful treatment of anxiety with buspirone was also associated with a reduction in alcohol use (Tollefson, Montague-Clouse, & Tollefson, 1992; Kranzler et al., 1994). These mixed findings are partially consistent with the self-medication hypothesis, although the paroxetine study does suggest that there is more to the maintenance of problematic drinking behavior in anxious individuals than just the self-medication process. There have also been mixed findings for the effectiveness of cognitive behavioral therapy (CBT) to improve anxiety and problematic drinking symptoms in comorbid patients. Thevos et al. (2000) found that, for female patients with comorbid social phobia and alcohol use disorders involved in project MATCH (the largest treatment-matching trial to date), CBT treatment for alcohol was more effective in delaying return to drinking than Twelve-Step Facilitation (TSF). It was hypothesized that TSF, which encourages participation in Alcoholics Anonymous (AA), a group-based treatment modality that heavily involves public speaking as patients share their experiences, may be too intimidating for women with social phobia. Subsequently, Randall, Thomas, & Thevos, (2001) examined whether conducting parallel CBT treatments aimed at decreasing social anxiety and at addressing problematic drinking behaviors would have additional benefits for comorbid patients compared to treatment of the alcohol disorder alone. For patients receiving the parallel treatments, the sessions consisted of CBT treatment for alcohol followed immediately by CBT for social anxiety (i.e. the two treatments are offered simultaneously, but independently of each other). Surprisingly, they found that patients who participated in the parallel treatment had worse drinking outcomes, as assessed by drinking quantity and frequency measures, than did patients who participated in the alcohol only treatment. There are several possible explanations for these unexpected findings. It is possible that clients in the parallel treatment group engaged in more social situations as a consequence of their social phobia treatment, resulting in more opportunities to drink. Additional research needs to be conducted that would include other types of outcome measures that are not specifically linked to frequency or quantity of drinking. As was mentioned
46
B. C. Sabourin, S. H. Stewart
earlier in the chapter, coping drinking motives and problematic consequences of drinking are useful therapy targets for comorbid individuals, particularly in the case of social phobia. It is also possible that the lack of integration of the two treatments or the excessive demands of combining two already intensive treatments may have affected results. The parallel treatment did in fact lead to somewhat higher drop out rates than the alcohol treatment alone, suggesting that the parallel treatment may have been too much for comorbid patients to handle (Conrod & Stewart, 2005). On the other hand, another study (Bowen, D’Arcy, Keegan, & Senthilselvan, 2000) found that parallel CBT for panic disorder and standard alcohol treatment in a group of comorbid panic disordered and alcoholic patients did not result in significantly different treatment outcomes than standard alcohol treatment alone. Both treatments resulted in significant decreases in anxiety and in drinking behaviors. The authors noted that the relaxation training and stress management components of the standard alcohol treatment might have limited the ability to distinguish between treatments as these components may have been useful in targeting the comorbid anxiety. A recent randomly-controlled study conducted by Schade and colleagues (2005) compared standard alcohol treatment alone to standard alcohol treatment with anxiety treatment consisting of CBT plus optional fluvoxamine (a selective serotonin re-uptake inhibitor) treatment (again, a parallel approach) in patients with a primary diagnosis of alcohol dependence and a comorbid diagnosis of panic disorder, agoraphobia, or social phobia. There were no differences in alcohol outcome measures between both groups of patients. The additional anxiety treatment did, on the other hand, improve anxiety symptoms. It can be speculated that improved anxiety scores are significant for this population, as decreased anxiety may serve as a protective factor for longer-term outcomes. The study examined outcome results 32 weeks after initial assessment, but did not look at longer- term outcomes (1 year or later) in these patients. Future studies should examine longer-term treatment outcomes in comorbid anxiety and alcohol patients. Few studies, however, have reported outcomes for truly integrated treatments. Integrated treatment models recognize the complex relationship between anxiety disorders and alcohol use disorders and their possible mutual maintenance (Zahradnik & Stewart, in press). Furthermore, their aim is to create a hybrid of the treatments that work best for each disorder separately, and also include in the treatment strategy an understanding of the reciprocal influences each disorder has on the other (Zahradnik & Stewart). Integrated treatments have been developed and tested for certain anxiety disorder – substance use disorder combinations, but until now only one study (Kushner et al., 2006) has investigated an integrated treatment focusing on comorbidity with alcohol use disorders in particular. The treatment integrated CBT for panic disorder with content focusing on the interaction between alcohol use and panic symptoms. The integrated treatment was provided on top of treatment as usual (TAU) for the alcohol use disorder and compared to a group who received only the TAU.
Alcohol and Anxiety
47
The trial was conducted on a sample of comorbid panic disorder – alcoholic patients, with promising results. The group receiving the integrated treatment showed better anxiety and alcohol outcomes than the TAU alcohol only treatment group. It is hoped that integrated treatments will provide a more effective strategy in treating comorbid patients. Integrated treatments appear to be the most recommended by ‘‘expert opinion’’; however few of the recommendations are supported by randomized controlled trials, or even quasi-experimental designs (Watkins, Hunter, Burnman, Pincus, & Nicholson, 2005). More research needs to be conducted to develop and test integrated treatment strategies and to compare them against parallel or sequential approaches.
Prevention and/or Early Intervention Another treatment approach receiving recent research attention involves targeting the vulnerability factors (e.g., AS) associated with problematic drinking in cases with, or at risk for, comorbid anxiety disorders (Conrod, Stewart, Comeau, & MacLean, 2006, Watt et al., 2006). A study by Watt et al. found promising results for brief CBT targeted at reducing AS in a sample of university women. Three 50-minute CBT sessions led to a decrease in the proportion of women with high AS who engaged in negative consequence drinking (based on elevated scores on the Rutgers Alcohol Problem Index; RAPI; White & Labouvie, 1989), as well as a decrease in conformity-motivated drinking (a high-risk drinking motive; Cooper et al., 1992; Cooper, 1994) and in emotional relief alcohol expectancies (i.e. a positive alcohol expectancy similar to tension reduction expectancies described earlier). The treatment also significantly reduced AS levels (Watt et al., 2006). Another similar AS-focused brief CBT delayed drinking onset in young at-risk adolescents (mean age = 14; Conrod, Castellanos, & Mackie, in press). Later drinking onset has been shown to be a factor protecting against the development of later alcohol use problems (Grant, Stinson, & Harford, 2001). The intervention also reduced panic attacks in high AS adolescents (Castellanos & Conrod, 2006). Together, these results suggest that brief CBT focused on reduction or management of AS may be a useful strategy for prevention of or early intervention with anxiety – alcohol use disorder comorbidity.
Conclusion Although there is ample evidence supporting the existence of a strong relationship between anxiety and its disorders, and alcohol use and its disorders, much remains unknown regarding the nature of the relationship. More research examining particular circumstances in which anxious individuals are more
48
B. C. Sabourin, S. H. Stewart
likely to self-medicate needs to be conducted, with a focus on potential differences in high-risk drinking situations across the various anxiety disorders. In addition, there has been little research about protective factors that can decrease anxious individuals’ needs to self-medicate their anxiety symptoms. For example, a few studies have explored the role of self-efficacy in heavy drinking among individuals with anxiety disorders (Burke & Stephens, 1997; Gilles et al., 2006). Initial results suggest that it might be beneficial for treatments to incorporate specific strategies to increase anxious individuals’ feelings of self-efficacy, especially about avoiding heavy drinking in particular high risk situations (e.g., those involving anxiety). Increased knowledge about this and other potential protective factors may be useful when designing specific treatments for comorbid populations (Burke & Stephens, 1997). It has also been found that alcohol expectancies, drinking motives, and anxiety sensitivity all moderate or mediate the relationship between anxiety and alcohol use/abuse. In addition, these three variables have been found to interact with or intervene with each other when explaining reasons and circumstances for increased and problematic alcohol use in anxious individuals (e.g., Stewart et al., 2001). More research exploring the interplay between these and other moderating and mediating variables would provide deeper and more complete understanding of the precise mechanisms through which anxiety and alcohol use affect one another. Finally, although research on treating and preventing comorbid anxiety disorders and alcohol use disorders is still in relatively early stages, promising approaches are emerging in this growing clinical research area. For example, in prevention/early intervention, recent studies have shown promising results for targeting personality risk factors directly (e.g., AS) in attempts to reduce both emergent problematic drinking (Conrod et al., 2006; Watt et al., 2006) and emerging anxiety disorder symptoms (Castellanos & Conrod, 2006). Recent research aimed at developing truly integrated treatments for comorbid patients that consider the interplay between anxiety symptoms and drinking behaviors (Kushner et al., 2006) has also provided positive preliminary results. Treatment research efforts should continue exploring ways to address the factors discussed in this chapter (e.g., moderating and/or mediating factors) linking anxiety and problematic alcohol use to improve the efficacy of treatments we have available for comorbid patients.
References Abrams, K., Kushner, M., Medina, K. L., & Voight, A. (2002). Self-administration of alcohol before and after a public speaking challenge by individuals with social phobia. Psychology of Addictive Behaviors, 16, 121–128. Abrams, K., Kushner, M., Medina, K. L., & Voight, A. (2001). The pharmacologic and expectancy effects of alcohol on social anxiety in individuals with social phobia. Drug and Alcohol Dependence, 64, 219–231.
Alcohol and Anxiety
49
Acierno, R., Resnick, H., Kilpatrick, D. G., Saunders, B., & Best, C. L. (1999). Risk factors for rape, physical assault, and posttraumatic stress disorder in women: Examination of differential multivariate relationships. Journal of Anxiety Disorders, 13, 541–563. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). Washington, DC: Author. Bandura, A. (1977). Self-efficacy: Toward a unifying theory of behavioral change. Psychological Review, 84, 191–215. Baron, R. M. & Kenny, D. A. (1986). The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. Journal of Personality and Social Psychology, 51, 1173–1182. Barrett, S. P., Darredeau, C., & Pihl, R. O. (2006). Patterns of simultaneous polysubstance use in drug using university students. Human Psychopharmocology: Clinical and Experimental, 21, 255–263. Berkson, J. (1949). Limitations of the application of four-fold tables to hospital data. Biological Bulletin, 2, 47–53. Bernstein, A., Zvolensky, M. J., Sachs-Ericsson, N., Schmidt, N. B., & Bonn-Miller, M. O. (2006). Associations between age of onset and lifetime history of panic attacks and alcohol use, abuse, and dependence in a representative sample. Comprehensive Psychiatry, 47, 342–349. Bowen, R. C., D’Arcy, C., Keegan, D., & Senthilselvan, A. (2000). A controlled trial of cognitive behavioral treatment of panic in alcoholic inpatients with comorbid panic disorder. Addictive Behvaviors, 25, 593–597. Bradizza, C. M., Stasiewicz, P. R., & Paas, N. D. (2006). Relapse to alcohol and drug use among individuals diagnosed with co-occurring mental health and substance use disorders: A review. Clinical Psychology Review, 26, 162–178. Breese, G. R., Overstreet, D. H., & Knapp, D. J. (2005). Conceptual framework for the etiology of alcoholism: A ‘‘kindling’’/stress hypothesis. Psychopharmacology, 178, 367–380. Brown, P. J. & Wolfe, J. (1994). Substance abuse and post-traumatic stress disorder comorbidity. Drug and Alcohol Dependence, 35, 51–59. Bruce, S. E., Yonkers, K. A., Otto, M. W., Eisen, J. L., Weisberg, R. B., Pagano, M., et al. (2005). Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: A 12-year prospective study. American Journal of Psychiatry, 162, 1179–1187. Burke, R. S. & Stephens, R. S. (1997). Effect of anxious affect on drinking self-efficacy in college students. Psychology of Addictive Behaviors, 11, 65–75. Castellanos, N. & Conrod, P. (2006). Brief interventions targeting personality risk factors for adolescent substance misuse reduce depression, panic and risk-taking behaviours. Journal of Mental Health, 15, 645–658. Chilcoat, H. D., & Breslau, N. (1998). Investigations of causal pathways between PTSD and drug use disorders. Addictive Behaviors, 23, 827–840. Conrod, P., Castellanos, N., & Mackie, C. (in press). Personality-targeted interventions delay the growth of adolescent drinking and binge drinking. Journal of Child Psychology and Psychiatry. Conrod, P. J., & Stewart, S. H. (2005). A critical look at dual-focused cognitive-behavioral treatments of comorbid substance use and psychiatric disorders: Strengths, limitations, and future directions. Journal of Cognitive Psychotherapy 19,, 261–284. Conrod, P. J., Stewart, S. H., Comeau, N., & Maclean, A. M. (2006). Efficacy of cognitivebehavioral interventions targeting personality risk factors for youth alcohol misuse. Journal of Clinical Child and Adolescent Psychology, 35, 550–563. Cooper, M. L. (1994). Motivations for alcohol use among adolescents: Development and validation of a four-factor model. Psychological Assessment, 6, 117–128. Cooper, M. L., Russell, M., Skinner, J. B., & Windle, M. (1992). Development and validation of a three-dimensional measure of drinking motives. Psychological Assessment, 4, 123–132.
50
B. C. Sabourin, S. H. Stewart
Cox, B. J., Norton, G. R., Swinson, R. P., & Endler, N. S. (1990). Substance abuse and panicrelated anxiety: A critical review. Behavior Research and Therapy, 28, 385–393. Cox, W. M. (1987). Personality theory and research. In H. Blane and K.Leonard (Eds.), Psychological Theories of Drinking and Alcoholism (pp. 55–89). New York: Guilford Press. Cox, W. M., & Klinger, E. (1988). A motivational model of alcohol use. Journal of Abnormal Psychology, 97, 168–180. Dawson, D. A., & Archer, L. D. (1993). Relative frequency of heavy drinking and the risk of alcohol dependence. Addiction 88,, 1509–1518. Deacon, B. J., & Valentiner, D. P. (2000). Substance use and non-clinical panic attacks in a young adult sample. Journal of Substance Abuse, 11, 7–15. DeHaas, R. A. B., Calamari, J. E., & Bair, J. P. (2002). Anxiety sensitivity and the situational antecedents to drug and alcohol use: An evaluation of anxiety patients with substance use disorders. Cognitive Therapy and Research, 26, 335–353. Driessen, M., Meier, S., Hill, A., Wetterling, T., Lange, W., & Junghanns, K. (2001). The course of anxiety, depression and drinking behaviors after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders. Alcohol and Alcoholism, 36, 249–255. Forbes, D., Creamer, M., Hawthorne, G., Allen, N., & McHugh, T. (2003). Comorbidity as a predictor of symptom change after treatment in combat-related posttraumatic stress disorder. Journal of Nervous and Mental Disease, 191, 93–99. Gilles, D. M., Turk, C. L., & Fresco, D. M. (2006). Social anxiety, alcohol expectancies, and self-efficacy as predictors of heavy drinking in college students. Addictive Behaviors, 31, 388–398. Goodwin, R. D., Fergusson, D. M., & Horwood, L. J. (2004). Association between anxiety disorders and substance use disorders among young persons: Results of a 21-year longitudinal study. Journal of Psychiatric Research, 38, 295–304. Goodwin, R. D., Lieb, R., Hoefler, M., Pfister, H., Bittner, A., Beesdo, K., et al. (2004). Panic attack as a risk factor for severe psychopathology. American Journal of Psychiatry, 161, 2207–2214. Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, P., Dufour, M. C., Compton, W., et al. (2004). Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders. Archives of General Psychiatry, 61, 807–816. Grant, B. F., Stinson, F. S., & Harford, T. C. (2001). Age of onset of alcohol use and DSM-IV alcohol abuse and dependence: A 12 year follow-up. Journal of Substance Abuse, 13, 493–504 Greeley, J., & Oei, T. (1999). Alcohol and tension reduction. In K. Leonard and H. Blane (Eds.), Psychological Theories of Drinking and Alcoholism (2nd ed.,pp. 14–53). New York: Guilford Press. Ham, L. S., Carrigan, M. H., Moak, D. H., & Randall, C. L. (2005). Social anxiety and specificity of positive alcohol expectancies: Preliminary findings. Journal of Psychopathology and Behavioral Assessment, 27, 115–121. Ham, L. S., & Hope, D. A. (2005). Incorporating social anxiety into a model of college student problematic drinking. Addictive Behaviors, 30, 127–150. Helzer, J. E., Bucholz, K. K., & Bierut, L. J. (2006). Should DSM-V include dimensional diagnostic criteria for alcohol use disorders? Alcoholism: Clinical and Experimental Research, 30, 303–310. Jang, K. L., Livesley, W. J., & Vernon, P. A. (1996). Heritability of the big five personality dimensions and their facets: A twin study. Journal of Personality, 64, 577–591. Jorm, A. F., Christensen, H., Henderson, A. S., Jacomb, P. A., Korten, A. E., & Rodgers, B. (2000). Predicting anxiety and depression from personality: Is there a synergistic effect of neuroticism and extraversion? Journal of Abnormal Psychology, 109, 145–149. Kandel D. B., Huang F. Y., Davies M. (2001). Comorbidity between patterns of substance use dependence and psychiatric syndromes. Drug and Alcohol Dependence, 64, 233–41.
Alcohol and Anxiety
51
Kessler, R. C., Crum, R. M., Warner, L. A., Nelson, C. B., Schulenberg, J., & Anthony, J. C. (1997). Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Archives of General Psychiatry, 54, 313–321. Kessler, R. C., Nelson, C. B., McGonagle, K. A., Edlund, M. J., Frank, R. G., & Leaf, P. J. (1996). The epidemiology of co-occurring addictive and mental disorders. American Journal of Orthopsychiatry, 66, 17–31. Kidorf, M., & Lang, A. R. (1999). Effects of social anxiety and alcohol expectancies on stressinduced drinking. Psychology of Addictive Behaviors, 13, 134–142. Kranzler, H. R., Burleson, J. A., Del Boca, F. K., Babor, T. F., Korner, P., Brown, J., et al. (1994). Buspirone treatment of anxious alcoholics: A placebo-controlled trial. Archives of General Psychiatry, 51(9), 720–731. Kushner, M. G., Abrams, K., & Borchardt, C. (2000a). The relationship between anxiety disorders and alcohol use disorders: A review of major perspectives and findings. Clinical Psychology Review, 20, 149–171. Kushner, M. G., Abrams, K., Thuras, P., & Hanson, K. L. (2000b). Individual differences predictive of drinking to manage anxiety among non-problem drinkers with panic disorder. Alcoholism: Clinical and Experimental Research, 24, 448–458. Kushner, M. G., Abrams, K., Thuras, P., Hanson, K. L., Brekke, M., & Sletten, S. (2005). Follow-up study of anxiety disorder and alcohol dependence in comorbid alcoholism treatment patients. Alcoholism: Clinical and Experimental Research, 29, 1432–1443. Kushner, M. G., Donahue, C., & Sletten, S. (2006). Cognitive behavioral treatment of comorbid anxiety disorder in alcoholism treatment patients: Presentation of a prototype program and future directions. Journal of Mental Health, 15, 697–707. Kushner, M. G., Sher, K. J., & Beitman, B. D. (1990). The relation between alcohol problems and the anxiety disorders. American Journal of Psychiatry, 147, 685–695. Kushner, M. G., Sher, K. J., & Erickson, D. J. (1999). Prospective analysis of the relation between DSM-III anxiety disorders and alcohol use disorders. American Journal of Psychiatry, 156, 723–732. Kushner, M. G., Sher, K. J., Wood, M. D., & Wood, P. K. (1994). Anxiety and drinking behavior: Moderating effects of tension-reduction alcohol outcome expectancies. Alcoholism: Clinical and Experimental Research, 18, 852–860. LaBounty, L. P., Hatsukami, D., Morgan, S. F., & Nelson, L. (1992). Relapse among alcoholics with phobic and panic symptoms. Addictive Behaviors, 17, 9–15. Lehman, C. L., Brown, T. A., Palfai, T., & Barlow, D. H. (2002). The effects of alcohol outcome expectancy on a carbon-dioxide challenge in patients with panic disorder. Behavior Therapy, 33, 447–463. MacDonald, A. B., Stewart, S. H., Hutson, R., Rhyno, E., & Loughlin, H. L. (2001). The roles of alcohol and alcohol expectancy in the dampening of responses to hyperventilation among high anxiety sensitive young adults. Addictive Behaviors, 26, 827–840. Marlatt, G. A., & Donovan, D.M. (Eds.). (2005). Maintenance strategies in the treatment of addictive behaviors (2nd ed.). New York: Guilford Press. Marquenie, L. A., Schade, A., Van Balkom, A. J., Koeter, M., Frenken, S.,Van Den Brink, W., et al. (2006). Comorbid phobic disorders do not influence outcome of alcohol dependence treatment: Results of a naturalistic follow-up study. Alcohol and Alcoholism, 41, 168–173. Marshall, J. R. (1997). Alcohol and substance abuse in panic disorder. Journal of Clinical Psychiatry, 58(suppl 2), 46–49. McFall, M. E., Mackay, P. W., & Donovan, D. M. (1992). Combat-related posttraumatic stress disorder and severity of substance abuse in Vietnam veterans. Journal of Studies on Alcohol, 53, 357–363. Merikangas, K. R., Mehta, R. L., Molnar, B. E., Walters, E. E., Swendsen, J. D., Aguilar, S., et al. (1998). Comorbidity of substance use disorders with mood and anxiety disorders:
52
B. C. Sabourin, S. H. Stewart
Results of the international consortium in psychiatric epidemiology. Addictive Behaviors, 23, 893–907. Merikangas, K. A., Stevens, D., & Fenton, B. (1996). Comorbidity of alcoholism and anxiety disorders. Alcohol Health and Research, 20, 100–105. Norton, G. R., Norton, P. J., Cox, B. J., & Belik, S. (in press). Panic spectrum disorders and substance use. In S. H. Stewart & P. J. Conrod (Eds.), The vicious cycle: Theoretical and treatment issues in comorbid anxiety and substance use disorders. New York: Springer. Norton, G. R., Rockman, G. E., & Ediger, J. (1997). Anxiety sensitivity and drug abuse in individuals seeking treatment for substance abuse. Behaviour Research and Therapy, 35, 859–862. Paavola, M., Vartiainen, E., & Haukkala, A. (2004). Smoking, alcohol use, and physical activity: A 13-year longitudinal study ranging from adolescence into adulthood. Journal of Adolescent Health, 35, 238–244. Persons, J. B. (1986). The advantage of studying psychological phenomena rather than psychiatric diagnoses. American Psychologist, 41, 1252–1260. Randall, C. L., Johnson, M. R., Thevos, A. K., Sonne, S. C., Thomas, S. E., Willard, S. L., et al. (2001). Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depression and Anxiety, 14, 255–262. Randall, C. L., Thomas, S., & Thevos, A. K. (2001). Concurrent alcoholism and social anxiety disorder: A first step toward developing effective treatments. Alcoholism: Clinical and Experimental Research, 25, 210–220. Schade, A., Marquenie, L. A., Balkom, A. J., Koeter, M. W. J., de Ceurs, E., van den Brink, W., et al. (2005). The effectiveness of anxiety treatment on alcohol-dependent patients with a comorbid phobic disorder: A randomized controlled trial. Alcoholism: Clinical and Experimental Research, 29, 794–800. Smith, S. M., Stinson, F. S., Dawson, D. A., Goldstein, R., Huang, B., & Grant, B. F. (2006). Race/ethnic differences in the prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychological Medicine, 36, 987–998. Sobell, L. C., Cunningham, J. A., Sobell, M. B., Agrawal, S., Gavin, D. R., Leo, G. I., et al. (1996). Fostering self-change among problem drinkers: A proactive community intervention. Addictive Behaviors, 21, 817–833. Stein, M. B., Lang, K. L., & Livesley, W. J. (1999). Heritability of anxiety sensitivity: A twin study. American Journal of Psychiatry, 156, 246–251. Stewart, S. H., & Conrod, P. J. (Eds.). (in press). The vicious cycle: Theoretical and treatment issues in co-morbid anxiety and substance abuse disorders. New York: Springer. Stewart, S. H., & Conrod, P. J. (2002). Psychosocial models of functional associations between posttraumatic stress disorder and substance use disorder. In P. C. Ouimette & P. J. Brown (Eds.), Trauma and substance abuse: causes, consequences, and treatment of comorbid disorders (pp. 29–55). Washington, DC: American Psychological Association. Stewart, S. H., Conrod, P. J., Samoluk, S. B., Pihl, R. O., & Dongier, M. (2000). Posttraumatic stress disorder symptoms and situation-specific drinking in women substance abusers. Alcoholism Treatment Quarterly, 18, 31–47. Stewart, S. H., & Kushner, M. G. (2001). Introduction to the special issue on ‘‘Anxiety sensitivity and addictive behaviors’’. Addictive Behaviors, 26, 775–785, Stewart, S. H., Morris, E., Mellings, T., & Komar, J. A. (2006) Relations of social anxiety variables to drinking motives, drinking quantity and frequency, and alcohol-related problems in undergraduates. Journal of Mental Health, 15, 671–682. Stewart, S. H., Peterson, J. B., & Pihl, R. O. (1995). Anxiety sensitivity and self-reported alcohol consumption rates in university women. Journal of Anxiety Disorders, 9, 283–292. Stewart, S. H., Pihl, R. O., Conrod, P. J., & Dongier, M. (1998). Functional associations among trauma, PTSD, and substance related disorders. Addictive Behaviors, 23, 797–812.
Alcohol and Anxiety
53
Stewart, S. H., Zvolensky, M. J., & Eifert, G. H. (2001). Negative-reinforcement drinking motives mediate the relation between anxiety sensitivity and increased drinking behavior. Personality and Individual Differences, 31, 157–171. Swendsen, J. D., Conway, K. P., Rounsaville, B. J., & Merikangas, K. R. (2002). Are personality traits familial risk factors for substance use disorders? Results from a controlled family study. American Journal of Psychiatry, 159, 1760–1766. Swendsen, J. D., Tennen, H., Carney, M. A., Affleck, G., Wilard, A., & Hromi, A. (2000). Mood and alcohol consumption: An experience sampling test of the self-medication hypothesis. Journal of Abnormal Psychology, 109, 198–204. Tambs, K., Harris, J. R., & Magnus, P. (1997). Genetic and environmental contributions to the correlation between alcohol consumption and symptoms of anxiety and depression: Results from a bivariate analysis of Norwegian twin data. Behavior Genetics, 27, 241–249. Thevos, A. K., Roberts, J. S., Thomas, S. E., & Randall, C. L. (2000). Cognitive behavioral therapy delays relapse in female socially phobic alcoholics. Addictive Behaviors, 25, 333–345. Thomas, S. E., Randall, C. L., & Carrigan, M. H. (2003). Drinking to cope in socially anxious individuals: A controlled study. Alcoholism: Clinical and Experimental Research, 27, 1937–1943. Tollefson, G. D., Montague-Clouse, J., & Tollefson, S. L. (1992). Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). Journal of Clinical Psychopharmacology, 12, 19–26. Tolstrup, J. S., Heitmann, B. L., Tjonnelands, A. M., Overvad, O. K., Sorensen, T. I. A., & Gronbaeki, M. N. (2005). The relation between drinking pattern and body mass index and waist and hip circumference. International Journal of Obesity, 29, 490–497. Tran, G. Q., Haaga, D. A. F., & Chambless, D. L., (1997). Expecting that alcohol use will reduce social anxiety moderates the relation between social anxiety and alcohol consumption. Cognitive Therapy and Research, 21, 535–553. Ullman, S. E., Filipas, H. H., & Townswend, S. M. (2005). Trauma exposure, posttraumatic stress disorder and problem drinking in sexual assault survivors. Journal of Studies on Alcohol, 65, 610–619. Watkins, K. E., Hunter, S. B., Burnman, S. B., Pincus, H. A., & Nicholson, G. (2005). Review of treatment recommendations for persons with a co-occurring affective or anxiety and substance use disorder. Psychiatric Services, 56, 913–926. Watt, M., Stewart, S., Birch, C., & Bernier, D. (2006). Brief CBT for high anxiety sensitivity decreases drinking problems, relief alcohol outcome expectancies, and conformity drinking motives. Journal of Mental Health, 15, 683–695. Weinstock, L. M., & Whisman, M. A. (2006). Neuroticism as a common feature of the depressive and anxiety disorders: A test of the revised integrative hierarchical model in a national sample. Journal of Abnormal Psychology, 115, 68–74. White, H. R., & Labouvie, E. W. (1989). Towards the assessment of adolescent problem drinking. Journal of Studies on Alcohol, 50, 30–37. Willinger, U., Lenzinger, E., Hornik, K., Fischer, G., Schonbeck, G., Aschauer, H. N., et al. (2002). Anxiety as a predictor of relapse in detoxified alcohol-dependent patients. Alcohol and Alcoholism, 37, 609–612. Zahradnik, M., & Stewart, S. (in press). Anxiety disorders and substance use disorder comorbidity: Epidemiology, theories of interrelation, and recent treatment approaches. In M. Antony & M. Stein (Eds.), Handbook of anxiety and the anxiety disorders. Oxford, UK: Oxford University Press. Zimmermann, P. Wittchen, H. U., Hofler, M., Pfister, H., Kessler, R. C. & Lieb, R. (2003). Primary anxiety disorders and the development of subsequent alcohol use disorders: A 4-year community study of adolescents and young adults. Psychological Medicine, 33, 1211–1222.
54
B. C. Sabourin, S. H. Stewart
Zinbarg, R. E., Mohlman, J., & Hong, N. N. (1999). Dimensions of anxiety sensitivity. In S. Taylor (Ed.), Anxiety sensitivity: Theory, research, and treatment of the fear of anxiety. (pp. 83–114). Mahwah, NJ: Lawrence Erlbaum.
Illicit Drug Use Across the Anxiety Disorders Prevalence, Underlying Mechanisms, and Treatment Matthew T. Tull, David E. Baruch, Michelle S. Duplinsky, and C. W. Lejuez
An increasing number of studies are beginning to recognize the heightened risk for the development of substance use disorders among individuals with an anxiety disorder diagnosis, and the possible interplay between these disorders is receiving more attention in theoretical, clinical, and empirical spheres (e.g., Goodwin et al., 2002; Morissette, Tull, Gulliver, Kamholz, & Zimering, 2007; Stewart, 1996; Zvolensky & Schmidt, 2004; Zvolensky, Schmidt, & Stewart, 2003). As the majority of this attention has been focused on nicotine or alcohol use, the goal of this chapter is to review the extant work specific to illicit drug use across the anxiety disorders. In keeping with this focus, we will consider only illicit drugs and refer interested readers to chapters 4 and 5 in this volume for reviews specific to nicotine and alcohol. We begin by providing a brief list of the drugs that would fall under the larger category of illicit drugs, as well as prevalence rates of illicit drug use within the general population. We then move to discuss prevalence rates of illicit drug use within the anxiety disorders and among individuals with anxiety-disorder relevant symptoms (e.g., non-clinical panic attacks). Of note, this chapter will focus primarily on illicit drug use within the anxiety disorders as opposed to anxiety disorder diagnoses among individuals who use illicit drugs. Next, we present theories and data pertaining to the temporal progression of illicit drug use and anxiety disorders. The chapter then concludes with a brief review of treatments that specifically address comorbid anxiety and illicit drug use.
Illicit Drugs The term illicit drug is used here in reference to any substance that is illegal, with the distinction of illegal being specific to the United States.1 Such drugs, as recognized by the Diagnostic and Statistical Manual of Mental Disorders, Matthew T. Tull Department of Psychology, University of Maryland, College Park, MD 20742, Tel: 301-4053281, FAX: 310-405-3223
[email protected] 1
Due to space limitations we do not consider legal drugs used in an illegal manner (e.g., pain medications used without a prescription).
M. J. Zvolensky, J. A. Smits (eds.), Anxiety in Health Behaviors and Physical Illness. Ó Springer 2008
55
56
M. T. Tull et al.
4th Edition (DSM-IV; American Psychiatric Association [APA], 1994), include opioids (e.g., heroin, morphine), cocaine and its variants (e.g., crack), amphetamines (e.g., crystal methamphetamine), hallucinogens (e.g., LSD, PCP), inhalants, and marijuana. Drug use diagnoses include abuse and dependence. Abuse refers to a pattern of drug use leading to significant functional impairment, as evidenced by one of the following within a 12 month period: 1) recurrent use leading to failures to fulfill major obligations at work, school, or home; 2) recurrent use in situations where it may be physically hazardous to do so; 3) legal problems resulting from use; or 4) continued use even when the drug use results in social or psychological problems (APA, 1994). Dependence refers to a history of drug use marked by: 1) substance abuse; 2) continued use despite problems associated with that use; 3) drug tolerance; and 4) withdrawal symptoms (APA, 1994). Specific reference to use, abuse, and dependence often differ across studies, which can limit more broad conclusions across studies. Therefore, throughout this chapter we refer more broadly to use and will refer specifically to abuse and dependence when appropriate. In regard to rates of illicit drug use within the general population, the National Comorbidity Survey (NCS; Kessler et al., 1994), a nationally representative household survey of 8,098 adults aged 15–54 in the United States, found that 4.4% (5.4% of men and 3.5% of women) of respondents met criteria for lifetime drug abuse and 7.5% (9.2% of men and 5.9% of women) met criteria for lifetime drug dependence. In regard to 12-month prevalence, 0.8% (1.3% of men and 0.3% of women) met criteria for 12-month drug abuse and 2.8% (3.8% of men and 1.9% of women) met criteria for 12-month drug dependence. Data from the NCS Replication (NCS-R; Kessler, Chiu, Demler, & Walters, 2005), a nationally representative household survey of adult English-speaking individuals in the United States, provides more recent 12-month prevalence rates. Specifically, the NCS-R found that 1.4% and 0.4% of 5,692 respondents met criteria for drug abuse or dependence (respectively) in the past 12 months (prevalence rates as a function of gender were not provided). A limitation of the majority of epidemiological surveys is the examination of prevalence rates across drugs, with limited specificity to particular drugs. As a notable exception, the Epidemiological Catchment Area (ECA) study, a representative household survey of 20,291 adults in the United States, provides 6-month and lifetime prevalence rates for drug use disorders, as well as rates for specific illicit drug use disorders (rates are collapsed across abuse or dependence)(Reiger, et al., 1990). In particular, 2% and 6.1% of the sample met criteria for a 6-month or lifetime drug use disorder respectively. In regard to specific drug use disorders, prevalence rates were provided for marijuana dependence-abuse (1.2% 6-month, 4.3% lifetime), cocaine dependence-abuse (0.0% 6-month, 0.2% lifetime), opiate dependence-abuse (0.1% 6-month, 0.7% lifetime), amphetamine dependence-abuse (0.2%
Drug Use and the Anxiety Disorders
57
6-month, 1.7% lifetime), and hallucinogen dependence-abuse (0.0% 6-month, 0.3% lifetime) (Reiger et al., 1990). The National Epidemiological Survey on Alcohol and Related Conditions (NESARC; Conway, Compton, Stinson, & Grant, 2006), a representative household and group quarters survey of 43,093 adults in the United States, provides a more recent estimate of lifetime prevalence rates of drug use disorders, as well as rates for specific illicit drug use disorders, than the ECA. Within their sample (which over-sampled for minorities and young adults between 18–24 years of age), 7.74% (10.6% for men and 5.1% for women) met criteria for lifetime drug abuse and 2.59% (3.3% for men and 2.0% for women) for lifetime drug dependence. In regard to specific illicit drug use disorders: 1.08% (1.6% men, 0.6% women) and 0.34% (0.4% men, 0.3% women) met criteria for lifetime opioid abuse and dependence respectively, 1.40% (1.9% men, 0.9% women) and 0.60% (0.6% men, 0.6% women) met criteria for lifetime amphetamine abuse and dependence respectively, 1.45% (2.1% men, 0.9% women) and 0.24% (0.4% men, 0.1% women) met criteria for lifetime hallucinogen abuse and dependence respectively, 1.83% (2.7% men, 1.0% women) and 0.98% (1.2% men, 0.7% women) met criteria for lifetime cocaine abuse and dependence respectively, 7.16% (10% men, 4.5% women) and 1.30% (1.7% men, 0.9% women) met criteria for lifetime marijuana abuse and dependence respectively, and 0.30% (0.5% men, 0.1% women) met criteria for lifetime inhalant/solvent abuse (Conway et al., 2006). In terms of racial/ethnic differences in drug use disorders, Smith et al. (2006) found in the NESARC that, in general, Native Americans evidenced the highest 12 month prevalence rates of drug abuse or dependence as compared to all other racial/ethnic groups. Rates of drug use disorders across racial/ethnic groups were as follows: White (1.93%), Black/African-American (2.39%, significantly different from rates for White participants), Native-American (4.91%, significantly different from rates for White and Black/African-American participants), Asian/Asian-American (1.39%, significantly different from rates for Black/African-Americans and Native-Americans), and Latino (1.74%, significantly different from rates for Black/African-Americans and NativeAmericans). Not surprisingly, illicit drug use is associated with a variety of health compromising behaviors including risky sexual behavior (Brook et al., 2004; Loxley, Bevan, & Carruthers, 1998), licit substance use such as smoking (Zvolensky, Bonn-Miller et al., 2006) and alcohol abuse or dependence (Stinson et al., 2005), and poor self-care including poor dietary (Benedict, Evans, & Calder, 1999; Morabia et al., 1989) and sleep patterns (Pace-Schott et al., 2005). Combined with an anxiety disorder (which may develop independently of, prior to, or as a result of a drug use disorder), the interactive effects of a co-morbid drug use and anxiety disorder may place an individual at risk for more severe and extensive health consequences than those with either disorder alone.
58
M. T. Tull et al.
Illicit Drug Use in the Anxiety Disorders A number of studies have demonstrated that prevalence rates of anxiety disorder diagnoses among illicit drug users are generally higher than what has been found among individuals from the general population (e.g., Kessler, Berglund, Demler, Jin, & Walters, 2005; Grant et al., 2004). For example, Kessler, et al. (1996), in examining the 1-year prevalence of anxiety disorders among 5,877 individuals with a substance use disorder from the NCS, found that 24% of individuals with drug use without dependence also met criteria for some anxiety disorder and 45.5% of individuals with an illicit drug use disorder met criteria for an anxiety disorder. Beyond evidence of anxiety disorders among substance users, a growing literature focuses on illicit drug use among those with an anxiety disorder.
General Relationships Between Anxiety Disorders and Illicit Drug Use Reiger et al. (1990), in analyzing data from the ECA study, found that individuals with any anxiety disorder (as determined by DSM-III criteria) were 2.5 times as likely to also exhibit a comorbid drug use disorder (Odds Ratio [OR] = 2.4 for drug dependence and OR = 2.3 for drug abuse). Specifically, 11.9% of participants with any anxiety disorder diagnosis also met criteria for a drug use disorder, and this rate was significantly greater than that found among participants without an anxiety disorder diagnosis. Grant et al. (2004) found slightly higher ORs in examining data from the NESARC. Individuals with any anxiety disorder were 4.58 times as likely to also exhibit a comorbid drug use disorder (OR = 2.15 for drug abuse and OR = 2.43 for drug dependence). In another large scale study of comorbidity, Merikangas et al. (1998) analyzed data from six international epidemiological study sites (Germany, Mexico, Netherlands, Ontario, and two sites in the United States). They found that, across all sites, approximately 24.9% of individuals with any lifetime DSM-III-R anxiety disorder diagnosis also exhibited lifetime drug use (e.g., marijuana, opioids, stimulants, sedatives, or inhalants, but not alcohol), 35.8% exhibited lifetime drug problems (met at least one DSM-III-R abuse criteria for any drug), and 45.8% met criteria for lifetime DSM-III-R drug dependence. Lopez, Turner, and Saavedra (2005) analyzed data from 1,747 young adults (92% aged 19–21) from Miami-Dade county (Florida) public schools, and examined drug dependence among individuals with pure anxiety disorder diagnoses (i.e., the occurrence of one or more anxiety disorders that is not accompanied by any additional psychiatric disorder) or an anxiety disorder that
Drug Use and the Anxiety Disorders
59
was comorbid with some other psychiatric disorder (depression, dysthymia, conduct disorder, or attention deficit/hyperactivity disorder) (DSM-IV diagnostic criteria was used for disorder classification). Of the 4.9% with a pure anxiety disorder diagnosis (75.3% met diagnostic criteria for posttraumatic stress disorder [PTSD], 16.5% for social anxiety disorder [SAD], 5.9% for panic disorder [PD], and 3.5% for generalized anxiety disorder [GAD]), 13.9% also exhibited drug dependence. Further, more men (20.8%) than women (10.9%) with a pure anxiety disorder diagnosis also met criteria for drug dependence. Among the 10.2% with a comorbid anxiety disorder diagnosis (76.4% met criteria for PTSD, 18% for PD, 15.7% for SAD, 12.4% for GAD, and in terms of non-anxiety disorder comorbid psychiatric diagnoses, 62.9% met criteria for depression/dysthymia, 53.5% for conduct disorder, 36.5% for antisocial personality disorder, and 28.1% for attention deficit hyperactivity disorder), 29.2% met criteria for drug dependence. Again, more men (33.3%) than women (26.9%) with a comorbid anxiety disorder diagnosis also met criteria for drug dependence. Studies have also been conducted among adolescent populations and produced similar findings regarding high prevalence of drug use disorders among adolescents with anxiety disorder diagnoses. For example, Swadi and Bobier (2003) examined 62 adolescent patients (Mage=16.35) from an inpatient mental health facility in New Zealand. Of the 16% of these patients who had a diagnosable anxiety disorder, 63% also exhibited a drug use disorder (primarily marijuana, stimulants, and hallucinogens). Goodwin, Fergusson, and Horwood (2004) examined DSM-IV anxiety disorder and illicit drug dependence comorbidity among 1265 16–18 year-olds from the New Zealand Christchurch Health and Development Study (CHDS). Of the 175 participants who met criteria for an anxiety disorder at the age of 16–18, 12% also met criteria for illicit drug dependence, compared to 3.4% among those without an anxiety disorder diagnosis. Participants were then assessed again at age 18–21. Of the 130 who met criteria for an anxiety disorder within this age range, only 9.2% met criteria for illicit drug dependence. Interestingly, this rate was not significantly different from rates obtained among participants without an anxiety disorder diagnosis (7%).
Relationships Between Specific Anxiety Disorders and Illicit Drug Use In addition to examining general relationships between anxiety and drug use disorders, studies have also focused their attention on examining the relationship between specific anxiety disorders or anxiety disorder-related symptoms (e.g., non-clinical panic attacks) and the use of specific drugs. Although these studies are limited, more focused attention on the relationship between specific anxiety disorder diagnoses and drugs of abuse may further our understanding
60
M. T. Tull et al.
of the functional relationship between disorders. That is, depending upon the type of anxiety disorder present, an individual may be at risk for the development of a particular drug use disorder. We will first present data from the NESARC that provides an overview of 12-month and lifetime prevalence rates of various illicit drug use disorders among individuals with specific anxiety disorder diagnoses. We will then direct more focused attention on additional research that examines illicit drug use within specific anxiety disorders. The National Epidemiological Survey on Alcohol and Related Conditions. Conway et al. (2006) have recently presented data from the NESARC on lifetime prevalence rates of illicit drug use disorders across the DSM-IV anxiety disorders (with the exception of PTSD and obsessive-compulsive disorder [OCD]). In doing so, Conway et al. (2006) have provided the most comprehensive overview of anxiety disorder-illicit drug use disorder comorbidity to date2. Among respondents with PD with agoraphobia, 6.2% met criteria for a lifetime opioid use disorder, 9.2% for amphetamine use disorder, 8.1% for hallucinogen use disorder, 25.6% for marijuana use disorder, 11.5% for cocaine use disorder, and 0.8% for inhalant/solvent abuse. Among respondents with PD without agoraphobia, 4.9% met criteria for a lifetime opioid use disorder, 5.8% for amphetamine use disorder, 4.3% for hallucinogen use disorder, 17.7% for marijuana use disorder, 7.6% for cocaine use disorder, 1.1% for inhalant/ solvent abuse. Of respondents with SAD, 3.6% met lifetime criteria for an opioid use disorder, 5.5% for amphetamine use disorder, 4.1% for hallucinogen use disorder, 17.8% for marijuana use disorder, 6.3% for cocaine use disorder, and 0.7% for inhalant/solvent abuse. In regard to specific phobia, 2.8% of respondents with a lifetime diagnosis of specific phobia also met lifetime criteria for an opioid use disorder, 4.9% for amphetamine use disorder, 3.9% for hallucinogen use disorder, 14.9% for marijuana use disorder, 4.8% for cocaine use disorder, and 0.5% for inhalant/solvent abuse. Finally, among respondents with GAD, 3.7% also met lifetime criteria for an opioid use disorder, 6.2% for amphetamine use disorder, 4.6% for hallucinogen use disorder, 18.5% for marijuana use disorder, 7.1% for cocaine use disorder, and 0.7% for inhalant/solvent abuse. Conway et al. (2006) also examined gender differences in the ORs of illicit drug use disorders across the anxiety disorders. Few differences were observed. However, women with SAD (OR = 4.4) were significantly more likely than men with SAD (OR = 2.3) to exhibit comorbid lifetime opioid use disorder. In addition, men with PD with agoraphobia (OR = 8.7) were significantly more likely than women with PD with agoraphobia (OR = 6.5) to exhibit comorbid lifetime cocaine dependence. Grant et al. (2004) also provide 12-month anxiety disorder-illicit drug use disorder co-morbidity prevalence data from the NESARC, although 2
Due to space limitations, only data pertaining to drug use disorders in general will be presented. Readers interested in data pertaining to rates of drug abuse or dependence separately across the anxiety disorder diagnoses are referred to Conway et al. (2006).
Drug Use and the Anxiety Disorders
61
prevalence rates pertaining to specific illicit drug use disorders were not examined. Among respondents who met 12-month criteria for a DSM-IV anxiety disorder of PD with agoraphobia, 10.58% also exhibited a 12-month drug use disorder (4.65% drug abuse and 5.94% drug dependence). Rates of 12-month drug use disorders for other anxiety disorders were: 6.32% (2.17% drug abuse and 4.16% drug dependence) for PD without agoraphobia, 5.52% (2.59% drug abuse and 2.94% drug dependence) for SAD, 4.08% (2.13% drug abuse, 1.95% drug dependence) for specific phobia, and 8.06% (2.82% drug abuse, 5.24% drug dependence) for GAD. Finally, data from the NESARC has been used to examine differences in racial/ethnic background across comorbid anxiety and drug use disorders. Specific to abuse, Smith et al. (2006) found significant 12-month associations between drug abuse and all anxiety disorders (with the exception of PD without agoraphobia). No other significant 12-month associations between drug abuse and anxiety disorders were found for any other racial/ethnic group, with the one exception of a significant 12-month association between drug abuse and specific phobia among Native American respondents. A greater number of significant associations were found when examining the relationship between drug dependence and specific anxiety disorders across racial/ethnic groups. Significant associations were found for drug dependence and all anxiety disorders examined (PD with and without agoraphobia, SAD, specific phobia, GAD) among White respondents. Significant associations were found for drug dependence and all anxiety disorders with the exception of specific phobia for Black/African American respondents. Among Native American respondents, significant associations were found for PD without agoraphobia and SAD. Asian/AsianAmerican respondents demonstrated significant associations between drug dependence and PD without agoraphobia, SAD, and GAD, and Latino respondents exhibited significant associations between drug dependence and PD with agoraphobia, SAD, specific phobia, and GAD. As mentioned previously, the NESARC is the first to provide comprehensive data on the co-occurrence of specific anxiety disorders and illicit drug use disorders. In general, though, limited data is available that examines drug use within specific anxiety disorders. The one exception, however, may be PTSD, as a number of studies have examined the co-occurrence of PTSD and illicit drug use (for a review, see Chilcoat & Menard, 2003). We now move to a review of this literature, followed by a review of the literature pertaining to drug use within other anxiety disorders besides PTSD. Posttraumatic stress disorder. Data from the ECA found that compared to men and women without a diagnosis of PTSD, men with PTSD were 5 times more likely to also exhibit a drug use disorder and women with PTSD were 1.4 times as likely to exhibit a drug use disorder (overall odds ratio of 2.2; Helzer et al., 1987). In the NCS, Kessler, Sonnega, Bromet, Hughes, and Nelson (1995) found that compared to men and women without a diagnosis of PTSD, men with PTSD were approximately 2.97 times as likely and women 4.46 times as likely to exhibit a drug use disorder. Giaconia and colleagues (1995, 2000)
62
M. T. Tull et al.
collected data from 384 18-year-olds as part of The Early Adulthood Research Project (EARP) and found that compared to individuals without a history of traumatic exposure, individuals with a lifetime diagnosis of PTSD were 8.8 times as likely to also meet criteria for a lifetime drug dependence diagnosis and 14.14 times as likely to meet criteria for past year drug dependence. Calhoun et al. (2000) assessed drug use among a sample of 341 veterans with PTSD seeking treatment for PTSD. Opiate and marijuana use was reported by the largest number of patients (23% and 20% respectively). Benzodiazepine use was reported by 11% of patients, cocaine use by 8% of the patients, barbiturates by 5% of the patients, amphetamines by 3% of the patients, psilocybin by 3% of the patients, LSD by 1% of the patients, and PCP by 1% of the patients. Other studies have produced similar findings in regard to the use of specific drugs. For example, Saxon et al. (2001) found that incarcerated veterans with PTSD were more likely to report a greater degree of cocaine and heroin use as compared to individuals without a PTSD diagnosis. Tarrier and Sommerfield (2003) assessed 120 civilians seeking treatment for chronic PTSD on their drug use histories. Of the 120 participants, 17 used marijuana, 6 used sedatives, 4 used stimulants, 2 used a psychedelic, and 1 used cocaine. Further, in regard to rates of drug use disorders among younger individuals with PTSD, Kilpatrick, et al. (2000) collected data from a national sample of 4,023 adolescents (between the ages of 12 and 17). They found that PTSD was significantly associated with illicit drug use, including marijuana abuse and dependence and ‘‘harder’’ drug abuse and dependence (e.g., stimulants). Panic disorder and panic disorder-related symptoms. Moving beyond PTSD, a number of studies have examined illicit drug use among individuals with PD or PD-related symptoms, such as the experience of non-clinical panic attacks. Biederman et al. (2005) examined the rates of comorbid disorders among 23 individuals with PD and found that 8% exhibited a comorbid psychoactive substance use disorder. Among individuals with PD and major depression, 21% exhibited a comorbid psychoactive substance use disorder. Further, Zvolensky, Bernstein et al. (2006) examined lifetime associations between marijuana use, abuse, and dependence and panic attacks in a representative sample of 4,745 individuals. They found a positive association between lifetime panic attack occurrence and marijuana use, even when controlling for the effect of polysubstance use, alcohol abuse, and demographic variables (e.g., age, gender, etc.). Bonn-Miller, Bernstein, Sachs-Ericsson, Schmidt, and Zvolensky (2007) also examined the relationship between psychedelic (e.g., PCP, LSD, mescaline, peyote, psilocybin, DMT) use, abuse, and dependence and lifetime panic attack history within this same sample. Psychedelic abuse and dependence (although not use) were significantly associated with a heightened risk for the experience of lifetime panic attacks, controlling for demographic variables, polysubstance use, alcohol abuse, and a history of major depressive disorder. Deacon and Valentiner (2000) examined the relationship between panic attacks and substance use within a sample of 279 college students. Students with non-clinical panic attacks (n = 25) were significantly more likely than
Drug Use and the Anxiety Disorders
63
students without panic (n = 222) to report the use of drugs, such as sedatives (not alcohol), cocaine, and stimulants. Further, among non-clinical panickers, sedative use was not found to be related to distress about panic attacks, panic attack frequency, the occurrence of unexpected attacks, or general anxiety or depression symptoms. Valentiner, Mounts, and Deacon (2004) also investigated the relationship between panic attacks and illicit drug use in a sample of 399 incoming college freshman. Similar to Deacon and Valentiner (2000), they found that non-clinical panickers (n = 47), compared to non-panickers (n = 290), were significantly more likely to report lifetime use of sedatives, stimulants, and opioids, but not tobacco, alcohol, cocaine, or hallucinogens. In regard to specific rates of drug use among panickers, 12.8% reported lifetime use of sedatives (not alcohol), 6.4% reported lifetime use of cocaine, 55.3% reported lifetime use of marijuana, 34% reported lifetime use of stimulants, 21.3% reported lifetime use of opioids, and 23.4% reported lifetime use of hallucinogens. Additional analyses were conducted by Valentiner et al. (2004) to determine whether the relationships between panic and substance use differed as a function of gender or racial/ethnic background. Gender only served as a moderator in the relationship between panic and cocaine use. In particular, male panickers were significantly more likely to use cocaine than males without panic. In addition, among non-clinical panickers, substance use was not due to the number of panic attacks in the past year, panic attack symptom severity, and the experience of unexpected panic attacks. Other anxiety disorders. There is a dearth of studies on the relationship between specific drug use disorders with SAD, GAD, OCD, and specific phobia. More research is needed, especially given extant evidence that these anxiety disorder diagnoses may be associated with heightened risk for the development of illicit drug use disorders. For example, using data from the ECA Study, Reiger et al. (1990) found that 18.4% of respondents with lifetime OCD also exhibited a lifetime drug use disorder (11% for drug dependence and 7.4% for drug abuse). Further, this rate was significantly greater than what was found among individuals without a diagnosis of OCD. In regard to SAD, Kessler et al. (1996), in examining data from the NCS, found that respondents with SAD were significantly at greater risk to exhibit a 12-month co-occurrence of drug dependence (OR = 3.2) and lifetime drug dependence (OR = 2.6). Kessler et al. (1996) also provide data on GAD and specific phobia. Respondents with GAD were at significantly greater risk to exhibit lifetime drug dependence (OR = 3.8). Respondents with specific phobia were at significantly greater risk to exhibit co-occurring 12-month (OR = 1.8) or lifetime (OR = 2.5) drug dependence. Fewer studies have specifically examined the relationship between specific drug use and SAD; however, of note, several studies have also found evidence of an association between SAD and marijuana use (Buckner, Mallott, Schmidt, & Taylor, 2006; Buckner, Schmidt, Bobadilla, & Taylor, 2006; Lindquist, Lindsay, & White, 1979; Lynskey et al., 2002).
64
M. T. Tull et al.
Anxiety and illicit drug use disorder comorbidity in the context of a mood disorder. It is important to recognize that anxiety disorders are also likely to cooccur with other disorders, especially mood disorders. Therefore, it will be important for future studies to begin to examine the impact of mood-anxiety disorder comorbidity on drug use behavior. Speaking to this potential impact of mood-anxiety disorder comorbidity on drug use, Goodwin et al. (2002) examined the relationship between anxiety and drug use disorders among a sample of 130 individuals with a severe affective disorder (recurrent major depression, bipolar disorder) to examine whether the presence of a comorbid anxiety disorder diagnoses increases risk for the presence of a drug use disorder. They found that, in general, among individuals with a severe affective disorder, having an anxiety disorder was associated with a significantly increased risk of a cocaine, sedative, stimulant, or opioid use disorder. In examining specific anxiety disorders, they found that a) the experience of panic attacks increased the likelihood of having a cocaine, sedative, stimulant, or opioid use disorder; b) the presence of an OCD diagnosis increase the likelihood of stimulant use disorder; c) a diagnosis of SAD increased risk for a sedative use disorder; and d) and a specific phobia diagnosis was associated with increased risk for a cocaine, sedative, stimulant, and opioid use disorder.
Temporal Order of Anxiety Disorders and Illicit Drug Use Many of the studies discussed above are cross-sectional in nature, and therefore, it is impossible to determine the temporal progression of the disorders. In regard to the specific relationship between anxiety and drug use disorders, three temporal paths are possible. First, the use of specific drugs may increase the risk for the onset of an anxiety disorder. Second, illicit drug use may follow the development of an anxiety disorder diagnosis, consistent with a self-medication model of illicit drug use. Finally, there may be an underlying third factor that increases the risk for both anxiety disorders and illicit drug use. That is, there may be a common underlying mechanism for the comorbid development of these disorders (Goodwin et al., 2002).3 3
It is of note that a fourth possibility also exists. Specifically, anxiety disorder and drug use disorder diagnoses may develop through a completely independent process. Goldenberg et al. (1995) examined 181 participants in the Harvard Anxiety Research Project who had a history of substance use disorders and anxiety disorders in order to test hypotheses pertaining to the chronology of substance use-anxiety disorder comorbidity. They found, among individuals with a primary anxiety disorder diagnosis, the anxiety disorder diagnosis was present for, on average, 11.6 years before the onset of the substance use disorder. Further, substance use tended to occur a mean of 9.6 years before the onset of a secondary anxiety disorder diagnosis. Given the amount of time between the onset of the diagnoses, the authors concluded that there is not an etiological connection between the disorders, but instead, the onset of these disorders are guided by independent processes.
Drug Use and the Anxiety Disorders
65
Illicit Drug Use Precedes Anxiety Disorder Onset In regard to the first hypothesis, Zvolensky, Bernstein et al. (2006) found that a lifetime history of marijuana dependence was significantly associated with an increased risk for panic attacks, even when controlling for polysubstance use, alcohol abuse, and relevant demographic variables. Further, Cottler, Compton, Mager, Spitznagel and Janca (1992) found evidence for the high-risk hypothesis of comorbid PTSD-substance use disorder development. This hypothesis essentially states that drug use increases the likelihood of traumatic exposure (due to the high risk behaviors drug use is often associated with), thereby increasing risk for PTSD. Using data from the St. Louis Epidemiologic Catchment Area study, Cottler et al. (1992) examined the order of onset of PTSD and drug use within the 2,663 respondents. Cottler et al. (1992) found that drug use tended to precede the development of PTSD. However, it is important to note, that rates of PTSD in this sample were low (1.35% overall). In another study, Compton, Cottler, Phelps, Abdallah, and Spitznagel (2000) examined the temporal relationship of drug dependence and DSM-IIIR psychiatric diagnoses among 425 individuals in drug treatment. In the majority of cases (90%), drug dependence was found to follow the onset of a phobic disorder (the authors did not indicate whether this referred to SAD, specific phobia, or both). However, among individuals with a diagnosis of GAD, in 65% of the cases, the onset of the anxiety disorder followed the onset of the drug dependence, suggesting that, at least with GAD, the diagnosis may be secondary to drug dependence.
Illicit Drug Use Follows Anxiety Disorder Onset Studies have also provided support for the hypothesis that illicit drug use follows an anxiety disorder diagnosis. This hypothesis has most extensively been studied in PTSD. For example, Chilcoat and Breslau (1998) found that a PTSD diagnosis greatly increased the risk for the subsequent development of a SUD; however, traumatic exposure not resulting in PTSD did not have this effect, suggesting that the relationship between traumatic exposure and substance use is unique to those individuals who develop PTSD. They also found that substance abuse/dependence did not increase risk for traumatic exposure or PTSD (thus not providing support for the high-risk hypothesis). Consistent with a self-medication model of illicit drug use where drug use develops in an attempt to alleviate anxiety disorder symptoms, it has been demonstrated that exposure to trauma cues among PTSD-SUD patients is associated with substance craving, suggesting that the experience of PTSD-related symptoms may increase motivation to use substances in an attempt to relieve those symptoms (Coffey et al., 2002; Saladin et al., 2003).
66
M. T. Tull et al.
Additional support for the hypothesis that the presence of an anxiety disorder increases risk for illicit drug use comes from findings of Lopez et al. (2005) who found that, within their sample of 1747 young adults, the mean age of onset for an anxiety disorder diagnosis was consistently lower than that for substance dependence. In addition, an anxiety disorder diagnosis tended to occur before the onset of substance dependence 80% of the time.
Common Third Variables that may Underlie Both Illicit Drug Use and Anxiety Disorders Much less research has examined the third hypothesis of third variables that may function as a common underlying mechanism for both anxiety disorders and illicit drug use, especially in regard to the identification of common neurobiological and psychological mechanisms for the relationship between anxiety and drug use disorders. Two variables that are worthy of strong consideration are neurobiology and individual difference variables, which we will review below. First, however, it is also important to note that another important third variable for future consideration is gene by environment interactions. Although no current research has directly examined shared genetic transmission of anxiety and illicit drug use disorders, this is likely an important area for further pursuit. Specifically, the interaction between life stress and a polymorphism in the regulatory region of the serotonin transporter gene may be a particularly promising area of study. Indeed, although the preponderance of the work in this area has focused on the development of depression, some emerging research has separately identified the role of this interaction in the development of anxiety (Kendler, 1996) and illicit drug use (see Kreek, Nielsen, Butelman, & LaForge, 2005). Neurobiology. One aspect of neurobiology that may be potentially relevant to the development and maintenance of both anxiety disorders and illicit drug use involves the hypothalamic-pituitary-adrenal (HPA) axis, which controls the secretion of hormones for the pituitary and adrenal cortex. The HPA axis plays a central role in mediating the body’s response to stress and anxiety and is extremely sensitive to inputs from the limbic system and prefrontal cortex, two brain areas that are important in modulating reinforcement and motivational processes. The activity of the HPA axis is reflected in changes in serum or salivary cortisol levels (de Kloet & Reul, 1987), and has been found to account for differences in stress reactivity to physical and psychological laboratory challenges (Kaye et al., 2004; Wetherell et al., 2006). Neurobiological models of drug addiction hypothesize that dysregulated HPA axis functioning contributes to a state of chronic deviation of the regulatory system from its normal operating level, resulting in increased reinforcing effects of illicit drugs (Koob & Le Moal, 2001). More specifically, the HPA and brain stem stress circuits are hypothesized to be recruited in feed forward loops during response to stress,
Drug Use and the Anxiety Disorders
67
such that the corticotrophin releasing factor (CRF) in the extended amygdala drives norepinephrine systems in the pons-medulla of the brain stem, which in turn drives CRF in the extended amygdala. The extended amygdala is thus hypothesized to play a key role in regulating the HPA axis (i.e., stress response) and subsequent recruitment of negative reinforcement behavior (Koob & Le Moal, 2006), which may be especially relevant if substances are used for self-medication of anxiety symptoms. As much of this work is focused more on the relationship between stress and illicit drug use, as opposed to anxiety disorders specifically, it will be important for additional work to target the relationship between anxiety disorders and illicit drug use specifically. It is important to note, though, that dysregulation of the HPA axis has been found to play a role in the anxiety disorders (for a review, see Risbrough & Stein, 2006) and especially in PD (e.g., Erhardt et al., 2006) and PTSD (e.g., de Kloet et al., 2006; Yehuda, 2001) – two anxiety disorders that have been found to frequently co-occur with illicit drug use, suggesting that dysregulated functioning of the HPA axis may be common pathway at least for PD or PTSD and illicit drug use. However, further research is needed to test this hypothesis. Anxiety sensitivity. Anxiety sensitivity (AS) is an individual difference variable representing the tendency to fear anxiety-related sensations (e.g., increased heart rate, shortness of breath) due to beliefs that they will have negative somatic, cognitive, or social consequences (Reiss, 1991). Reiss (1991) originally proposed AS as a predisposing personality factor for the pathogenesis of the anxiety disorders, and research supports this, as demonstrated through the finding of elevated levels of AS across the anxiety disorders, with the exception of specific phobia (see Cox, Borger, & Enns, 1999). Although AS was originally proposed as a vulnerability factor for the anxiety disorders in general, its role as a specific vulnerability factor for PD has been examined most extensively. Studies consistently find higher levels of AS among individuals with PD, compared to individuals with other anxiety disorders (with the exception of PTSD) and healthy controls (see Cox et al., 1999). Further, AS has been predictive of the later development of spontaneous panic attacks (e.g., Schmidt, Lerew, & Jackson, 1997, 1999), as well as fearful responding to biological challenge tasks, such as hyperventilation and CO2 inhalation (Donnell & McNally, 1990; Harrington, Schmidt, & Telch, 1996; Rapee & Medoro, 1994; Schmidt & Telch, 1994; Telch, Silverman, & Schmidt, 1996; see also Zvolensky & Eifert, 2001, for a review). Similarly, successful treatment of PD has been found to be associated with corresponding reductions in AS following a cognitive behavioral group for PD (Telch et al., 1993) and individual cognitive behavior therapy (CBT) for anxiety medication discontinuation (Bruce, Spiegel, Gregg, & Nuzzarello, 1995). Research exploring AS as an underlying vulnerability for psychopathology in general has also been conducted, producing evidence that AS may underlie other psychiatric conditions as well, including depression (e.g., Otto, Pollack, Fava, Uccello, & Rosenbaum, 1995; Taylor, Koch, Woody, & McLean, 1996; Tull & Gratz, in press; Tull, Gratz, & Lacroce, 2006), borderline personality
68
M. T. Tull et al.
disorder (Gratz, Tull, & Gunderson, in press), and certain types of drug use patterns (see Lejuez, Paulson, Daughters, Bornovalova, & Zvolensky, 2006; Otto, Safren, & Pollack, 2004; Stewart & Kushner, 2001; Zvolensky & Schmidt, 2004). In regard to AS and drug use in particular, across the substance use disorders, McNally (1996) predicted that those individuals high in AS should specifically be at risk for drugs that include anxiolytic or depressive psychopharmacological effects as opposed to those with arousal properties (i.e., stimulants). However, research examining the role of AS in drug use is in its infancy, and across substances, alcohol and tobacco use have been most extensively studied (see chapters in this book; for reviews, see also Stewart, Samoluk, & MacDonald, 1999; Zvolensky et al., 2003). Few studies have been conducted that specifically examine the relationship between AS and other drug use. However, there is some evidence to suggest that elevated levels of AS may be associated with certain drug classes (besides tobacco and alcohol). Consistent with the relationship between arousal dampening drugs and AS, individuals reporting both chronic back pain and high AS report greater use of analgesic medications (Asmundson & Norton, 1995), and heightened AS has been found to be associated with elevated use of anxiety medications in general (Telch, Lucas, & Nelson, 1989). Bruce et al. (1995) examined successful benzodiazepine (Alprazolam) medication discontinuation in individuals receiving treatment as usual or the same procedure together with CBT treatment. While CBT significantly decreased anxiety and depression compared to control at 6-month follow-up, across both groups successful drug discontinuation was predicted by AS reduction from baseline to post-treatment. While McNally’s prediction has been generally supported regarding arousal dampening effects (but see Forsyth, Parker, & Finlay, 2003), the prediction that individuals with high AS should avoid arousal related drugs have not been confirmed to date. No differences have been found in preferences for illicit stimulants (e.g., cocaine or amphetamines) between high and low AS individuals (Norton et al., 1997; DeHaas, Calamari, Bair, & Martin, 2001; Forsyth et al., 2003) or for other stimulants such as caffeine (Stewart, Karp, Pihl, & Peterson, 1997). These findings suggest that while AS may act as a risk factor for drugs with arousal dampening effects, it does not act as a prophylactic against arousal producing self-medication. Research investigating the role of AS in marijuana use has provided mixed results. Whereas marijuana use has been reported to correlate with high AS in adolescents (Comeau, Stewart, & Loba, 2001), the opposite was found among adults in which low AS correlated with marijuana use (Norton et al., 1997; Stewart et al., 1997). In a recent investigation into adult tobacco users, marijuana users high in AS were at increased risk for more severe anxiety-related symptoms (Zvolensky, Bonn-Miller et al., 2006), controlling for the effects of cigarettes per day, alcohol use, and negative affectivity. In addition, AS has been found to predict the severity of marijuana withdrawal symptoms among young adult marijuana smokers, controlling for frequency of past 30-day marijuana use, number of cigarettes smoked per day, alcohol consumption,
Drug Use and the Anxiety Disorders
69
anxious arousal, and anhedonic depressive symptoms. These conflicting results indicate that future research is needed to better clarify the interactions between AS, marijuana, and other variables such as age and co-occurrence with other addictive substances. This research will aid in determining potential confounding factors, as well as facilitate the identification of more complex relationships between factors associated with vulnerability for illicit drug use and anxiety disorders. Further, given evidence that AS may be associated with the severity of marijuana withdrawal symptoms (Bonn-Miller, Zvolensky, Marshall, & Bernstein, 2007), it will be important for future research to examine whether AS may function to maintain drug use (due to fears of withdrawal symptoms) and/or increase risk for relapse for certain drugs during periods of attempted abstinence. Limited research has also been conducted that investigates the relationship between AS and heroin use. Lejuez et al. (2006) investigated AS among primarily African-American inner city substance users receiving treatment in a residential treatment facility. Specifically, measures of AS were collected among heroin users, crack/cocaine users, users of both heroin and crack/cocaine, and those that used neither. It was found that even when controlling for demographic variables, depressive symptoms, and the use of other drugs (e.g., alcohol, marijuana), primary heroin users evidenced higher levels of AS than all other groups, suggesting a unique relationship between heroin use and AS. Elevated AS has also been found to be a risk factor for worse treatment outcomes among heroin users in residential substance use treatment. Specifically, Lejuez, et al. (2007) examined AS as a predictor of residential substance use treatment drop-out among heroin and crack/cocaine users. Heightened levels of AS were found to predict residential substance use treatment dropout among heroin users but not crack/cocaine users. Prospective studies are needed to determine the specific role AS may play in the concurrent development of both anxiety and drug use disorders, as well as to identify the particular mechanisms through which AS may lead to these disorders. In regard to the pathogenesis of an anxiety disorder such as PD, heightened AS may be associated with attempts to avoid anxiety-related physical symptoms, thereby preventing functional exposure to the feared stimulus and maintaining anxious responding. Likewise, in regard to the pathogenesis of drug use, motivational models acknowledge the influence of positive consequences factoring into substance use yet posit a special role for the removal or avoidance of negative internal invents especially among chronic users (Cooper, 1994; Simons, Correia, Carey, & Borsari, 1998; Simons, Gaher, Correia, Hansen, & Christopher, 2005; Tate, Pomerleau, & Pomerleau, 1994). Baker, Piper, McCarthy, Majeskie, and Fiore (2004) comprehensively reviewed the basic experimental learning literature and concluded that negative reinforcement remains the primary mechanism behind addiction. Of utmost interest to the role of AS in addiction, Baker et al. (2004) argue that addiction is maintained by the avoidance and or escape of negative affect and other associated interoceptive cues (i.e. cognitive processes) that signal withdrawal symptoms.
70
M. T. Tull et al.
This is consistent with Hayes and colleagues proposal to reconceptualize psychopathology, including substance use, as a behavior that serves an experientially avoidant function. Experiential avoidance (defined as attempts to alter the form or frequency of internal experience such as thoughts, emotions, and bodily sensations; Hayes, Wilson, Gifford, Follette, & Strosahl, 1996) may be a particularly useful construct to examine in attempting to understand the pathway through which heightened AS leads to both the pathogenesis of anxiety disorders and illicit drug use. Experiential avoidance has been found to be associated with AS (e.g., Zvolensky & Forsyth, 2002), as well as a variety of anxiety disorder diagnoses and anxiety disorder-related symptoms (for reviews, see Hayes, Luoma, Bond, Masuda, & Lillis, 2006; Salters-Pedneault, Tull, & Roemer, 2004), as well as substance use behaviors (Hayes et al., 1996; Stewart, Zvolensky, & Eifert, 2002). Impulsivity (delay discounting). Impulsivity, defined as delay discounting, may also provide a useful framework for considering the concurrent development of anxiety disorders and illicit drug use. Traditionally, delay discounting has served as a behavioral operationalization for understanding the construct of impulsivity, which was developed following concern regarding the prevailing trait conceptualizations of the construct. Simply put, a delay discounting perspective considers impulsive behavior to be the choice of a smaller, immediate reinforcer instead of a larger, delayed reinforcer (Ainslie, 1975; Rachlin & Green, 1972). Taking this approach, studies have shown that compared to non-users, illicit drug users are more likely to select smaller amounts of immediate money instead of larger amounts that are delayed (e.g., $5 today over $20 in 30 days; Coffey, Gudleski, Saladin, & Brady, 2003; Kirby, Petry, & Bickel, 1999). In this way, this procedure provides an analogue for real world behavior of illicit drug users where more high impact yet delayed long-term goals (e.g., career development, relationship building) are sacrificed in favor of immediate gain in the form of drug use. Complimenting this approach to reinforcers, delay discounting also may be applied in its reciprocal form to aversive stimuli. In this case impulsivity involves the selection of a larger, delayed aversive stimulus over a smaller, yet immediate aversive stimulus. Said differently, this describes the tendency to put off experiencing an aversive event, even though this delay will result in an exacerbation of the negative consequences. A theoretical account of the relevance of this reciprocal approach to delayed discounting for SAD was provided by McNeil, Lejuez, and Sorrell (2001), describing the tendency of individuals with SAD to avoid potentially uncomfortable social interactions despite acute awareness that this will result in considerably larger long-term consequences. This approach is easily applied to other anxiety disorders as well. For example in the case of PD with agoraphobia, an individual may choose to only leave home with a ‘‘safe’’ person due to fear that of what will happen if alone in public during a panic attack, thereby resulting in the more severe yet delayed consequences associated with a loss of independence in the service of avoiding smaller yet immediate discomfort associated with leaving home alone.
Drug Use and the Anxiety Disorders
71
Combining both the reinforcer and reciprocal aversive conceptualizations of delay discounting provides a unique approach for understanding anxiety disorder-illicit drug use comorbidity. This may be particularly powerful in individuals where drug use is not only positively reinforcing (drug induced euphoria, social interaction) but also highly negatively reinforcing in regard to anxiety (the removal of overwhelming anxiety). It is also of note that although discounting is typically considered in terms of delay as discussed here, it is quite difficult to have a delay without also adding a degree of uncertainty. In this way, the extent to which delayed positive reinforcers and delayed aversives also are not perceived as guaranteed, their impact on keeping an individual from making an impulsive choice is further diminished. For example, while benefits of sobriety participating in exposure-based anxiety treatments seem strikingly powerful (good health, job security, trust, family), the delay to attaining the rewards are often long and relatively uncertain (will trust ever be fully returned? Will employers give you the benefit of the doubt if something goes missing? Will the anxiety ever really go away?), while pain (anxiety, withdrawal) remains immediate and certain. Thus, delayed discounting provides a framework to conceptualize the myriad of environmental factors influencing preference between two alternatives and suggests intervention implications (i.e., increasing the immediacy and certainty of alternative behaviors).
Treatment for Anxiety and Drug Use Disorder Comorbidity Given the high rates of comorbidity between anxiety disorders and substance use disorders, as well as suggestions that comorbid anxiety and substance use disorders may be better characterized as a single unique disorder (Hien, Cohen, Miele, Litt, & Capstick, 2004; Morissette et al., 2007), specialized treatments designed to specifically target this comorbidity are beginning to be developed. Of those treatments that are available, the majority are focused on the comorbidity between PTSD and substance use disorders. Seeking Safety. Najavits (2002) developed Seeking Safety to specifically target comorbid PTSD and substance use disorders. Seeking Safety is a 24-session cognitive behavioral group therapy protocol treatment that teaches individuals with this comorbid symptom presentation a variety of cognitive, behavioral, and interpersonal skills particularly applicable to individuals with both PTSD and substance use difficulties, all of which are designed with the idea that safety is the top priority in recovery from each disorder (Najavits, Weiss, & Liese, 1996). That is, coping skills are focused on maintaining abstinence, reducing self-destructive and high-risk behavior, and establishing support. Seeking Safety has been found to be effective, with patients exhibiting significant reductions in substance use behavior, trauma-related symptoms, suicide risk, suicidal thoughts, depression, and thoughts about substance use, and improvements in social adjustment, family functioning, and problem
72
M. T. Tull et al.
solving (e.g., Hien et al., 2004; Najavits et al., 1996; Zlotnick, Najavits, Rohsenow, & Johnson, 2003). Concurrent Treatment of PTSD and Cocaine Dependence. Another treatment specifically designed for individuals with comorbid PTSD and substance use disorders is Back, Dansky, Carroll, Foa, and Brady’s (2001) Concurrent Treatment of PTSD and Cocaine Dependence (CTPCD). This treatment consists of 16 individual 90-minute sessions. The treatment was designed by integrating previously validated cognitive behavioral treatments for substance dependence (Carroll, 1998) and PTSD (Foa, Rothbaum, Riggs, & Murdock, 1991; Foa & Rothbaum, 1998). CTPCD involves psychoeducation on the link between PTSD and cocaine dependence, coping skills training, relapse prevention skills, and cognitive restructuring. Further, patients undergo in-vivo and imaginal exposure in order to address their PTSD symptoms. In an initial examination of CTPCD, Brady, Dansky, Back, Foa, and Carroll (2001) found that individuals who completed treatment evidenced significant reductions in depressive symptoms, PTSD symptoms, and cocaine use severity. Anxiety Sensitivity Treatment for Heroin Users. Targeting AS, as opposed to any specific disorder, we (Tull, Schulzinger, Schmidt, Zvolensky, & Lejuez, 2007) recently developed an acceptance-based behavioral treatment (the Anxiety Sensitivity Treatment for Heroin Users; AST-H) meant to be used in conjunction with standard substance abuse treatment. Our treatment was designed to have specific relevance for heightened heroin users with heightened AS. Previous research (Lejuez et al., 2006) has demonstrated that heightened AS may increase risk for substance use treatment drop-out among heroin users. In particular, a tendency to fear of and unwillingness to have anxiety-related sensations may prompt individuals to attempt to avoid these sensations through the use of heroin. Therefore, we developed a six session adjunctive treatment where individuals engage in interceptive exposure exercises in order to facilitate acceptance of, and tolerance for, aversive internal sensations, with the goal of preventing the use of heroin for selfmedication of these sensations. In an initial examination of this treatment’s effectiveness, the AST-H was found to result in reductions in AS, heroin cravings, avoidance behavior, and emotion dysregulation (Tull et al., 2007). Improvements were maintained when measured over one month post-treatment. Current efforts are underway to replicate this finding within a randomized controlled trial.
Conclusion Recent years have seen a rise in studies examining the co-occurrence of illicit drug use and anxiety disorder diagnoses, and these studies provide convincing evidence that illicit drug use is prevalent among individuals with anxiety disorder diagnoses. Further, the impact of this co-occurrence on psychological functioning and physical health is clear. Yet, although studies have begun to address the mechanisms underlying this co-occurrence, all anxiety disorders
Drug Use and the Anxiety Disorders
73
and forms of illicit drug use have not been examined equally. Therefore, future research is needed to better understand the functional relationship between all anxiety disorders and forms of illicit drug use, with the goal of informing the development of novel and targeted interventions for this comorbidity, as well as prevention efforts.
References Ainslie, G. (1975). Specious reward: A behavioral theory of impulsiveness and impulse control. Psychological Bulletin, 82, 463–496. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author. Asmundson, G. J., & Norton, G. R. (1995). Anxiety sensitivity in patients with physically unexplained chronic back pain: A preliminary report. Behaviour Research and Therapy, 33, 771–777. Back, S. E., Dansky, B. S., Carroll, K. M., Foa, E. B., & Brady, K. T. (2001). Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: Description of procedures. Journal of Substance Abuse Treatment, 21, 35–45. Baker, T. B., Piper, M. E., McCarthy, D. E., Majeskie, M. R., & Fiore, M. C. (2004). Addiction motivation reformulated: An affective processing model of negative reinforcement. Psychological Review, 111, 33–51. Benedict, J., Evans, W., & Calder, J. C. (1999). An exploratory study of recreational drug use and nutrition-related behaviors and attitudes among adolescents. Journal of Drug Education, 29, 139–155. Biederman, J., Petty, C., Faraone, S. V., Hirshfeld-Becker, D. R., Henin, A., Pollack, M. H., et al. (2005). Patterns of comorbidity in panic disorder and major depression: Findings from a nonreferred sample. Depression and Anxiety, 21, 55–60. Bonn-Miller, M. O., Bernstein, A., Sachs-Ericsson, N., Schmidt, N. B., & Zvolensky, M. J. (2007). Associations between psychedelic use, abuse, and dependence and lifetime panic attack history in a representative sample. Journal of Anxiety Disorders, 21, 730–741. Bonn-Miller, M. O., Zvolensky, M. J., Marshall, E. C., & Bernstein, A. (2007). Incremental validity of anxiety sensitivity in relation to marijuana withdrawal symptoms. Addictive Behaviors, 32, 1843–1851. Brady, K. T., Dansky, B. S., Back, S. E., Foa, E. B., & Carroll, K. M. (2001). Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: Preliminary findings. Journal of Substance Abuse Treatment, 21, 47–54. Brook, J. S., Adams, R. W., Balka, E. B., Whiteman, M., Zhang, C., & Sugerman, R. (2004). Illicit drug use and risky sexual behavior among African American and Puerto Rican urban adolescents: The longitudinal links. Journal of Genetic Psychology, 165, 203–220. Bruce, T. J., Spiegel, D. A., Gregg, S. F., & Nuzzarello, A. (1995). Predictors of alprazolam discontinuation with and without cognitive behavior therapy in panic disorder. American Journal of Psychiatry, 152, 1156–1160. Buckner, J. D., Mallott, M. A., Schmidt, N. B., & Taylor, J. (2006). Peer influence and gender differences in problematic cannabis use among individuals with social anxiety. Journal of Anxiety Disorders, 20, 1087–1102. Buckner, J. D., Schmidt, N. B., Bobadilla, L., & Taylor J. (2006). Social anxiety and problematic cannabis use: Evaluating the moderating role of stress reactivity and perceived coping. Behaviour Research and Therapy, 44, 1007–1015. Calhoun, P. S., Sampson, W. S., Bosworth, H. B., Feldman, M. E,. Kirby, A. C., Hertzberg, M. A. et al. (2000). Drug use and validity of substance use self-reports in
74
M. T. Tull et al.
veterans seeking help for posttraumatic stress disorder. Journal of Consulting and Clinical Psychology, 68, 923–927. Carroll, K. M. (1998). A cognitive-behavioral approach: Treating cocaine addiction. (pp. 98–4308). Rockville, MD: National Institute on Drug Abuse, NIH Publication. Chilcoat, H. D., & Breslau, N. (1998). Posttraumatic stress disorder and drug disorders. Archives of General Psychiatry, 55, 913–917. Chilcoat, H. D., & Menard, C. (2003). Epidemiological investigations: Comorbidity of posttraumatic stress disorder and substance use disorder. In P. Ouimette and P. J. Brown (Eds.), Trauma and Substance Abuse: Causes, Consequences, and Treatment of Comorbid Disorders (pp. 9–28). Washington, DC: American Psychological Association. Coffey, S. F., Gudleski, G. D., Saladin, M. E., & Brady, K. T. (2003). Impulsivity and rapid discounting of delayed hypothetical rewards in cocaine-dependent individuals. Experimental & Clinical Psychopharmacology, 11, 18–25. Coffey, S. F., Saladin, M. E., Drobes, D. J., Brady, K. T., Dansky, B. S., & Kilpatrick, D. G. (2002). Trauma and substance cue reactivity in individuals with comorbid posttraumatic stress disorder and cocaine or alcohol dependence. Drug and Alcohol Dependence, 65, 115–127. Comeau, N., Stewart, S. H., & Loba, P. (2001). The relations of trait anxiety, anxiety sensitivity, and sensation seeking to adolescents’ motivations for alcohol, cigarette, and marijuana use. Addictive Behaviors, 26, 803–825. Compton, W. M., Cottler, L. B., Phelps, D. L., Abdallah, A. B., & Spitznagel, E. L. (2000). Psychiatric disorders among drug dependent subjects: Are they primary or secondary? The American Journal on Addictions, 9, 126–134. Conway, K. P., Compton, W., Stinson, F. S., & Grant, B. F. (2006). Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry, 67, 247–257. Cooper, M. L. (1994). Motivations for alcohol use among adolescents: Development and validation of a four-factor model. Psychological Assessment, 6, 117–128. Cottler, L. B., Compton, W. M., Mager, D., Spitznagel, E. L., & Janca, A. (1992). Posttraumatic stress disorder among substance users from the general population. American Journal of Psychiatry, 149, 664–670. Cox, B. J., Borger, S. C., & Enns, M. W. (1999). Anxiety sensitivity and emotional disorders: Psychometric studies and their theoretical implications. In S. Taylor (Ed.), Anxiety sensitivity: Theory, research, and treatment of the fear of anxiety (pp. 115–148). Mahwah, NJ: Lawrence Erlbaum. de Kloet, E. R., & Reul, J. M. (1987). Feedback action and tonic influence of corticosteroids on brain function: A concept arising from the heterogeneity of brain receptor systems. Psychoneuroendocrinology, 12, 83–105. de Kloet, C. S., Vermetten, E. Geuze, E., Kavelaars, A., Heijnen, C. J., & Westenberg, H. G. M. (2006). Assessment of HPA-Axis functioning in posttraumatic stress disorder: Pharmacological and non-pharmacological challenge tests, a review. Journal of Psychiatric Research, 40, 550–567. Deacon, B. J., & Valentiner, D. P. (2000). Substance use and non-clinical panic attacks in a young adult sample. Journal of Substance abuse, 11, 7–15. DeHaas, R. A., Calamari, J. E., Bair, J. P., & Martin, E. D. (2001). Anxiety sensitivity and drug or alcohol use in individuals with anxiety and substance use disorders. Addictive Behaviors, 26, 787–801. Donnell, C. D., & McNally, R. J. (1990). Anxiety sensitivity and panic attacks in a nonclinical population. Behavior Research and Therapy, 28, 83–85. Erhardt, A., Ising, M., Unschuld, P. G., Kern, N., Lucae, S., Pu¨tz, B. et al. (2006). Regulation of the hypothalamic-pituitary-adrenocortical system in patients with panic disorder. Neuropsychopharmacology, 31, 2515–2522.
Drug Use and the Anxiety Disorders
75
Foa, E. B., & Rothbaum, B. O. (1998). Treating the Trauma of Rape: Cognitive-behavioral Therapy for PTSD. New York: Guilford Press. Foa, E. B., Rothbaum, B. O., Riggs, D. S., & Murdock, T. B. (1991). Treatment of posttraumatic stress disorder in rape victims: A comparison between cognitive-behavioral procedures and counseling. Journal of Consulting and Clinical Psycholoy, 59, 715–723. Forsyth, J. P., Parker, J., & Finlay, C. G. (2003). Anxiety sensitivity, controllability, and experiential avoidance and their relation to drug of choice and addiction severity in a residential sample of substance abusing veterans. Addictive Behaviors, 28, 851–870. Giaconia, R. M., Reinherz, H. Z., Hauf, A. C., Paradis, A. D., Wasserman, M. S., & Langer hammer, D. M. (2000). Comorbidity of substance use and posttraumatic stress disorders in a community sample of adolescents. American Journal of Orthopsychiatry, 70, 253–262. Giaconia, R. M., Reinherz, H. Z., Silverman, A. B., Pakiz, B., Frost, A. K., & Cohen, E. (1995). Traumas and posttraumatic stress disorder in a community population of older adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1369–1380. Goldenberg, I. M., Mueller, T., Fierman, E. J., Gordon, A., Pratt, L., Cox, K. et al. (1995). Specificity of substance use in anxiety-disordered subjects. Comprehensive Psychiatry, 36, 319–328. Goodwin, R. D., Fergusson, D. M., & Horwood, L. J. (2004). Association between anxiety disorders and substance use disorders among young persons: Results of a 21-year longitudinal study. Journal of Psychiatric Research, 38, 295–304. Goodwin, R. D., Stayner, D. A., Chinman, M. J., Wu, P., Kraemer Tebes, J., & Davidson, L. (2002). The relationship between anxiety and substance use disorders among individuals with severe affective disorders. Comprehensive Psychiatry, 43, 245–252. Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., et al. (2004). Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders. Archives of General Psychiatry, 61, 807–816. Gratz, K. L., Tull, M. T., & Gunderson, J. G. (in press). The relationship between anxiety sensitivity and borderline personality disorder: The role of experiential avoidance. Journal of Psychiatric Research. Harrington, P. J., Schmidt, N. B., & Telch, M. J. (1996). Prospective evaluation of panic potentiation following 35% CO2 challenge in nonclinical subjects. American Journal of Psychiatry, 153, 823–825. Hayes, S. C., Luoma, J. B., Bond, F. W., Masuda, A., & Lillis, J. (2006). Acceptance and commitment therapy: Model, processes and outcomes. Behaviour Research and Therapy, 44, 1–25. Hayes, S. C., Wilson, K. G., Gifford, E. V., Follette, V. M., & Strosahl, K. D. (1996). Emotional avoidance and behavioral disorders: A functional dimensional approach to diagnosis and treatment. Journal of Consulting and Clinical Psychology, 64, 1152–1168. Helzer, J. E., Robins, L. N., & McEvoy, L. (1987). Post-traumatic stress disorder in the general population: Findings of the Epidemiological Catchment Area Survey. New England Journal of Medicine, 317, 1630–1634. Hien, D. A., Cohen, L. R., Miele, G. M., Litt, L. C., & Capstick, C. (2004). Promising treatments for women with comorbid PTSD and substance use disorders. American Journal of Psychiatry, 161, 1426–1432. Kaye, J., Buchanan, F., Kendrick, A., Johnson, P., Lowry, C., Bailey, J. et al. (2004). Acute carbon dioxide exposure in healthy adults: Evaluation of a novel means of investigating the stress response. Journal of Neuroendocrinology, 16, 256–264. Kendler, K. S. (1996). Major depression and generalised anxiety disorder. Same genes, (partly) different environments–revisited. British Journal of Psychiatry, 168 (Suppl. 30), 68–75. Kessler, R. C., Berglund, P., Demler, O., Jin, R., & Walters, E. E. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62, 593–602.
76
M. T. Tull et al.
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62, 617–627. Kessler, R. C., McGonagle, K. A., Zhao, S., Nelson, C. B., Hughes, M., Eshleman, S., et al. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Archives of General Psychiatry, 51, 8–19. Kessler, R. C., Nelson, C. B., McGonagle, K. A., Edlund, M. J., Frank, R. G., & Leaf, P. J. (1996). The epidemiology of co-occurring addictive and mental disorders: Implications for prevention and service utilization. American Journal of Orthopsychiatry, 66, 17–31. Kessler, R. C., Sonnega, A., Bromet, E., Hughes, M., & Nelson, C. B. (1995). Posttraumatic stress disorder in the National Comorbidity Survey. Archives of General Psychiatry, 52, 1048–1060. Kilpatrick, D. G., Acierno, R., Saunders, B., Resnick, H. S., Best, C. L., & Schnurr, P. P. (2000). Risk factors for adolescent substance abuse and dependence: Data from a national sample. Journal of Consulting and Clinical Psychology, 68, 19–30. Kirby, K. N., Petry, N. M., & Bickel, W. K. (1999). Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. Journal of Experimental Psychology: General, 128, 78–87. Kreek, M., Nielsen, D., Butelman, E., & LaForge, K. (2005). Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nature Neuroscience, 8, 1450–1457. Koob, G. F., & Le Moal, M. (2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology, 24, 97–129. Lejuez, C. W., Paulson, A., Daughters, S. B., Bornovalova, M. A., & Zvolensky, M. J. (2006). The association between heroin use and anxiety sensitivity among inner-city individuals in residential drug use treatment. Behaviour Research and Therapy, 44, 667–677. Lejuez, C. W., Zvolenksy, M. J., Daughters, S. B., Bornovalova, M. A., Paulson, A., Tull, M. T. et al. (2007). Anxiety sensitivity: A unique predictor of drop-out among inner-city heroin and crack/cocaine users in residential substance use treatment. Manuscript submitted for publication. Lindquist, C. U., Lindsay, J. S., & White, G. D. (1979). Assessment of assertiveness in drug abusers. Journal of Clinical Psychology, 35, 676–679. Lopez, B., Turner, R. J., & Saavedra, L. M. (2005). Anxiety and risk for substance dependence among late adolescents/young adults. Journal of Anxiety Disorders, 19, 275–294. Loxley, W., Bevan, J., & Carruthers, S. (1998). Sex, gender, drugs, and risk: The Australian study of HIV and injecting drug use. International Journal of Drug Policy, 9, 255–262. Lynskey, M. T., Heath, A. C., Nelson, E. C., Bucholz, K. K., Madden, P. A. F., Slutske, W. S. et al. (2002). Genetic and environmental contributions to cannabis dependence in a national young adult twin sample. Psychological Medicine, 32, 195–207. McNally, R. J. (1996). Anxiety sensitivity is distinct from trait anxiety. In R. M. Rapee (Ed.), Current controversies in the anxiety disorders (pp. 214–227). New York, NY: Guilford. McNeil, D. W., Lejuez, C. W., & Sorrell, J. T. (2001). Behavioral theories of social phobia: Contributions of basic behavioral principles. In S. G. Hofmann & P. M. DiBartolo (Eds.), From social anxiety to social phobia: Multiple perspectives (pp. 235–253). Boston, MA: Allyn & Bacon. Merikangas, K. R., Mehta, R. L., Molnar, B. E., Walters, E. E., Swendsen, J. D., Aguilar-Gaziola, S., et al. (1998). Comorbidity of substance use disorders with mood and anxiety disorders: Results of the International Consortium in Psychiatric Epidemiology. Addictive Behaviors, 23, 893–907. Morabia, A., Fabre, J., Chee, E., Zeger, S, Orsat, E., & Robert, A. (1989). Diet and opiate addiction: A quantitative assessment of the diet of non-institutionalized opiate addicts. British Journal of Addiction, 84, 173–180.
Drug Use and the Anxiety Disorders
77
Morissette, S. B., Tull, M. T., Gulliver, S. B., Kamholz, B. W., & Zimering, R. T. (2007). Anxiety, anxiety disorders, tobacco use, and nicotine: A critical review of interrelationships. Psychological Bulletin, 133, 245–272. Najavits, L. M. (2002). Seeking safety: A treatment manual for PTSD and substance abuse. New York, NY: Guilford Press. Najavits, L. M., Weiss, R. D., & Liese, B. S. (1996). Group cognitive-behavioral therapy for women with PTSD and substance use disorder. Journal of Substance Abuse Treatment, 13, 13–22. Norton, G. R., Rockman, G. E., Ediger, J., Pepe, C., Goldberg, S., Cox, B. J., & Asmundson, G. J. G. (1997). Anxiety sensitivity and drug choice in individuals seeking treatment for substance abuse. Behaviour Research and Therapy, 35, 859–862. Otto, M. W., Pollack, M. H., Fava, M., Uccello, R., & Rosenbaum, J. F. (1995). Elevated Anxiety Sensitivity Index scores in patients with major depression: correlates and changes with antidepressant treatment. Journal of Anxiety Disorders, 9, 117–123. Otto, M. W., Safren, S. A., & Pollack, M. H. (2004). Internal cue exposure and the treatment of substance use disorders: Lessons from the treatment of panic disorder. Journal of Anxiety Disorders, 18, 69–87. Pace-Schott, E. F., Stickgold, R., Muzur, A., Wigren, P. E., Ward, A. S., Hart, C. L. et al. (2005). Sleep quality deteriorates over a binge-abstinence cycle in chronic smoked cocaine users. Psychopharmacology, 179, 873–883. Rachlin, H., & Green, L. (1972). Commitment, choice, and self-control. Journal of the Experimental Analysis of Behavior, 17, 15–22. Rapee, R., & Medoro, L. (1994). Fear of physical sensations and trait anxiety as mediators of the response to hyperventilation in nonclinical subjects. Journal of Abnormal Psychology, 4, 693–699. Reiger, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Journal of the American Medical Association, 21, 2511–2518. Reiss, S. (1991). Expectancy theory of fear, anxiety, and panic. Clinical Psychology Review, 11, 141–153. Risbrough, V. B., & Stein, M. B. (2006). Role of corticotropin releasing factor in anxiety disorders: A translational research perspective. Hormones and Behavior, 50, 550–561. Saladin, M. E., Drobes, D. J., Coffey, S. F., Dansky, B. S., Brady, K. T., & Kilpatrick, D. G. (2003). PTSD symptom severity as a predictor of cue-elicited drug craving in victims of violent crime. Addictive Behaviors, 28, 1611–1629. Salters-Pedneault, K., Tull, M. T., & Roemer, L. (2004). The role of avoidance of emotional material in the anxiety disorders. Applied and Preventive Psychology, 11, 95–114. Saxon, A. J., Davis, T. M., Sloan, K. L., McKnight, K. M., McFall, M. E., & Kivlahan, D. R. (2001). Trauma symptoms of posttraumatic stress disorder and associated problems among incarcerated veterans. Psychiatric Services, 52, 959–964. Schmidt, N. B., Lerew, D. R., & Jackson, R. J. (1997). The role of anxiety sensitivity in the pathogenesis of panic: Prospective evaluation of spontaneous panic attacks during acute stress. Journal of Abnormal Psychology, 106, 355–364. Schmidt, N. B., Lerew, D. R., & Jackson, R. J. (1999). Prospective evaluation of anxiety sensitivity in the pathogenesis of panic: Replication and extension. Journal of Abnormal Psychology, 108, 532–537. Schmidt, N. B., & Telch, M. J. (1994). Role of fear of fear and safety information in moderating the effects of voluntary hyperventilation. Behavior Therapy, 25, 197–208. Simons, J. S., Correia, C. J., Carey, K. B., & Borsari, B. E. (1998). Validating a five-factor marijuana motives measure: Relations with use, problems, and alcohol motives. Journal of Counseling Psychology, 45, 265–273.
78
M. T. Tull et al.
Simons, J. S., Gaher, R. M., Correia, C. J., Hansen, C. L., & Christopher, M. S. (2005). An affective-motivational model of marijuana and alcohol problems among college students. Psychology of Addictive Behaviors, 19, 326–334. Smith, S. M., Stinson, F. S., Dawson, D. A., Goldstein, R., Huang, B., & Grant, B. F. (2006). Race/ethnic differences in the prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiological Survey on Alcohol and Related Conditions. Psychological Medicine, 36, 987–998. Stewart, S. H. (1996). Alcohol abuse in individuals exposed to trauma: A critical review. Psychological Bulletin, 120, 83–112. Stewart, S. H., Karp, J., Pihl, R. O., & Peterson, R. A. (1997). Anxiety sensitivity and selfreported reasons for drug use. Journal of Substance Use, 9, 223–240. Stewart, S. H., & Kushner, M. G. (2001). Introduction to the special issue on anxiety sensitivity and addictive behaviors. Addictive Behaviors, 26, 775–785. Stewart, S. H., Samoluk, S. B., & MacDonald, A. B. (1999). Anxiety sensitivity and substance use and abuse. In S. Taylor (Ed.), Anxiety sensitivity: Theory, research, and treatment of the fear of anxiety (pp. 287–319). Mahwah, NJ: Lawrence Erlbaum. Stewart, S. H., Zvolensky, M. J., & Eifert, G. H. (2002). The relations of anxiety sensitivity, experiential avoidance, and alexithymic coping to young adults’ motivations for drinking. Behavior Modification, 26, 274–296. Stinson, F. S., Grant, B. F., Dawson, D. A., Ruan, W. J., Huang, B., & Saha, T. (2005). Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug and Alcohol Dependence, 80, 105–116. Swadi, H., & Bobier, C. (2003). Substance use disorder comorbidity among inpatient youths with psychiatric disorder. Australian and New Zealand Journal of Psychiatry, 37, 294–298. Tarrier, N., & Sommerfield, C. (2003). Alcohol and substance use in civilian chronic PTSD patients seeking psychological treatment. Journal of Substance Use, 8, 197–204. Tate, J. C., Pomerleau, C. S., & Pomerleau, O. F. (1994) Pharmacological and non-pharmacological smoking motives: a replication and extension. Addiction, 89, 321–330. Taylor, S., Koch, W. J., Woody, S., & McLean, P. (1996). Anxiety sensitivity and depression: how are they related? Journal of Abnormal Psychology, 105, 474–479. Telch, M. J., Lucas, J. A., & Nelson, P. (1989). Nonclinical panic in college students: An investigation of prevalence and symptomatology. Journal of Abnormal Psychology, 98, 300–306. Telch, M. J., Lucas, J. A., Schmidt, N. B., Hanna, H. H., Jaimez, T. L., & Lucas, R. (1993). Group cognitive-behavioral treatment of panic disorder. Behaviour Research and Therapy, 31, 279–287. Telch, M. J., Silverman, A., & Schmidt, N. B. (1996). Effects of anxiety sensitivity and perceived control on emotional responding to caffeine challenge. Journal of Anxiety Disorders, 10, 21–35. Tull, M. T., & Gratz, K. L. (in press). Further investigation of the relationship between anxiety sensitivity and depression: The role of experiential avoidance and difficulties engaging in goal-directed behavior when distressed. Journal of Anxiety Disorders. Tull, M. T., Gratz, K. L., & Lacroce, D. M. (2006). The role of anxiety sensitivity and lack of emotional approach coping in depressive symptom severity among a nonclinical sample of uncued panickers. Cognitive Behaviour Therapy, 35, 74–87. Tull, M. T., Schulzinger, D., Schmidt, N. B., Zvolensky, M. J., & Lejuez, C. W. (2007). Development and initial examination of a brief intervention for heightened anxiety sensitivity among heroin users. Behavior Modification, 31, 1–23. Valentiner, D., Mounts, N., & Deacon, B. (2004). Panic attacks, depression and anxiety symptoms, and substance use behaviors during late adolescence. Journal of Anxiety Disorders, 18, 573–585.
Drug Use and the Anxiety Disorders
79
Wetherell, M. A., Crown, A. L., Lightman, S. L., Miles, J. N. V., Kaye, J., & Vedhara, K. (2006). The four-dimensional stress test: Psychological, sympathetic-adrenal-medullary, parasympathetic and hypothalamic-pituitary-adrenal responses following inhalation of 35% CO2. Psychoneuroendocrinology, 31, 736–747. Yehuda, R. (2001). Biology of posttraumatic stress disorder. Journal of Clinical Psychiatry, 62, 41–46. Zlotnick, C., Najavits, L. M., Rohsenow, D. J., & Johnson, D. M. (2003). A cognitivebehavioral treatment for incarcerated women with substance abuse disorder and posttraumatic stress disorder: Findings from a pilot study. Journal of Substance Abuse Treatment, 25, 99–105. Zvolensky, M. J., Bernstein, A., Sachs-Ericsson, N., Schmidt, N. B., Buckner, J. D., & Bonn-Miller, M. O. (2006). Lifetime associations between cannabis, use, abuse, and dependence and panic attacks in a representative sample. Journal of Psychiatric Research, 40, 477–486. Zvolensky, M. J., Bonn-Miller, M. O., Bernstein, A., McLeish, A. C., Feldner, M. T., & Leen-Feldner, E. W. (2006). Anxiety sensitivity interacts with marijuana use in the prediction of anxiety symptoms and panic-related catastrophic thinking among daily tobacco users. Behaviour Research and Therapy, 44, 907–924. Zvolensky, M. J., & Eifert, G. H. (2001). A review of psychological factors/processes affecting anxious responding during voluntary hyperventilation and inhalations of carbon dioxideenriched air. Clinical Psychology Review, 21, 375–400. Zvolensky, M. J., & Forsyth, J. P. (2002). Anxiety sensitivity dimensions in the prediction of body vigilance and emotional avoidance. Cognitive Therapy and Research, 26, 449–460. Zvolensky, M. J., & Schmidt, N. B. (2004). Anxiety and substance use disorders: Introduction to the special series. Journal of Anxiety Disorders, 18, 1–6. Zvolensky, M. J., Schmidt, N. B., & Stewart, S. H. (2003). Panic disorder and smoking. Clinical Psychology: Science and Practice, 10, 29–51.
The Promise of Exercise Interventions for the Anxiety Disorders Jasper A. J. Smits, Angela C. Berry, Mark B. Powers, Tracy L. Greer, and Michael W. Otto
Introduction There is consistent evidence for the role of exercise in increasing longevity (Lee & Paffenbarger, 2000; Lee, Hsieh, & Paffenbarger, 1995) and reducing risk for coronary disease (Berlin & Colditz, 1990; Kohl, 2001), stroke (Wannamethee & Shaper, 1992), diabetes (Chipkin, Klugh, & Chasan-Taber, 2001), obesity (Ross & Janssen, 2001) and various cancers (Lee et al., 1995; Lee, Paffenbarger, & Hsieh, 1991; Lee, Paffenbarger, & Hsieh, 1992; Lee, Sesso, & Paffenbarger, 1999). Evidence from a variety of sources also suggests that physical activity benefits mental health (see for review Biddle, 2000; Stathopoulou, Powers, Berry, Smits, & Otto, 2006). Several large cross-sectional population studies have demonstrated that physical activity is associated with fewer symptoms of anxiety and depression (Stephens, 1988), lower levels of stress, anger, and cynical distrust (Hassmen, Koivula, & Uutela, 2000) as well as better social functioning and vitality among persons with anxiety and substance use disorders (Schmitz, Kruse, & Kugler, 2004). Prospective studies have further shown that physical activity is associated with a decreased risk of developing depression (Camacho, Roberts, Lazarus, Kaplan, & Cohen, 1991; Paffenbarger, Lee, & Leung, 1994) even after controlling for age, social economic status and educational level (Farmer, Locke, Mosciki, Larson, & Radloff, 1998). Lastly, there is a growing body of research demonstrating the efficacy of exercise interventions for mental health (Stathopoulou et al., 2006). If effective for the prevention and treatment of anxiety disorders, physical activity interventions would have a significant public health impact. In this chapter, we review the literature on the relationship between physical activity and anxiety. Specifically, we discuss findings from epidemiological, basic and clinical studies, and consider potential mechanisms by which physical activity Jasper A. J. Smits Southern Methodist University, Department of Psychology, 6424 Hilltop Lane, Dallas, TX. Tel: 214-768-4125, Fax: 214-768-0821
[email protected]
M. J. Zvolensky, J. A. Smits (eds.), Anxiety in Health Behaviors and Physical Illness. Ó Springer 2008
81
82
J. A. Smits et al.
may confer protective or anxiolytic effects. We conclude this chapter with suggested avenues for further research in this area.
Physical Activity Defined Caspersen, Powell, and Christenson (1985) defined physical activity as ‘‘any bodily movement produced by skeletal muscle that results in energy expenditure.’’ As such, physical activity encompasses a variety of activities, including occupational work, leisure activities and exercise, which is defined as a physical activity that is planned for fitness or health purposes (Caspersen et al., 1985). Exercise can be further sub-divided into aerobic or anaerobic exercise. Aerobic exercise includes activities such as walking, swimming, cycling and running, all of which require maintenance of increased heart rate. The American College of Sports Medicine (ACSM, 2005) defines aerobic exercise as a physical activity that lasts longer than three minutes during which glycogen is consumed with oxygen. In contrast, anaerobic exercise, which includes activities such as weight training and sprinting, lasts less than three minutes during which glycogen is consumed without oxygen (ACSM, 2005). Physical fitness has been defined as a set of attributes related to the ability to engage in physical activity (Caspersen et al., 1985). It is a multidimensional construct (President’s Council on Physical Fitness, 2000) that includes skill-related (e.g., agility, balance, speed, reaction time), health-related (e.g., cardiorespiratory endurance, muscular endurance, muscular strength, body composition, and flexibility) and physiologic components (e.g., glucose tolerance, blood lipid and cholesterol profiles, fatness, and bone mass). The latter two components have been more directly linked with physical health and evidence suggests that they can be more easily improved, relative to the other component of physical fitness, by engaging in regular physical activity (ACSM, 2006). Quantifying the level of physical activity involves the determination of energy expenditure, which is typically expressed in kilocalories, or the amount of heat required to increase the temperature of 1 kg of water by 18C. Energy expenditure is best measured by a method called ‘‘doubly labeled water’’ (Schoeller, 1988). This procedure involves several steps, starting with the administration of water labeled with stable isotopes of hydrogen and oxygen. Participants are then subjected to regular urine sampling to track the loss of these isotopes over a 7- to 14-day period. This procedure allows for an estimation of daily carbon dioxide production, which can be converted to total daily energy expenditure in kilocalories. However, instead of determining energy expenditure, most investigations of the relationship between physical activity or exercise and anxiety have relied on less expensive and more practical methods such as self-report questionnaires and interviews.
Promise of Exercise Interventions for the Anxiety Disorders
83
These instruments typically assess several dimensions of physical activity including type, intensity, frequency, and duration, thereby allowing researchers to estimate the total expended kilocalories during a given time point (e.g., week, month). Such instruments are also often used merely to categorize participants’ physical activity habits (e.g., engaging in regular exercise versus not engaging in regular exercise, active versus non-active, sedentary versus non-sedentary). Research examining the link between anxiety pathology and fitness has mostly focused on cardiorespiratory fitness, which is operationalized as the volume of oxygen consumed while exercising at maximum capacity (i.e., VO2max). VO2max can be expressed in absolute values (liters/minute) or relative values (ml/kg/min). The values tend to be higher among men compared to women and decline with age. According to the ACSM (2006), mean absolute values for men over age 20 range from 44.2 to 34.6 ml/kg/min, whereas mean absolute values for women in the same age range are between 37.8 to 26.7 ml/ kg/min. VO2max can be measured directly using open-circuit spirometry, or indirectly by means of maximal or submaximal exercise tests. Since open-circuit spirometry and maximal exercise testing require specialized settings, submaximal exercise tests are more commonly employed. One of the most widely used submaximal exercise tests is the Astrand-Ryhming ergometer test (Astrand & Ryhming, 1954). During this 6-minute protocol, participants peddle at 50 rotations per minute at a work rate (i.e., watts) that is determined by the participant’s gender and fitness status. The objective is to reach a steady-state heart rate between 125 and 170 beats per minute. A nomogram is then used to estimate VO2max based on the average heart rate during minutes 5 and 6. Because it provides an index of cardiorespiratory fitness, VO2max can be used to guide the prescription of exercise intensity. Specifically, the intensity of exercise (e.g., very light, light, moderate, vigorous, very hard, maximal) can be Table 1 Physical activity intensity Intensity VO2R (%) HRR (%)
HR Max (%)
RPE
Very Light <20 <50 9 Light 20–39 50–63 11 Moderate 40–59 64–76 13 Hard 60–84 77–93 15 Very Hard 85 94 17 Maximal 100 100 20 Note: VO2R is oxygen reuptake reserve (i.e., the difference between resting VO2 and maximal VO2); HRR is heart rate reserve (i.e., difference between resting heart rate and maximum heart rate, where maximum heart rate is 220-age); HR Max is maximum heart rate; RPE is rating of perceived exertion using a scale from 6 to 20 (Borg, 1998). Table is adapted from ACSM guidelines for exercise testing and prescription (2006)
84
J. A. Smits et al.
anchored to VO2R (i.e., the difference between resting VO2 and maximal VO2) values. As can be seen in Table 1, intensity of exercise prescriptions can also be guided by a person’s heart rate reserve, maximal heart rate, or subjective ratings of perceived exertion (i.e., RPE; Borg, 1998).
Physical Activity in the United States Data from the 2002–2004 National Health Interview Survey (NHIS), which included a representative sample of 93,222 U.S. adults, indicated that 62% of adults engaged in at least in some leisure-time physical activity over the past year (i.e., light, moderate or vigorous activity episodes that last at least 10 minutes; Adams & Schoenborn, 2006). Physical activity status further varies as a function of several demographic factors. For example, physical activity is significantly more prevalent among men compared to women (64% versus 60.2%) and among White and Asian adults (63.7% and 62.1%) compared to Black and Hispanic adults (51.3% and 47.6%). Likewise, physical activity decreases with age and increases with education and family income (Adams & Schoenborn, 2006).
Developmental Stages of Adopting Physical Activity Understanding contributors to the adoption and maintenance of physical activity is critical to the implementation of physical activity interventions (see for review Marcus et al., 2000). The Transtheoretical Model (TTM) or ‘‘Stages of Change’’ (Prochaska & DiClemente, 1983) has been applied to many health-related activities, including physical activity, to describe the process of adopting a new behavior. The model describes five stages as follows: 1) precontemplation, in which there is no intent to change behavior within 6 months; 2) contemplation, in which there is intent to change behavior within 6 months; 3) preparation, in which there are small or inconsistent changes in a behavior; 4) action, in which there is active involvement in a behavior for less than 6 months’ duration; and 5) maintenance, in which a behavioral change is sustained for 6 months or more. Utilization of the stages in intervention management frequently involves assessment of individuals’ readiness to change, evaluation and contributors to stage transition, and stage-targeted strategies that target behaviors and issues specific to that stage. For example, in the PACEþ study (Calfas et al., 2002), behaviors such as targeting a specific exercise behavior (e.g., setting a goal to increase moderate or vigorous physical activity) was associated with a greater likelihood of moving to the next stage of change. Self-efficacy has also been shown to be an important factor in transition to subsequent stages (Plotnikoff, Hotz, Birkett, & Courneya, 2001). Marshall et al. (2003) reported that a stage-targeted physical activity intervention was associated with significantly greater increases in amount of post-baseline
Promise of Exercise Interventions for the Anxiety Disorders
85
physical activity (78 minutes) compared to a control group receiving no intervention (12 minutes) after 2 months, although this effect was attenuated by 6 months. In the Project Active study, Dunn and colleagues (1999) showed that interventions based on the Stages of Change model yield comparable benefits to physical activity when utilized as a lifestyle or structured intervention, further supporting the incorporation of the model in intervention strategies. Indeed, research examining the TTM model has led to the development of multi-component approaches to adoption of and adherence to exercise. When assessing the feasibility of a treatment, it is important to consider behavioral factors that may limit the likelihood of treatment compliance. Multi-component interventions have been shown to be more effective than single component interventions because no one strategy is effective for all individuals (Ockene, Hayman, Pasternak, Schron, & Dunbar-Jacob, 2002; Roter et al., 1998). Multi-component strategies include behaviors such as developing a specific action plan for activity and targeting barriers to completion of the activity to increase the likelihood of exercise behaviors. This is particularly true with psychiatric populations, where psychological aspects of the disease process may increase barriers to exercise or create difficulty in moving on to the next stage of behavioral change.
Population-based Studies of the Relationship Between Physical Activity and Anxiety There have been several large-scale studies providing evidence for the negative association between physical activity and anxiety. For example, Stephens (1988) collapsed data from four national health surveys conducted in the United States and Canada between 1971 and 1981 (e.g., the National Health and Nutrition Examination Study, Canada Health Survey, National Survey of Personal Health Practices and Consequences, and the Canada Fitness Survey). This procedure yielded a total sample size of approximately 55,000 persons between ages 10 and 74. Both mental health and level of leisure time exercise were assessed by self-report. The findings supported the hypothesis that physical activity is associated with good mental health, including fewer symptoms of depression and anxiety, even after controlling for education and physical health status. Interestingly, the strength of this relationship varied as a function of age and sex, where a stronger link was observed among women and among those over age 40. Recently, Schmitz and colleagues (Schmitz et al., 2004) extended these findings by showing a link between physical activity and enhanced psychological and health-related well-being among persons suffering from DSM-IV anxiety disorders. They used data from the German National Health Interview and Examination Survey (GHS) which comprised a representative sample of approximately 7,000 persons between ages 18 and 79. Diagnoses (12-month prevalence) were determined by a combination of
86
J. A. Smits et al.
self-report and interviewer measures, while physical activity level and emotional well-being were assessed by self-report. Of those suffering from anxiety disorders (n = 573), 63% indicated that they were inactive. These inactive individuals reported significantly lower quality of life across a number of health and mental health domains relative to anxiety disorder sufferers who reported regular exercise. Further, the associations remained significant after controlling for theoretically-relevant variables, but they did not depend on age or gender. In addition to evidence for the association between physical activity and general emotional well-being, there is also survey data indicating that physical inactivity is related to clinical levels of anxiety. Using data from the National Comorbidity Survey (NCS), which comprised a probability sample of approximately 6,000 individuals between ages 15 and 54, Goodwin (2003) estimated the 12-month prevalence of DSM diagnoses among persons who indicated that they exercised ‘‘regularly’’ (60.3%) and compared the rate to those exercised occasionally, rarely or never. Findings revealed a dose-response relationship between physical activity and the likelihood of having an anxiety disorder. Specifically, physical activity was associated with a significantly decreased likelihood of agoraphobia, panic attacks, generalized anxiety disorder (GAD), specific phobia, and social phobia, even after controlling for comorbid physical illness and demographic variables. Interestingly, the relationship between physical activity and GAD was no longer significant after additionally adjusting for comorbid mental disorders, suggesting that physical inactivity may not be directly linked with GAD.
Clinical Studies of the Relationship Between Physical Fitness and Anxiety The linkage between phobic anxiety and cardiovascular disease and mortality (Coryell, Noyes, & House, 1986; Coryell, Noyes, & Clancy, 1982; GomezCaminero, Blumentals, Russo, Brown, & Castilla-Puentes, 2005; Kawachi et al., 1994; Kawachi, Sparrow, Vokonas, & Weiss, 1994; Kawachi, Sparrow, Vokonas, & Weiss, 1995; Weissman et al., 1990; see also White et al. in Chapter 11 in this volume) has prompted research on physical fitness among individuals suffering from pathological anxiety, and particularly panic disorder. There have been several studies that have employed standardized exercise testing protocols to determine cardiorespiratory fitness among individuals with panic disorder (Broocks et al., 1997; Gaffney, Fenton, Lane, & Lake, 1988; Martinsen, Raglin, Hoffart, & Friis, 1998; Meyer, Broocks, Bandelow, Hillmer-Vogel, & Ruther, 1998; Schmidt, Lerew, Santiago, Trakowski, & Staab, 2000; Taylor et al., 1987). For example, Martinsen and colleagues (1998) subjected 35 patients to a submaximal bicycle ergometer test and found that their VO2max was on average at 82% (1.9 liters/min) of the expected value. Similarly, Brooks and colleagues (1997) reported that, relative to a group of non-psychiatric participants (n = 24), individuals with panic disorder (n = 38) showed significantly
Promise of Exercise Interventions for the Anxiety Disorders
87
reduced VO2max. Specifically, the mean relative VO2max values for panic disorder patients was 31.0 ml/kg/min (SD = 9.1) versus 37.6 ml/kg/min (SD = 6.3) for non-psychiatric controls. In a follow-up study, the authors (Meyer et al., 1998) showed that a 10-session exercise training program was associated with significant improvements in VO2max values. To clarify the link between panic disorder and fitness, Schmidt and colleagues (Schmidt et al., 2000) designed a study to determine whether the relatively poor cardiorespiratory fitness estimates among individuals with panic disorder may be biased by elevated levels of anxiety symptoms. To this end, they randomly assigned 27 panic disorder and 27 matched healthy control participants to a submaximal bicycle ergometer test with or without heart rate feedback. This study yielded several important findings. First, panic disorder participants showed reduced cardiorespiratory fitness relative to non-psychiatric participants even after controlling for anxiety responses during the testing protocol (26.4 ml/kg/min (SD = 11.4) versus 34.11 ml/kg/min (SD = 9.8), respectively). Second, although anxiety sensitivity (i.e., fear of anxiety-related sensations), a cognitive disposition that has been implicated in the onset and maintenance of panic disorder (McNally, 2002), was not directly associated with poorer fitness, it appeared to moderate the effects of diagnostic status and heart rate feedback on cardiorespiratory fitness. Specifically, cardiorespiratory fitness was particularly poor among panic disorder suffers with elevated levels of anxiety sensitivity. Similarly, heart rate feedback during testing was only associated with poorer fitness among individuals who reported elevated levels of anxiety sensitivity. Collectively, these findings suggest that cardiovascular conditioning is impaired among individuals with panic disorder, and emphasize the importance of considering anxiety sensitivity in investigations of the relationship between physical activity and anxiety. Indeed, support for the linkage between anxiety sensitivity and physical activity is growing. Recently, McWilliams and Asmundson (2001) observed an inverse relationship between exercise frequency and anxiety sensitivity in a non-clinical sample. Likewise, Smits and Zvolensky (2006) reported that anxiety sensitivity mediated the relationship between physical inactivity and measures of panic severity in a community sample of individuals with panic disorder. Further research regarding the linkage between exercise and anxiety sensitivity will be discussed in the next section on the effects of exercise interventions on anxiety.
Reductions in Anxiety with Exercise Although the studies discussed above support the hypothesis that physical activity plays a role in the etiology, maintenance and treatment of anxiety pathology, the cross-sectional nature of many of these investigations leave open several alternative explanations for the observed relationships. In this section, we will discuss a number of studies that have experimentally manipulated physical activity, providing some evidence for the causal effects of physical activity on anxiety.
88
J. A. Smits et al.
The Effects of Acute Exercise on Anxiety Evaluation of the beneficial effects of single episodes of exercise on anxiety has been the focus of numerous quantitative and qualitative reviews (e.g., Ekkekakis & Petruzzello, 1999; Petruzzello, Landers, Hatfield, Kubitz, & Salazar, 1991; Schlicht, 1994). For example, Petruzzello and associates (1991) conducted a meta-analysis of 119 studies that examined the pre- to post-exercise reductions in self-reported state anxiety. The mean controlled effect size was d = 0.23, although randomized controlled studies yielded smaller effect sizes (d = 0.16). In a more recent review, Ekkekakis and Petruzzello (1999) aptly pointed out that many of the studies examining the effect of acute exercise on anxiety lack the methodological rigor (e.g., adequate sample sizes and control conditions) necessary to significantly advance knowledge regarding the doseresponse relationship. They did, however, observe some robust findings. First, the duration of exercise session is not predictive of anxiety reduction beyond the effects explained by the degree of exercise intensity. Second, the degree of benefit is linked to the degree of fitness; in non-clinical samples, demanding exercise tasks result in greater anxiety reductions among high-fit individuals versus low-fit individuals (Ekkekakis et al., 1999). In addition to fitness level, the participant’s baseline anxiety level appears to be predictive of the degree of benefit. Long and Stavel (1995) reported that effect sizes for studies that employed high-anxious samples were significantly larger than those that employed low anxious samples (d = 0.51 and 0.28, respectively). One implication of this finding is that the degree of benefit from exercise may be much more profound in clinical samples. In addition to reducing state anxiety, single exercise sessions also appear to buffer the effects of social stressor tasks. Using a counterbalanced design, Rajeski and colleagues (Rejeski, Thompson, Brubaker, & Miller, 1992) asked 48 low-to-moderate physically fit women to exercise or rest prior to completing two stressor tasks. The experimental sessions began with either 40 minutes of cycling at 70% heart rate reserve or 40 minutes of rest after which participants rested 30 minutes. Following this 30 minute period, participants completed a Stroop mental challenge and a 3-minute impromptu speech on a controversial topic (e.g., abortion, role of women in society). Relative to rest, exercise was associated with less blood pressure reactivity following psychosocial stress, and reduced anticipatory anxiety prior to speech task. Similar findings have been observed in studies using biological challenge procedures. Biological provocations such as caffeine ingestion, inhalation of carbon dioxide-enriched air, and lactate infusion have been shown to reliably increase bodily and subjective symptoms of anxiety and panic in healthy controls (Zvolensky & Eifert, 2001). A series of recent studies (Esquivel, Schruers, Kuipers, & Griez, 2002; Strohle et al., 2005; Youngstedt, O’Connor, Crabbe, & Dishman, 1998) has demonstrated that emotional responding to these challenges is significantly attenuated when preceded by a single brief
Promise of Exercise Interventions for the Anxiety Disorders
89
(e.g., 12–30 minutes) intense exercise session (e.g., 70% of max HR; 60–70% VO2max, >6mm of blood lactate). Together, these findings suggest that single exercise sessions result in anxiolysis in non-clinical participants.
Parameters of Exercise Interventions Petruzzello and colleagues (1991) reviewed 62 studies of exercise interventions that were at least four weeks in length. Most studies involved non-clinical (n = 48) or non-clinical high anxious (n = 11) individuals. Less than half of the studies (n = 25) employed a randomized controlled design; the other 37 studies were non-experimental or quasi-experimental in nature. Comparison groups involved waitlist control, relaxation or motivational control conditions and anxiety was generally measured using the trait version of the State-Trait Anxiety Inventory (STAI-T; Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983). The average controlled effect size for anxiety reduction with exercise training was (d = 0.34). However, post-hoc analyses revealed that the effect size significantly varied as a function of characteristics of study design and the exercise intervention. Specifically, randomized controlled studies yielded larger effects sizes (d = 0.54). Moreover, length of training was significantly associated with the degree of improvement in anxiety; interventions with a minimum length of 10 weeks were associated with greater effect sizes (d =0.36 to 0.90) compared to interventions with a duration of less than 10 weeks (d = 0.14 to 0.17). Similarly, only interventions with session durations between 21 and 30 minutes or greater than 40 minutes yielded significant effect sizes.
Exercise Training Programs for Clinical Anxiety Despite the wealth of studies devoted to the application of exercise interventions to stress and non-clinical anxiety, to our knowledge, there are only two randomized controlled clinical trials of exercise interventions for individuals meeting criteria for anxiety disorders. This limited evidence stands in stark contrast to studies of exercise interventions for major depression. For depression, exercise interventions are associated with reliable benefit. For example, a recent meta-analysis of 11 controlled studies of the efficacy of exercise interventions for depression yielded a controlled effect size of (d = 1.42) (Stathopoulou et al., 2006). For anxiety disorders, the available evidence for the efficacy of exercise interventions is limited to the treatment of panic disorder. Panic disorder is a particularly apt disorder for the application of exercise interventions (see for review Smits et al., 2007) given that fears of somatic sensations of anxiety (i.e., anxiety sensitivity) are central to the etiology and
90
J. A. Smits et al.
maintenance of the disorder (McNally, 2002; Smits, Powers, Cho, & Telch, 2004). Cognitive-behavioral treatments for panic disorder target anxiety sensitivity by prescribing exposure to these feared sensations (i.e., interoceptive exposure) in conjunction with cognitive interventions to help patients eliminate catastrophic interpretations of these symptoms (Margraf, Barlow, Clark, & Telch, 1993). Accordingly, in addition to the general benefits of exercise on anxiety reduction, as documented for nonclinical samples, exercise also has the potential to provide patients with exposure to feared sensations of bodily arousal. Indeed, aerobic exercise induces many of the somatic sensations (e.g., heart racing, rapid breathing, and sweating) that have shown to elicit increased anxiety reactions in panic disorder patients (Rief & Hermanutz, 1996). The notion that exercise can serve as an interoceptive exposure procedure is also consistent with early reports that exercise can be anxiogenic for these patients. For example, Cameron and Hudson (1986) observed significant increases in subjective anxiety during submaximal exercise testing in 31% of patients with panic disorder, but only in 7% of patient and non-patient controls. Similarly, two more recent studies reported that panic disorder patients are more likely to prematurely terminate submaximal exercise testing compared to non-clinical controls (Schmidt et al., 2000; Stein, Tancer, & Uhde, 1992). Consistent with previous evidence that repeated exposure to biological provocation procedures is associated with clinical benefits for panic disorder sufferers (van den Hout, van der Molen, Griez, Lousberg, & Nansen, 1987), Broman-Fulks, Berman, Rabian and Webster (2004) developed a brief exercise intervention to target anxiety sensitivity. The intervention consisted of six 20-minute high-intensity (60–90% maximal heart rate) sessions on a treadmill. This intervention was compared to a similar protocol low-intensity (below 60% of maximal heart rate) level aerobic exercise program. Neither group received a specific treatment rationale or cognitive interventions. Results revealed that the high intensity intervention was associated with significantly greater reductions in anxiety sensitivity compared to the low intensity intervention (pre- to posttreatment raw score mean reductions of 9.14 and 2.88, respectively). Preliminary results from our own laboratories suggest that preceding the interventions with a rationale emphasizing the importance of exposure to reducing anxiety sensitivity coupled with coaching participants during and following exercise sessions (i.e., ‘‘what are you learning from this?’’) may enhance the effect of this exercise intervention on anxiety sensitivity (Smits et al., 2007). In addition to the direct application of exercise as an interoceptive exposure procedure to reduce anxiety sensitivity, exercise may also have general anxiolytic properties for patients with panic disorder. Using a counterbalanced design, O’Connor (2005) asked 10 women with panic disorder to complete a maximal treadmill exercise test, 25 minutes of submaximal treadmill walking (i.e., 65% of VO2 max), and 25 minutes of seated rest during three consecutive sessions. Self-report of state anxiety was assessed 5 and 15 minutes before and after each session. Consistent with hypothesis, patients reported significant
Promise of Exercise Interventions for the Anxiety Disorders
91
reductions in anxiety after both maximal and submaximal exercise testing. Importantly, these reductions were evident within 5 minutes following exercise. A much broader study of the efficacy of aerobic exercise for panic disorder was conducted by Broocks et al. (1998). These investigators examined the efficacy of aerobic exercise relative to clomipramine and pill placebo in a sample of patients with panic disorder (N = 46). Patients randomized to clomipramine were prescribed the medication following evidence-based guidelines. Patients in the aerobic exercise condition were medication-free and underwent a 10-week endurance training program. Specifically, patients were asked to find a four-mile route (forest or park) that was easily accessible from their home, and complete this entire route at least three times a week, where walking was allowed during the first six weeks, and running was expected during the last four weeks. Patients also met with a trainer once each week to run together. Exercise led to significantly more benefit than placebo treatment at week 10, and clomipramine yielded significantly greater effects compared to placebo after four weeks. At posttreatment, both active treatments outperformed the placebo condition and were equally effective in reducing anxiety. Additionally, clomipramine yielded greater changes in global improvement ratings compared to aerobic exercise. In discussing the magnitude of the effects observed for exercise in their study, Broocks et al. (1998) hypothesized that additional cognitive interventions would have enhanced the benefits among participants in the exercise condition. Specifically, therapists could have assisted patients in preparing to reappraise some of the feared consequences of exercise-induced sensations. This type of preparation could have potentially prevented avoidance of more intense exercise that was evident in a subset of the patients (Broocks et al., 1998). The findings reported by Broocks and colleagues (1998) comport well with an earlier report (Martinsen, Hoffart, & Solberg, 1989). Martinsen et al. (1998) randomly assigned in-patient participants with panic disorder with agoraphobia (n = 56), social phobia (n = 13), or generalized anxiety disorder (n = 10) to either an aerobic or non-aerobic exercise treatment program. Both programs were conducted in group format, were eight weeks in length, and involved three weekly one-hour sessions, of which thirty minutes were devoted to exercise. The aerobic program involved walking or running at 70% of maximal aerobic capacity, whereas the intensity of the anaerobic program, which comprised muscular strength training, was unspecified. The study attrition rate was 11% and involved only panic disorder patients (n= 9) in the aerobic exercise condition. Although aerobic exercise was associated with greater improvements in physical fitness, both conditions showed comparable significant pre- to post treatment improvements on interviewer and self-report measures of anxiety. Based on these results, the authors concluded that exercise programs are effective for reducing pathological anxiety and that this effect cannot be accounted for by enhanced cardiorespiratory fitness. Initial feasibility data also supports the application of exercise to obsessivecompulsive disorder (OCD). Brown and colleagues (Brown et al., 2007) recently
92
J. A. Smits et al.
completed an open trial of an exercise intervention with 15 patients who were also on a stable dose of cognitive-behavioral treatment, pharmacotherapy, or their combination. The exercise intervention involved a combination of supervised and home-based aerobic exercise at 55 to 69% of age predicted maximal heart rates. Over the course of the 12-week protocol, participants progressed from 20-minute to 40-minute sessions three to four times a week. Prior to each supervised group session, participants participated in a 30-minute meeting with a clinical psychologist and an exercise physiologist to discuss topics related to compliance with the intervention program (e.g., benefits of exercise, goal setting, identifying and overcoming barriers to exercise). Compliance was further stimulated by providing monetary remuneration for adherence. The Cohen’s d effect size for reductions in Y-BOCS scores was d = 1.69 from pre- to posttreatment, and d = 1.11 for pretreatment to 6-month follow-up. Moreover, clinically meaningful changes were observed for 69% and 50% of patients at posttreatment and 6-month follow up, respectively. The initial successes of the application of exercise interventions to the treatment of clinical anxiety problems encourage a more in-depth study of the feasibility and efficacy of exercise protocols for patients with anxiety disorders. In addition to large-scale randomized controlled trials, these efforts should include investigations of the mechanism underlying the effects of exercise on anxiety.
Mechanisms of Exercise Anxiolysis There is little research on the mechanism by which exercise exerts its ameliorative effects on anxiety. In this section, we will discuss several proposed physiological and psychological mechanisms of exercise anxiolysis for which there is some preliminary supporting evidence.
Central Neurotransmitter Function Several animal studies have demonstrated that physical activity results in alterations in many neural systems that are also presumed to underlie the reductions in depression and anxiety with pharmacological treatments. For example, increased release of serotonin has been observed in animals both during (Wilson & Marsden, 1996) and following treadmill running (Dunn & Dishman, 1991; Meeusen & De Meirleir, 1995). Based upon other animal studies showing that physical activity leads to increased serotonin metabolism (Broocks, Schweiger, & Pirke, 1991; Chaouloff, 1997), Broocks and colleagues (Broocks et al., 1999; Broocks et al., 2001; Broocks et al., 2003) posited that physical activity may result in down-regulation of postsynaptic serotonin
Promise of Exercise Interventions for the Anxiety Disorders
93
receptors, and specifically the 5-HT2C receptors. In a first study to test this hypothesis, they compared marathon runners to sedentary controls on their responses to meta-chlorophenylpiperazine (m-CPP), a 5-HT agonist that produces anxiogenic symptoms via 5-HT2C receptors (Broocks et al., 1999). Marathon runners showed a diminished cortisol response to m-CPP, providing evidence consistent with the idea that chronic exercise results in a reduced hormonal reaction to m-CPP mediated by postsynaptic 5-HT2C receptors. In a second study, the authors (Broocks et al., 2001) found that untrained participants show a similar blunted cortisol response to m-CPP following a 10-week aerobic exercise program of moderate intensity. The authors concluded that these data collectively suggest that the anxiolytic effects of exercise may be mediated by the downregulation of 5-HT2C receptors. The efficacy of benzodiazepines for reducing anxiety forms the basis of research examining the potential of exercise on -aminobutyric acid (GABA) function. Studies suggest that measuring the amount of time a rat spends in an open field (open field locomotion) with or without treadmill exercise is a useful animal model for studying the anxiolytic effects of exercise (Dishman, Armstrong, Delp, Graham, & Dunn, 1988; Morgan, Olson, & Pedersen, 1982; Royce, 1977). Injections of GABA into the nucleus accumbens septi (NAS) reduces open field locomotion and injections of a GABA antagonist into the NAS increases locomotion in rats (Jones & Mogenson, 1980a; Jones & Mogenson, 1980b; Jones, Mogenson, & Wu, 1981). Since exercise also increases open field locomotion in rats (Tharp & Carson, 1975); (Weber & Lee, 1968), Dishman and colleagues (1996) have posited that exercise may reduce anxiety by the downregulation of GABAa receptor density in the corpus striatum. Consistent with this hypothesis, they found that voluntary exercise in rats increased open field locomotion with a corresponding GABAa downregulation (Dishman et al., 1996). Human studies are needed to test the hypothesis that exercise anxiolysis in humans can be accounted for by GABAa downregulation or other changes in central neurotransmitter function.
Sleep Restoration Improved sleep as a proposed mechanism of change first emerged with the delayed onset hypothesis, or the observation that antidepressant drugs rapidly change plasma levels and sleep parameters (48–72 hours), and that corresponding mood and anxiety changes in the weeks following (Chen, 1979; Ehlers, Havstad, & Kupfer, 1996; Hyttel, 1994; Kupfer et al., 1994; Shipley et al., 1984). There is also evidence that pharmacologic treatment of sleep symptoms improves depression outcomes (Fava et al., 2006). Moreover, several studies have now shown that exercise training programs are associated with significant improvements in self-reported sleep quality (King, Oman, Brassington, Bliwise, & Haskell, 1997; Singh, Clements, & Fiatarone, 1997). Interestingly, some
94
J. A. Smits et al.
findings converge to suggest that changes in slow wave sleep (SWS), which occurs during restorative stages 3 and 4 of the sleep cycle, may be particularly relevant to the anxiolysis following exercise. Specifically, reduced SWS is ubiquitous among anxiety disorder sufferers (Arriaga & Paiva, 1990; Arriaga et al., 1996; Bourdet & Goldenberg, 1994; Fuller, Waters, Binks, & Anderson, 1997) and exercise appears to enhance SWS (Horne, 1981; Shapiro, Griesel, Bartel, & Jooste, 1975). There is some controversy with respect to the mechanism underlying the effects of exercise on SWS. Some studies suggest that it may be the elevation in body temperature created by exercise that may be responsible for sleep effects (Atkinson & Davenne, 2006; Horne & Moore, 1985; Horne & Shackell, 1987; Horne & Staff, 1983). However, other studies show that low intensity activity without a corresponding increase in body temperature can also increase SWS (Naylor et al., 2000). Also, well-controlled studies show that the anxiolytic effects of acute exercise are not solely due to body temperature (Youngstedt, Dishman, Cureton, & Peacock, 1993).
Cognitive Refocusing and Self-efficacy There is some evidence suggesting that exercise may exerts its effect on anxiety by enhancing perceived coping ability. Steptoe and colleagues (Moses, Steptoe, Mathews, & Edwards, 1989) observed parallel decreases in perceived coping and anxiety in anxious individuals who initiated an exercise program. Similarly, Bodin and Martinsen (2004) found that exercise that targeted self-efficacy (e.g., 45 minutes of martial arts) corresponded with significantly greater improvements in positive affect and state anxiety compared to exercise that did not target self-efficacy (e.g., 45 minutes of stationary bike exercise). As an alternative to enhanced self-efficacy, some have suggested that physical exercise may only serve as distraction from ruminations, worries, and anxiety (Bahrke & Morgan, 1978; Leith, 1994). Interestingly, Goode and Roth (1993) found that it is not distraction per se but the content of the distraction techniques in which people engage that is associated with changes in emotional well-being. They found that that runners who focused on nonassociative thoughts (those not related to exercising) showed less fatigue and in some cases decreases in tension and anxiety, compared to runners who focused on associative thoughts (monitoring the body and the exercise itself).
Exposure Recently, Stathopoulou and colleagues (2006) proposed that, among other effects, exercise may exert positive effects on mental health by teaching persistence in the presence of negative somatic or emotional states. Indeed, the modification of some of the self-perpetuating patterns in affective disorder
Promise of Exercise Interventions for the Anxiety Disorders
95
(e.g., social withdrawal and inaction in response to feelings of depression, and avoidance in response to feelings of anxiety), by facilitation of adaptive pursuit of goals regardless of the presence of aversive thoughts or emotions, is increasingly being discussed as a general feature of adaptive change in therapy (Barlow, Allen, & Choate, 2004). Accordingly, by training persistence with exercise, despite the presence of the physical and emotional symptoms of exertion, exercise interventions may have more general effects on returning participants to adaptive activity. As we discussed above, this persistence in the presence of symptoms may take on special meaning in the case of panic disorder. We discussed exercise, with its induced array of symptoms that are similar to many of the symptoms of anxious arousal, as a form of interoceptive exposure – exposure to the somatic symptoms of anxiety under controlled circumstances. As suggested by the research to date, inclusion of specific preparation and cognitive coaching for the symptoms to be induced both mimics typical interoceptive exposure procedures used in cognitive behavior therapy (Smits et al., 2007) and appears to lead to more optimal outcomes for exercise interventions (Smits et al., 2005; Broocks et al., 1998).
Conclusions and Future Directions The application of exercise interventions to clinical anxiety is in the early stages of development, but the few trials completed to date, as well as the wealth of evidence for the effects of exercise on non-clinical anxiety, encourage further study. Although most work to date has been completed with persons suffering from panic disorder, preliminary findings with respect to the mechanisms of exercise anxiolysis suggest that exercise of may also offer significant benefits for those suffering from other forms of anxiety psychopathology. This hypothesis awaits testing in large-scale randomized controlled trials. The development of exercise interventions for the anxiety disorders will likely benefit from studies focused on identifying intervention parameters critical to efficacy of exercise. There is evidence from the depression literature suggesting that high intensity exercise provides superior results compared to lower intensity exercise. For example, Dunn and associates (Dunn, Trivedi, Kampert, Clark, & Chambliss, 2005) reported that the public health recommended dose of aerobic exercise (total energy expenditure of 17.5 kcal/kg/week) was more effective in reducing depression relative to low dose aerobic exercise (total energy expenditure 7.0 kcal/kg/week) or flexibility exercise. A public health dose of exercise has also yielded reductions in depressive symptom severity and improvements in quality of life in a preliminary study of exercise augmentation to antidepressant